WO2001046200A1 - Novel piperidine and piperazine derivatives - Google Patents

Novel piperidine and piperazine derivatives Download PDF

Info

Publication number
WO2001046200A1
WO2001046200A1 PCT/SE2000/002580 SE0002580W WO0146200A1 WO 2001046200 A1 WO2001046200 A1 WO 2001046200A1 SE 0002580 W SE0002580 W SE 0002580W WO 0146200 A1 WO0146200 A1 WO 0146200A1
Authority
WO
WIPO (PCT)
Prior art keywords
acetamide
methyl
dimethylpiperazin
methylphenyl
phenyl
Prior art date
Application number
PCT/SE2000/002580
Other languages
French (fr)
Other versions
WO2001046200A8 (en
Inventor
Premji Meghani
Colin Bennion
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00989102A priority Critical patent/EP1242427B1/en
Priority to AU25648/01A priority patent/AU776592B2/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to DE60004564T priority patent/DE60004564T2/en
Priority to US10/168,094 priority patent/US6969713B2/en
Priority to CA002394095A priority patent/CA2394095A1/en
Priority to MXPA02006261A priority patent/MXPA02006261A/en
Priority to JP2001547110A priority patent/JP2003518126A/en
Priority to BR0016543-3A priority patent/BR0016543A/en
Priority to NZ519498A priority patent/NZ519498A/en
Priority to AT00989102T priority patent/ATE247123T1/en
Priority to IL15020100A priority patent/IL150201A0/en
Publication of WO2001046200A1 publication Critical patent/WO2001046200A1/en
Publication of WO2001046200A8 publication Critical patent/WO2001046200A8/en
Priority to IL150201A priority patent/IL150201A/en
Priority to NO20023037A priority patent/NO20023037L/en
Priority to US11/125,335 priority patent/US20050272745A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to piperidine and piperazine derivatives, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
  • the P2X 7 receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflarmnatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B).
  • Activation ofthe P2X 7 receptor by extracellular nucleotides, in particular adenosine triphosphate leads to the release of interleukin- l ⁇ (IL-l ⁇ ) and giant cell formation (macrophages/ icroglial cells), degranulation (mast cells) and L-selectin shedding (lymphocytes).
  • P2X 7 receptors are also located on antigen-presenting cells
  • APC keratinocytes
  • salivary acinar cells parotid cells
  • hepatocytes erythrocytes
  • erythroleukaemic cells monocytes
  • fibroblasts bone marrow cells
  • neurones neurones and renal mesangial cells.
  • P2X 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X 7 receptor may play a role.
  • X represents a nitrogen atom or a group C(R );
  • Y represents an oxygen or sulphur atom or a group NR , preferably an oxygen atom;
  • R and R each independently represent a hydrogen atom or a C ⁇ -C alkyl
  • R and R together represent a group -CH 2 ZCH 2 -;
  • Z represents a bond, an oxygen or sulphur atom or a group CH 2 or NR , and is preferably a bond; is O or 1;
  • R represents a 5- to 10-membered unsaturated ring system which may comprise from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, nitro, cyano, NR 8 R 9 , C r C 4 alkyl-C(O)NH-, NHR 12 C(O)-,
  • R represents a phenyl or pyridinyl group, each of which is substituted in an ortho position with a substituent selected from halogen, C ⁇ -Q ⁇ alkoxy, 0 ⁇ 4 alkylthio, and
  • C r C 4 alkyl optionally substituted by one or more fluorine atoms, the phenyl or pyridinyl group being optionally further substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, C r C 4 alkylthio, C r C 4 alkyl-NH-, NHR 13 -C r C 4 alkyl-, C r C 4 alkyl-SO 2 -, C r C 4 alkyl-SO 2 NH-, C r C 4 alkyl-NHSO 2 -, C r C 4 alkyl-C(O)NH-, C r C 4 alkyl-NHC(O)-, -D-G, C r Q 4 alkoxy optionally substituted by -NR R or by R , and Ci -C 4 alkyl optionally substituted by one or more fluorine atoms or by one or more hydroxyl groups, or R represents a 9- or 10-membered unsaturated
  • D represents an oxygen atom or a group (CH 2 ) n or CH 2 NH; n is i, 2 or 3; G represents a piperazinyl, morpholinyl or 2,5-diazabicyclo[2.2.1]heptyl group, or G represents a piperidinyl group optionally substituted by amino (-NH 2 );
  • R represents a hydrogen atom, or a hydroxyl or C 1 -C 4 alkoxy group
  • R represents a hydrogen atom, or a cyano, nitro, hydroxyl, C ⁇ -C 4 alkyl or C 1 -C alkoxy group
  • R 7 , R 8 and R 9 each independently represent a hydrogen atom or a C r C 4 alkyl group
  • R and R each independently represent a hydrogen atom or a C r C alkyl group, or R and R together with the nitrogen atom to which they are attached form a 5- or 6- membered saturated heterocyclic ring comprising one or two ring nitrogen atoms;
  • R 12 represents a hydrogen atom, or a Ci -C 4 alkyl group optionally substituted by amino (-NH 2 );
  • R 13 represents a hydrogen atom, or a C C 4 alkyl group optionally substituted by hydroxyl;
  • R and R each independently represent a hydrogen atom or a C C 4 alkyl group optionally substituted by hydroxyl, or R 14 and R 15 together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprising one or two ring nitrogen atoms;
  • R represents a l-(C ⁇ -C 4 -alky ⁇ )-piperidinyl group; with the proviso that when m is 0, X is N and Y is O, then R does not represent 2-benzothiazolyl; or a pharmaceutically acceptable salt or solvate thereof.
  • an alkyl substituent or alkyl moiety in a substituent group may be linear or branched.
  • an alkyl group or moiety may contain up to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl.
  • the substituent group is NHR 13 -C 1 -C 4 alkyl-
  • the NHR 13 moiety may be attached to a terminal or internal carbon atom ofthe alkyl moiety and when the substituent group is alkoxy substituted by -NR R , the alkoxy group will contain at least 2 carbon atoms and the group -NR R is not attached to the same carbon atom to which the oxygen atom is attached.
  • 3 R represents a 5- to 10-membered unsaturated ring system which may comprise 1, 2, 3 or 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more (i.e. at least one), e.g. one, two or three, substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), nitro, cyano, NR ⁇ R 9 , C r C 4 alkyl-C(O)NH- (e.g. CH 3 C(O)NH-), NHR 12 C(O)- (e.g.
  • fluorine atoms e.g. trifluoromethyl
  • substituents include: methyl, amino (-NH 2 ), cyano, methoxy, chloro, nitro, NH 2 C(O)-, CH 3 C(O)NH-, CH 3 SO 2 -, CH 3 SO 2 NH- andNH 2 CH 2 CH 2 NHC(O)-.
  • the ring system may be monocyclic or poly cyclic. If polycyclic, e.g. bicyclic, the two rings may " be fused to one another or may be joined by a bond. If the ring system is bicyclic, it is preferred that the rings are fused to one another.
  • ring systems examples include phenyl, pyridinyl, pyrimidinyl, naphthyl, furanyl, pyrryl, thieiryl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, quinolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, triazinyl, benzothiazolyl, benzooxazolyl, imidazopyrazinyl, triazolopyrazinyl, naphthyridinyl, furopyridinyl, ⁇ uopyranopyrimidinyl, pyridazinyl, quinazolinyl, pteri
  • Preferred ring systems are phenyl, thienopyrimidinyl, purinyl, pyrimidinyl, thiazolopyrimidinyl, quinazolinyl, benzooxadiazolyl, benzothiadiazolyl, thienyl, imidazolyl, tetrahydroisoquinilinyl, isoquinolinyl, pyrazolyl, isoxazolyl, 2-(isoxazol-3-yl)thienyl and pyridinyl.
  • 4 R may represent a phenyl or py ⁇ dmyl group comprising at least one substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C ⁇ -C , preferably C r C 2 , alkoxy, C r C , preferably C 1 -C 2 , alkylthio or C r C 4 , preferably C r C 2 , alkyl optionally substituted by one or more (i.e. at least one) fluorine atoms (e.g.
  • trifluoromethyl which substituent is attached to the phenyl or pyridinyl group at a position ortho (*) with respect to the point of attachment of R to the rest ofthe molecule, for example as illustrated below.
  • ortho substituents include chloro, methyl and trifluoromethyl.
  • the phenyl or pyridinyl group may be optionally further substituted by one or more (i.e. at least one) (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, hydroxyl, C ⁇ -C alkylthio (e.g. methylthio or ethylthio), -C4 alkyl-NH- (e.g.
  • R may represent a 9- or 10-membered unsaturated fused bicyclic ring system which may comprise 1, 2, 3 or 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more (i.e. at least one) (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), oxo, C C 4 , preferably C ⁇ -C 2 , alkyl, C' 1 -C 4 , preferably C C 2 , alkoxy, C r C , preferably C ⁇ -C , alkylthio and NR R .
  • halogen e.g. fluorine, chlorine, bromine or iodine
  • bicyclic ring systems examples include naphthyl, benzimidazolyl, quinolinyl, indolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, benzthiazolyl, benzoxazolyl and quinazolinyl.
  • An example of an unsaturated fused bicyclic ring system substituted by an oxo group is oxindolyl.
  • D represents an oxygen atom or a group (CH 2 ) n or CH 2 NH (in that orientation), where n is 1, 2 or 3.
  • G represents a piperazinyl, morpholinyl or 2,5-diazabicyclo[2.2.1]heptyl group, or G represents a piperidinyl group optionally substituted by at least one amino group (e.g. 1 -piperidinyl, 4-piperidinyl, 1 -piperazinyl, 1 -morpholinyl or 4-amino-l -piperidinyl).
  • R represents a hydrogen atom, or a hydroxyl or C ⁇ -C alkoxy group. In a preferred embodiment, R represents a hydrogen atom.
  • R represents a hydrogen atom, or a cyano, nitro, hydroxyl, preferably C 1 -C 2 , alkyl or C j - i, preferably Cj-02, alkoxy group.
  • R 7 , R 8 and R 9 each independently represent a hydrogen atom or a C C 4 , preferably C 1 -C 2 , alkyl group.
  • R and R each independently represent a hydrogen atom or a C ⁇ -C , preferably C 1 -C 2 , alkyl group, or R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprismg one or two ring nitrogen atoms (e.g. pyrrolidinyl, piperidinyl or piperazinyl).
  • R represents a hydrogen atom, or a C 1 -C 4 , preferably C ⁇ -C 2 , alkyl group optionally substituted by at least one amino group (-NH 2 ).
  • R represents a hydrogen atom, or a C r C 4 , preferably C r C 2 , alkyl group optionally substituted by at least one hydroxyl group.
  • R and R each independently represent a hydrogen atom or a C r C 4 , preferably
  • R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprising one or two ring nitrogen atoms (e.g. pyrrolidinyl, piperidinyl or piperazinyl).
  • R represents a l-(C 1 -C 4 -alkyl)-piperidinyl group, e.g. 1-methylpiperidinyl, specifically l-methylpiperidin-3-yl.
  • Preferred compounds ofthe invention include:
  • the present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises: (a) reacting a compound of general formula wherein X, Y, R , R and R are as defined in formula (I), with a compound of general formula (III), R 3 -(SO 2 ) m -L 1 , wherein L 1 represents a leaving group (e.g. a halogen atom
  • L represents a leaving group such as a halogen atom or hydroxyl group and m, X,
  • Y, R 1 , R2 and R 3 are as defined in formula (I), with a compound of general formula (Nil), H 2 ⁇ - R , wherein R is as defined in formula (I);
  • Processes (a) and (b) are conveniently carried out in the presence of a base, e.g. a metal carbonate such as potassium or caesium carbonate or a trialkylamine such as triethylamine, preferably N,N-diisopropylethylamine, and in the presence of a polar solvent (e.g. l-methyl-2-pyrrolidinone, dimethylformamide, ethanol, tetrahydrofuran or 1,4-dioxane).
  • a base e.g. a metal carbonate such as potassium or caesium carbonate or a trialkylamine such as triethylamine, preferably N,N-diisopropylethylamine
  • a polar solvent e.g. l-methyl-2-pyrrolidinone, dimethylformamide, ethanol, tetrahydrofuran or 1,4-dioxane.
  • Process (c) is conveniently carried out in the presence of a base and a polar solvent as described above for processes (a) and (b).
  • a coupling reagent is suitably used, for Example, l,r-carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide or bromo-tris-oxy- tripyrrolidinophosphonium hexafluorophosphate.
  • the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, furnarate, maleate, tartrate, citrate, oxalate, methanesulphonate or jp-toluenesulphonate, or an alkali metal salt such as a sodium or potassium salt.
  • an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, furnarate, maleate, tartrate, citrate, oxalate, methanesulphonate or jp-toluenesulphonate
  • an alkali metal salt such as a sodium or potassium salt.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will ⁇ ie understood that the invention encompasses all geometric and optical isomers ofthe compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect ofthe present invention.
  • the compounds of the present invention are advantageous in that they possess pharmacological activity and have utility as modulators of P2X 7 receptor activity. They are therefore indicated as pharmaceuticals for use in the treatment or prevention of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, hyperresponsiveness ofthe airway, chronic obstructive pulmonary disease (COPD), bronchitis, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, neurodegenerative disease, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke, peripheral vascular disease and varicose veins.
  • COPD chronic obstructive pulmonary disease
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
  • the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history ofthe disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
  • the invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis, psoriasis, pulmonary disease, e.g. COPD or bronchitis, or diseases ofthe central nervous system, e.g. Alzheimer's disease or stroke) which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined to a patient.
  • a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof as hereinbefore defined to a patient.
  • the daily dosage of the compound of formula (I) will typically be in the range from 0.001 mg/kg to 30 mg/kg.
  • the compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the invention further provides a process for the preparation of a pharmaceutical composition ofthe invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the pharmaceutical composition ofthe invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
  • the gum was further purified by reverse phase high pressure liquid chromatography (methanol / 0.1% aqueous ammonium acetate, gradient elution 15% to 85% organic phase) to give the title product, after freeze drying, as a beige solid. Yield 0.095g.
  • step (ii) ⁇ 2,6-Dimethyl-l-(thieno[2,3-rflpyri ⁇ nidin-4-yl)piperazine, trifluoroacetic acid salt
  • the subtitle compound was prepared from the product of step (i) (0.15g) by the method of Example 1 step (ii) as a gum. This was used without purification in the next step.
  • Example 4 ⁇ s-N-[3-Hydroxymethyl-2-methylphenyl]-2-(3,5- ⁇ 4-yl)piperazin-l-yl)acetamide i) s-N-[3 (l,l-Dimet yl)-l-dimethylethyl)silyloxymethyl-2-methylphenyl]-2-(3,5- dimethyl-4-(thieno[2,3- ⁇ pyrimidjm-4-yl)piperazin-l-yl)acetamide
  • the subtitle compound was prepared from N-(3-((l,l-dimethyl-l- dimethylethyl)silyloxymethyl)-2-methylphenyl)-2-chloroacetamide (Chem.
  • step (i) (0.15g) in anhydrous tetrahydrofuran was treated with a 1M solution of tetrabutyl ammonium fluoride in tetrahydrofi ⁇ ran (0.31ml) and the mixture stirred at room temperature for 1 hour.
  • the solvent was removed under reduced pressure and the residue purified by high pressure liquid chromatography (acetonitrile / 0.1% aqueous ammonium acetate, gradient elution 20% to 80% organic phase) to give the title compound as a white solid. Yield 0.025g.
  • the subtitle compond was prepared from the product of step (ii) (0.5g) and 1- methylimidazole-4-sulphonyl chloride (0.5g) by the method of Example 80 step (i) as a pale yellow solid. Yield: 0.53g ⁇ NMR ⁇ (CDCI 3 ) 7.46(s, IH), 7.38(s, IH), 7.29(m, 5H), 3.80(s, 2H), 3.47(d, IH), 3.3(d+m, 2H), 2.64(4 2H), 2.08(m, 2H), 1.79(m, 2H), 0.82(t, 3H)
  • Example 6 c/5-2-[3,5-Dimethyl-4-(thieno[2,3-ciIpyri ⁇ nidin-4-yl)piperazin-l-yl]-N-(2- methylphenyl)acetamide
  • the title compound was prepared from the product of Example 9 step (ii) (0.316g) and 2-methylaniline (0.09g) by the method of Example 8 step (v) as a white solid. Yield 0.202g
  • Example 8 step (ii) (0.316g) and 2-chloroaniline (0.107g) by the method of Example 1 step (iii) as a white solid. Yield 0.119g.
  • the subtitle compound was prepared from 6-chloro-9-methyl-9H-purine (J. Org. Chem., 1983, 48(6), 850-5) (2g) and cis- 1,1-dimethylethyl, 3,5-dimethylpiperazine-l-carboxylate (2.74g) by the method of Example 2 step (i) as beige solid. Yield 0.2g.
  • the subtitle compound was prepared from the product of step (i) (0.2g) by the method of Example 1 step (ii) as a red gum. This was used directly in the next step.
  • step (iii) (0.12g) in dichloromethane was treated with 1M hydrogen chloride in diethyl ether (12 ml). The mixture was stirred at room temperature for 18 hours. The solvent was evaporated under reduced pressure to give the subtitle product as a pale yellow solid. Yield 0.15g.
  • the subtitle compound was prepared from the product of Example 2 step (ii) (3.0g) and tert-butyl bromoacetate (1.15g) by the method of Example 8 step (iii) as a white solid. Yield l.Og.
  • step (i) The product from step (i) (1.0g) in 1,4-dioxane was treated with 4M hydrogen chloride in 1,4-dioxane (40 ml). The mixture was stirred at room temperature for 18 hours. The solvent was evaporated under reduced pressure to give the subtitle compound as a white solid. Yield 1.9g.
  • Example 10 c 5-2-(3,5-Dm ⁇ ethyl-4-thieno[2,3- ⁇ pyrimidm-4-yl)piperazm-l-yl)-N-(quinolin-5- yl)acetamide
  • the title compound was prepared from the product of Example 9 step (ii) (0.207g) and 5-aminoquinoline (0.072g) by the method of Example 8 step (v) as a white solid. Yield 0.1 lg.
  • Example 12 c s-2-(3,5-Dm ⁇ ethyl-4-(thieno[2,3- ⁇ pyrimidi ⁇ -4-yl)piperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide i) c 5-2-(3,5-Dimethyl-4-(thieno[2,3- ⁇ pyrimidin-4-yl)piperazin-l-yl)acetyl chloride, hydrochloride salt
  • Example 12 step (i) 0.2g
  • 2-amino-3-methylpyridine 0.076g
  • Example 14 c 5-2-(3,5-Dimethyl-4-(thieno[2,3- ⁇ pyri ⁇ nidm-4-yl)piperazm-l-yl)-N-(isoqumolin-l- yl)acetamide
  • the title product was prepared by from the product of Example 12 step (i) (0.2g) and isoquinolin-1-ylamine (O.lg) by the method of Example 12 step (ii) as a cream solid. Yield 0.055g.
  • step (i) The product of step (i) (5.9g) was dissolved in ethanol (50ml) and cz5-2,6-dimethylpiperazine (3g) and sodium hydrogencarbonate (6.63g) were added at room temperature under a nitrogen atmosphere. The mixture was heated under reflux for 24 hours and the cooled solution was filtered and the filtrate was evaporated under reduced pressure. The residue was dissolved in 1M HCl (22ml) and washed with dichloromethane. The aqueous solution was then basified to pH13 with a solution of sodium hydroxide and the product was extracted with dichloromethane. The organic layer was washed with water, brine, collected, dried (MgSO 4 ) and concentrated under reduced pressure to give the subtitle compound as a beige solid. Yield 4g.
  • Benzenesulphonyl chloride (0.124g) was added to a solution ofthe product from Example 15 step (ii) (0.2g) in pyridine (2ml). The mixture was stirred at room temperature for 16 hours and then the solvent was evaporated under reduced pressure. The residue was purified by flash silica-gel chromatography eluting with 1% EtOH, 1% Et 3 N, 98%CH 2 C1 2 followed by trituration with ethyl acetate to give the title compound. Yield 0.03 g.
  • the subtitle compound was prepared from 2-chloro-N-(2,6-dimethylphenyl)acetamide (7g) and (+)-2-methyl-piperazine (3.55g) by the method of Example 15 step (ii) as a white solid, s Yield 7g.
  • step (i) The title compound was prepared from the product of step (i) (0.38 lg) and 7-chloro- thiazolo[5,4,d]pyrimidine (Chem. Pharm. Bull. 1968, (16(4), 750-755) (0.25g) by the method of Example 15 step (iii) as a beige solid. Yield 0.0 lg. s MS: ES(+ve) 397(M+1, 100%)
  • the subtitle compound was prepared from the product of step (i) (0.068g) by the method of Example 1 step (ii) as a white solid. Yield 0.06 lg.
  • step (ii) (0.06 lg) by the method of Example 15 step (iii), with heating for 1 hour only, as a white solid. Yield 0.04g.
  • the subtitle compound was prepared from the product of Example 20 step (ii) (0.24g) and 2-chloro-N-(quinolin-5-yl)acetamide (J. Indian Chem. Soc, 1940, 17, 619-621) (0.234g) by the method of Example 20 step (iii) as a pale yellow solid. Yield 0.38g.
  • the subtitle compound was prepared from the product of step (i) (0.38g) by the method Example 20 step of step (iv) as a pale yellow gum. This was used directly in the next step.
  • Example 21 step (ii) (O.lg) and 7-chlorothiazolo[5,4-u pyrimidine (Chem. Pharm. Bull, 1968, 16(4), 750-755) (0.06g) by the method of Example 21 step (iii) as a pale yellow solid. Yield O.lg.
  • the subtitle compound was prepared from the product of step (ii) (0.45 g) by the method of Example 20 step (iv) as a white solid. Yield 0.42g.
  • the subtitle compound was prepared from the product of step (iii) (0.2g) and 6-chloro-9- methylpurine (J. Org. Chem., 1983, 48(6), 850-855) (O.lg) by the method of Example 20 step (v) as white solid. Yield O.lg.
  • the subtitle compound was prepared from the product of Example 24 step (iii) (0.2 lg) and 7-chloro-thiazolo[5,4-d]pyrimidine (Chem. Pharm. Bull, 1968, 16(4), 750-755) (0.069g) by the method of Example 20 step (v) as a white solid. Yield 0.113g.
  • the subtitle compound was prepared from the product of Example 24 step (iii) (0.216g) and 4-chlorothieno[2,3--f]pyrimidine (0.056g) by the method of Example 20 step (v) as a white solid. Yield 0.13g.
  • step (i) The product from step (i) (9.6g), 10% palladium on charcoal (lOOmg) in ethanol (100ml) was stirred under an atmosphere of hydrogen gas for 24h.
  • the catalyst was filtered through celite and the mother liquor collected and solvent evaporated under reduced pressure to give the subtitle compound as a pale yellow oil. Yield. 9g
  • step (iii) (0.17mg) was dissolved in 4M hydrogen chloride in 1,4- dioxane (2ml). After 48h the solvents were evaporated under reduced pressure to leave the title compound as a white solid. Yield: 0.16g
  • step (i) (0.14g) in ethanol (0.3ml) was treated with IN sodium hydroxide (0.6ml) at ambient temperature for 48h.
  • the mixture was acidified to pH4 with 2N hydrochloric acid and the solvents evaporated under reduced pressure.
  • the residue was treated with ethanol (5ml) and inorganic salts filtered.
  • the mother liquor collected and solvent evaporated under reduced pressure to leave a gummy residue. Purification was by trituration with diethyl ether. Yield: 0.097g
  • step (iii) (O.lg), potassium carbonate (0.14g), water (5ml) and 1,4- dioxane (5ml) were heated at 110 °C for Ih. The mixture was treated with acetic acid (2ml) and solvents evaporated under reduced pressure. Purification was by silica gel chromatography eluting with ethyl acetate to give the title compound as a white solid. Yield: 0.01 lg
  • the subtitle compound was prepared from the product of step (i) (380mg) by the method of Example 1 step (ii). The product was used without further purification directly in next step.
  • iii) Methyl, 2-(8-(thieno[2,3-rf]pyrimidin-4-yl)-(3,8-diazabiyclo[3.2.1]oct-3-yl)acetate
  • the subtitle compound was prepared from the product of step (ii) (400mg) and 4-chloro- thieno[2,3- ⁇ ]pyrimidine (288mg), N,N-diisopropylethylamine (232ul) in 1,4-dioxane at 100 °C for 48h. Solvent was evaporated under reduced pressure. Purification was by silica gel chromatography eluting with 2% ethanol in dichloromethane to give the subtitle compound as a beige solid. Yield: 170mg.
  • step (iii) The product from step (iii) (170mg) was dissolved in ethanol (1ml) and treated with IN sodium hydroxide solution (0.8ml) at room ambient temperature. After 3h the mixture was acidified with 2M hydrochloric acid to pH4. The solvents were then evaporated under reduced pressure and the residue treated with ethanol and filtered to remove inorganic salts. The mother liquor was collected and evaporated under reduced pressure to leave the subtitle compound as a white solid. Yield: 160mg.
  • step (iv) The product of step (iv) (83mg), the product of Example 27 step (ii) (92mg), benzotriazol- 1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (PyBrop) (153mg) and N,N- diisopropylethylamine (95ul) were stirred in N,N-dimethylformamide (5ml) at ambient temperature for 12h. The solvents were evaporated under reduced pressure and purification was by silica gel chromatography eluting with iso-hexane/acetone (7:3) containing 1% triethylamine to give the subtitle compound as a white solid. Yield: 40mg.
  • the subtitle compound was prepared from the product of step (i) (lg) by the method of Example 50 step (ii) as an off white solid. Yield: 0.9g
  • Example 9 step (ii) (0.54g), the product from step (ii) (0.35g), benzotriazol-0 1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (PyBrop) (0.59g), N,N- diisopropylethylamine (0.8ml) in dry N,N-dimethylformamide (15ml) were stirred together under nitrogen for 24h. The mixture was poured onto water (50ml) and the resulting precipitate filtered as a pale yellow solid. Purification was by silica gel chromatography eluting with diethyl ether/ethyl acetate (9:1) as eluant to give the subtitle compound as as white solid. Yield: 0.5 lg
  • Th ⁇ title compound was prepared from the product of step (iii) (0.42g) according to the method of Example 27 step (iv) as a white solid. Yield: 0.36g
  • the subtitle compound was prepared from 4-methyl-3-nitrophenol (0.5g) and 1,1- dimethylethyl, 2-hydroxyethyl-(N-methylamino)-l -carboxylate (0.69g) by the method of Example 50 step (i) as a beige solid. Yield: 0.67g
  • the subtitle compound was prepared from the product of Example 9 step (ii) (0.26g), the product of step (ii) (0.175g) by the method of Example 31 step (iii). Purification was by silica gel chromatography eluting with diethyl ether/ethyl acetate (9:1) as eluant to give the subtitle compound as a white solid. Yield: 0.25g MS: APCI(+ve) 569 (M+l)
  • step (ii) (lOOmg), sodium bicarbonate (99mg), potassium iodide (5mg) in ethanol (6ml) was treated with the product of step (iii) at 70 °C for 12h. The mixture was partitioned between ethyl acetate and water. The organic phase collected, dried (MgSO 4 ) and Solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with iso-hexane/acetone (7:3) containing 1% triethylamine to give the subtitle compound as a white solid. Yield: 126mg
  • the subtitle compound is prepared from the product of Example 31 step (ii) (650mg) and chloroacetyl chloride (213ul) by the method of Example 33 step (iii) as a beige foam,s Yield: 900mg
  • the subtitle compound was prepared from the product of step (i) (148mg) and the product of Example 33 step (ii) by the method of Example 33 step (iv) as a pale yellow solid. Yield: 150mg. 5 MS: APCI(+ve) 561 (M+l), APCI (-ve) 559 (M-1) iii) Cs-N-[5-(2-(Aminoethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl-3,5- dimethyl)piperazin- 1-yl] acetamide, hydrochloride salt
  • the subtitle compound was prepared from 4-amino-oxindole (0.19g) (J. Org. Chem., 1983, 48 (15), 2468-72) and chloroacetyl chloride (0.1ml) by the method of Example 15 step (i). Yield: 0.25g
  • the subtitle compound was prepared from the product of step (i) (0.24g) and 1,1 -dimethyl, 3,8-diaza-bicyclo[3.2. l]octane-8-carboxylate (0.26g) by the method of Example 19 step (i) Yield: 0.8g
  • step (ii) (0.8g) was dissolved in 2M hydrogen chloride in 1,4-dioxane (10ml), 1,4-dioxane (10ml), methanol (10ml) and the reaction mixture was stirred at ambient temperature for 2 hours. The solvents evaporated under reduced pressure to dryness. Yield: 0.8g
  • the subtitle compound was prepared from 3-fluoro-2-methylaniline (0.232g) and chloroacetyl chloride (0.164ml) by the method of Example 33 step (iii) as a beige solid. 5 Yield: 0.3g
  • the subtitle compound was prepared from the product of step (i) (179mg) and 1,1- dimethyl-3,8-diaza-bicyclo[3.2.1]octane-8-carboxylate (0.2g) by the method of Example 33 step (iv) as a white solid. Yield: 305mg
  • the subtitle compound was prepared from the product of step (ii) (303mg) by the method 20 of Example 27 step (iv) as a white solid. Yield: 305mg
  • Example 20 step (iv) The trifluoroacetate salt of Example 20 step (iv) was converted to the free base by use of aqueous 2N NaOH solution followed by extraction with ethyl acetate. The extracts were dried (MgSO 4 ), filtered and evaporated to dryness, leaving an oil which crystallised on standing.
  • step (i) A mixture ofthe product of step (i) (0.53g), potassium carbonate (0.66g) and benzenesulphonyl chloride (0.32ml) in acetone (10ml) and 1,4-dioxane (10ml) was stirred at ambient temperature for 4 hours. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with water, saturated sodium bicarbonate and brine, dried (MgSO 4 ) and evaporated. The product was purified by silica gel chromatography eluting with 0.5% ethanol in dichloromethane. Yield 0.29g.
  • step (ii) A solution ofthe product of step (ii) (0.29g) in ethanol (5ml) was treated with 1ml of IN sodium hydroxide solution. After 1 hour at ambient temperature the reaction mixture was acidified with 2N hydrochloric acid to pH4 and evaporated to dryness to give a white solid. This was dried at 40° C in vacuo over phosphorous pentoxide for 2 hours and used directly in the next step.
  • Example 33 step (ii) 152mg
  • Example 36 step (i) 132mg
  • Example 33 step (iv) a white solid.
  • Purification was by silica gel chromatography eluting with iso-hexane/acetone (7:3). Yield: 58mg.
  • step (iv) The title compound was prepared from the product of step (iv) (0.24g) by the method of Example 27 step (iv) as a white solid. Purification was by reverse phase HPLC eluting with aq. l%ammonium acetate/acetonitrile (95% to 60%). Yield. 80mg
  • the subtitle compound was prepared from the product of Example 33 step (ii) (0.42g) and the product of Example 50 step (iii) (0.55g) by the method of Example 33 step (iv). Purification was by silica gel chromatography eluting with dichloromethane/ethyl acetate (95:5) to give the subtitle compound as colourles gum. Yield: 0.23g
  • the subtitle compound was prepared from the product of step (ii) (0.56g) and the product of Example 50 step (iii) (0.37g) by the method of Example 33 step (iv). Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane (9:1) to give the subtitle compound as a white solid. Yield. 0.18g
  • the subtitle compound was prepared from the product of Example 27 step (ii) (O.lg) by the method of Example 33 step (iii) as a beige foam. Yield:0.15g
  • the subtitle compound was prepared from the product of Example 52 step (ii) (0.2g) and the product of step (i) (0.21g) by the method of Example 33 step (iv). Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane (9:1) to give the subtitle compound as a white solid. Yield. 0.068g
  • the subtitle compound was prepared from the product of Example 52 step (ii) (0.64g) and the product from Example 33 step (iii) (0.59g) by the method of Example 33 step (iv). Yield. 0.45g MS: APCI(+ve) 563 (M+l), APCI(-ve) 561 (M-1)
  • step (i) c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
  • 4-dimethylaminopyridine (0.14g) in pyridine (2.0ml) was stirred while 3-cyanobenzenesulphonyl chloride (0.46g) was added.
  • the mixture was stirred for 10 minutes after which it solidified. After 1 hour the solid was triturated with water and filtered off. It was purified by chromatography on silica eluting with ethyl acetate/iso-hexane (1:1) to give the title compound as a pale yellow solid. Yield: 0.22g.
  • Example 56 c s-N-(2-Methylphenyl)-2-[4-(3-nitrobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]- acetamide
  • the title compound was prepared from the product of Example 55 step (i) and 3- nitrobenzenesulphonyl chloride by the method of Example 55 step (ii) as an off white solid. Yield: 3.06g
  • step (i) 4-N,N-dimethylaminopyridine (31mg) in pyridine (0.5ml) was treated in one portion with 3-cyanobenzenesuphonyl chloride (leq) and then immediately heated for 30 minutes. The mixture was partitioned between dichloromethane and water. The organic phase collected, dried (MgSO 4 ) and solvent removed under reduced pressure. The reisdue was purified by reverse phase HPLC eluting with 0.1% aq. ammonium acetate/acetontrile (95%> to 50%) as eluant to give the title compound as a white solid. Yield: 8mg
  • Example 65 cis-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide i) c s-[3,5-Dimethylpiperazm-l-yl]-N-(3-methoxy-2-methylphenyl)acetamide
  • the subtitle compound was prepared from 2-chloro-N-(3-methoxy-2- methylphenyl)acetamide (10.72g) and cts-2,6-dimethylpiperazine (6.29g) by the method of Example 58 step (i) as a tan solid. Yield: 13.13g
  • Example 58 step (i) The title compond was prepared from the product of Example 58 step (i) (0.503mmol) and l-methylimidazole-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 16mg
  • Example 68 s-2-[4-(l-MethyUmidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide
  • the title compound was prepared from the product of Example 65 step (i) (0.503mmol) and l-methylimidazol-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 3 lmg
  • Example 70 c/s-2-[4-(3-Methanesulphonylbenzeuesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide i) 2-Chloro-N-(2-trifluoromethylphenyl)acetamide The subtitle compound was prepared from 2-trifluoromethylaniline(10.5g) and chloroacetyl chloride (6.8ml) by the method of Example 33 step (iii) as a white solid. Yield: 13.7g
  • the subtitle compound was prepared from the product of step (i) (7.6g ) and cis-2,6- dimethylpiperazine (3.53g) by the method of Example 58 step (i) as a white solid. Yield: 8.57g
  • step (iii) (0.25g) and 3-methanesulphonylbenzenesulphonyl chloride (0.606g), potassium carbonate (0.275g) in 2,6-lutidine(0.5ml) were heated in a lOOWatt microwave oven at 120 °C for lOmin. The mixture was then partitioned between dichloromethane and water. The organic phase collected, dried (MgSO 4 ), and the solvent evaporated under reduced pressure. Purification was by revese phase HPLC eluting with l%t ⁇ q. ammonium acetate/acetonitrile (95% to 60%) to give the title compound as a white solid. Yield: O.lg
  • Example 72 c/5-2-[4-(l,l,2,2-Tetrahydroisoqumj in-7-sulphonyl-7-yl)-3,5-dimethylpiperazm-l-yl]- N-(2,6-dimethylphenyl)acetamide i) cw-3,5-Dimethylpiperazin-l-yl]-N-(2,6-dimethylphenyl)acetamide
  • the subtitle compound was prepared from 2-chloro-N-(2,6-dimethylphenyl)acetamide (6.54g) and cz -2,6-dimethylpiperazine (3.78 ' g) by the method of Example 58 step (i) as a white solid. Yield:7.85g MS: APCI(+ve): 276(M+1)
  • the subtitle compound was prepared from the product of step (i) (0.165g) and N-trifluoroacetyl(l,l,2,2-tetrahydroisoquinolin)-7-sulphonyl chloride (0.39g) by the method of Example 58 step (ii) as a white solid. Yield: 96mg
  • step (ii) The product from step (ii) (90mg), potassium carbonate (200mg) in water (10ml) and methanol (15ml) were heated at reflux for 2h. Water (50ml) was added and the mixture extracted with ethyl acetate. The organic phase collected, dried (MgSO 4 ) and solvent evaporated under reduced pressure to give the title compound as a white solid. Yield: 55mg
  • Example 75 cis-2-[4-(2-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2,6- dimethylphenyl)acetamide, hydrochloride salt
  • the free base ofthe title compound was prepared from the product of Example 72 step (i) (0.165g) and 2-cyanobenzenesulphonyl chloride (0.15g) by the method of Example 58 step (ii).
  • the title compound was prepared by adding IM hydrogen chloride in diethyl ether to a solution ofthe free base to produce a white precipitate. This was filtered and further washed with diethyl ether to give the title compound as a white solid. Yield: 20mg
  • Example 77 2-[8-(Isqumolin-l-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2-methylphenyl)acetamide
  • the title compound was prepared from the product Example 20 step (iv) (0.32g) and 1- chloroisoquinoline (0.14g) by the method of Example 52 step (i) as a beige solid. Yield: 40mg
  • 2,6-Lutidine (0.3ml) was added to a mixture of 4-acetamidobenzenesulphonyl chloride (0.25g), potassium carbonate (0.18g) and the product of Example 55 step (i) (0.14g).
  • the reaction mixture was heated at 100°C for 5 minutes in a 100 Watt microwave oven, allowed to cool and partitioned between dichloromethane and water.
  • the organic phase was washed with brine, dried (MgSO 4 ) and evaporated under reduced pressure. Purification was by reverse phase HPLC (acetonitrile/ 1% aq.ammonium acetate). Yield 15mg.
  • Example 79 cts-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide
  • the title compound was prepared from the product of Example 70 step (i) (0.189g) and 3- cyanobenzenesulphonyl chloride (0.15g) by the method of Example 58 step (ii) as a white solid. Yield: 17mg
  • Example 80 c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methauesuIphonamidophenyl)acetamide i) c 5-l-(3-Cyanobenzenesulphonyl)-2,6-dimethyl-4-phenyh ⁇ ethylpiperazme
  • Example 84 c 5-2-[4-(5-Chloro-l,3-dimethylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl]-N-(3-methoxy-2-methylphenyl)acetamide
  • the title compound was prepared from the product of Example 65 step (i) (0.503mmol) and 5-chloro-l,3-dimethyl-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 6mg
  • Example 87 c 5-2-[4-(5-Chloro-l,3-dimethylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl] -N-(2-methylphenyl)acetamide
  • the title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 5-chloro-l,3-dimethylpyrazole-4-sulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: 12mg
  • Example 90 c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3-methoxy-2- methylphenyl)acetamide
  • T ie title compound was prepared from the product of Example 65 step (i) (0.503mmol) and 3-cyanobenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 21mg
  • Example 92 ct5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-cyano-2- methylphenyl)acetamide i) 2-Chloro-N-(5-cyano-2-methylphenyl)acetamide The subtitle compound was prepared from 5-cyano-2-methylaniline (1.6g) and chloroacetyl chloride (1.1ml) by the method of Example 33 step (iii) as a white solid. Yield: 1.85g
  • Ther subtitle compound was prepared from 5-acetamido-2-methylaniline (0.5g) and chloroacetyl chloride (0.27ml) by the method of Example 33 step (iii) as a beige solid. Yield: 0.55g
  • the subtitle compound was prepared from 2-chloro-N-(quinolin-5-yl)acetamide (lg) (J Indian Chem Soc, 1940, 17, 619-621) and (R)-2-methylpiperazine (0.5g) by the method of Example 58 step (i) as a white solid. Yield: 1.4g
  • the subtitle compound was prepared from 5-methanesulphonyl-2-methylaniline (0.82g) and chloroacetyl chloride (0.72ml) by the method of Example 33 step (iii) as a beige solid. Yield: 0.6 lg
  • the subtitle compound was prepared from the product of step (i) (18.3g) and chloroacetyl chloride (17.5ml) by the method of Example 33 step (iii) as a beige solid. Yield: 23g
  • the subtitle compound was prepared from the product of step (ii) (1.25g) and the product of Example 80 step (ii) (lg) by the method of Example 80 step (iii) as a beige foam. Yield: 1.3g
  • step (v) cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- amino-l-piperidinyl)methyl)phenyl]acetamide
  • the crude product from step (v) (0.2g) was treated with 1,1-dimethylethyl, 4- aminopiperidinyl-4-carboxylate (0.13g) in tetrahydrofuran (2ml) at 55 °C for 24h. The solvent was evaporated under reduced pressure. The residue was then treated with 4M hydrogen chloride in 1,4-dioxane (3ml) for 5h. The solvents were then evaporated under reduced pressure. Purification was by reverse phase HPLC to give the title compound as a white solid. Yield. 0.1 g
  • the subtitle compound was prepared from (R)- 1,1 -dimethylethyl, 3-methylpiperazin- 1-yl- 1 -carboxylate (4g) (J. Med. Chem, 1993, 36(6), 690) and 4-acetamidobenzenesulphonyl chloride (4.68g) by the method of Example 58 step (ii) as white solid. Yield: 4.9g
  • Example 97 step (v) The title compound was prepared from the product of Example 97 step (v) (0.2g) and 1,1- dimethylethyl, piperazine- 1 -carboxylate (0.12g) by the method of Example 97 step (vi) to give the title compound as a white solid. Yield: 74mg
  • Example 101 s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- piperidinylamino)methyl)phenyl)acetamide
  • the title compound was prepared from the product of Example 97 step (v) (0.2g) and 1,1- dimethylethyl, 4-aminopiperidinyl-l -carboxylate (0.12g) by the method of Example 97 step (vi) as a white solid. Yield: 34mg
  • Example 102 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- morpholinyl)methyl)phenyl)acetamide
  • Example_97 step (vi) The title compound was prepared from the product of Example 97 step (v) (0.2g) and morpholine (0.058g) by the method of Example_97 step (vi). The solvents evaporated under reduced pressure and the residue purified by reverse phase HPLC to give the title compound as a white solid. Yield: 97mg
  • Example 97 step (v) 0.2g
  • ethanolamine 0.4 lg
  • the solvents evaporated under reduced pressure and the residue purified by reverse phase HPLC to give the title compound as a white solid. Yield: 37mg
  • Example 104 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(S,S)- (2,5-diazabicy clo [2.2.1 ] hept-2-yl)methy l)phenyl)acetamide
  • Example 97 step (v) The title compound was prepared from the product of Example 97 step (v) (0.2g) and 1,1- dimethylethyl, (S,S)-2,5-diazabicyclo[2.2.1]heptane-5-carboxylate (0.13g) by the method of Example 97 step (vi) as a white solid. Yield: 107mg
  • the subtitle compound was prepared from the product of step (i) (2.5g) by the method of Example 27 step (iv) as a white solid. Yield: 2.5g
  • the subtitle compound was prepared from the product of step (i) (4.13g) and chloroacetyl chloride (1.5ml) by the method of Example 33 step (iii) as a beige solid. Yield: 3.12g
  • the subtitle compound was prepared from the product of step (iii) (1.4g) and IM tetrabutylammonium fluoride in tetrahydrofuran (2.7ml) by the method of Example 97 step (iv) as a white solid. Yield: lg
  • step (iv) cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2-methyl-3- iodomethyl)phenyl] acetamide
  • the product from step (iv) (O.lg) in tetrahydrofuran (2ml), N,N-diisopropylethylamine (0.15ml), potassium iodide (2mg) was treated with methanesulphonyl chloride (0.34ml). After stirring at ambient temperature for 40h. The solvent was evaporated under reduced pressure to leave a beige gum. This was used directly in the next step.
  • the title compound was prepared from the product of Example 106 step (v) (0.2g) and 1,1- dimethylethyl, 4-aminopiperidinyl-l -carboxylate (0.12g) by the method of Example 106 step (vi) as a white solid. Yield: 38mg MS: APCI(+ve) 539(M+1)
  • Example 106 step (v) The title compound was prepared from the product of Example 106 step (v) (0.2g) and 1,1- dimethylethyl, piperazine- 1 -carboxylate (0.12g) by the method of Example 106 step (vi) as a white solid. Yield: 74mg
  • Example 109 c 5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(S,S)- (2,5-diazabicyclo[2.2.1]hept-2-yl)methyl)phenyl)acetamide
  • the title compound was prepared from the product of Example 106 step (v) (0.2g) and 1,1- dimethylethyl, (S,S)-2,5-diazabicyclo[2.2.1]heptane-5-carboxylate (0.13g) by the method of Example 106 step (vi) as a white solid. Yield: 82mg
  • Example 106 step (v) The title compound was prepare from the product of Example 106 step (v) (0.2g) and morpholine (0.058g) by the method of Example 106 step (vi) as a white solid. Yield: 69mg
  • the subtitle compound was prepared from 3-amino-2-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 15g
  • step (i) The product from step (i) (5g), PyBrop (9.82g), chloroacetic acid (1.99g), N,N- diisopropylethylamine (11ml) in dichloromethane (100ml) were stirred at ambient temperature for 16h. The mixture was partitioned between water and dichloromethane, the organic phase collected, dried (MgSO 4 ) and solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with 10% diethyl ether in iso-hexane containing 1% triethylamine to give the subtitle compound as a pale yellow oil. Yield: 3.5g
  • the subtitle compound was prepared from the product of step (ii) (lg) and the product of
  • Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a beige solid. Yield: 1.6g 'H NMR ⁇ (CDCI 3 ) 8.67(s, IH), 8.12(s, IH), 8.03(4 IH), 7.85(4 IH), 7.67(t, IH), 7.59(4 IH), 7.07(t, IH), 6.64(d, IH), 4.05-4.10(m, 2H), 3.10(s, 2H), 2.73(d, 2H), 2.19(4 2H), 2.10(s, 3H), 1.54(s, 6H), 1.01(s, 9H), 0.22(s, 6H)
  • the subtitle compound was prepared from the product of step (iii) (1.6g) and tetrabutylammonium fluoride (3.18ml) by the method of Example 97 step (iv) as a white solid Yield: 0.5g
  • Example 111 step (iv) (O.lg) and ( ⁇ ) l-methyl-3-chloromethylpiperidine (83mg) by the method of Example 111 step (v) as a white solid. Yield: 19mg
  • the subtitle compound was prepared from 4-amino-3-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 14g
  • the subitle compound was prepared from the product of step (ii) (lg) and the product of Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a white solid. Yield: 1.6g
  • the subtitle compound was prepared from the product of step (iii) (1.6g) and tetrabutylammonium fluoride (3.21ml) by the method of Example 97 step (iv) as a white solid Yield: 0.4g
  • the subtitle compound was prepared from 3-amino-4-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 15g
  • the subtitle compound was prepared from the product of step (i) (5g) by the method of Example 111 step (ii) as pale yellow oil. Yield: 5.3g
  • the subtitle compound was prepared from the product of step (ii) (lg) and the product of Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a white solid. Yield: l. ' 8g
  • the subtitle compound was prepared from the product of step (iii) (1.81g) and tetrabutylammonium fluoride (3.24ml) by the method of Example 97 step (iv) as a white solid Yield: 0.8g
  • the subtitle compound was prepared from the product of step (i) (5g) by the method of Example 111 step (ii) as pale yellow oil. Yield: 4.6g
  • the subitle compound was prepared from the product of step (ii) (lg) and the product of Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a white solid. This product was used directly in the next step
  • the subtitle compound was prepared from the product of step (iii) (2g) and tetrabutylammonium fluoride (3.18ml) by the method of Example 97 step (iv) as a white solid Yield: 0.8g
  • the subtitle compound was prepared from the product of step (ii) (0.82g) and the product of Example 111 step (ii) (lg) by the method of Example 80 step (iii) as a white solid. Yield: 1.6g
  • the subtitle compound was prepared from the product of step (iii) (1.51g) by the method of Example 111 step (iv) as a white solid. Yield: 0.4g
  • bbATP benzoylbenzoyl adenosine triphosphate
  • each ofthe title compounds ofthe Examples was tested for antagonist activity at the P2X 7 receptor.
  • the test was performed in 96-well flat bottomed microtitre plates, the wells being filled with 250 ⁇ l of test solution comprising 200 ⁇ l of a

Abstract

The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.

Description

Novel piperidine and piperazine derivatives
The present invention relates to piperidine and piperazine derivatives, processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
The P2X7 receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflarmnatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B). Activation ofthe P2X7 receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin- lβ (IL-lβ) and giant cell formation (macrophages/ icroglial cells), degranulation (mast cells) and L-selectin shedding (lymphocytes). P2X7 receptors are also located on antigen-presenting cells
(APC), keratinocytes, salivary acinar cells (parotid cells), hepatocytes, erythrocytes, erythroleukaemic cells, monocytes, fibroblasts, bone marrow cells, neurones and renal mesangial cells.
It would be desirable to make compounds effective as P2X7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X7 receptor may play a role.
In accordance with the present invention, there is therefore provided a compound of general formula
Figure imgf000002_0001
wherein,
X represents a nitrogen atom or a group C(R ); Y represents an oxygen or sulphur atom or a group NR , preferably an oxygen atom;
1 2 either R and R each independently represent a hydrogen atom or a Cι-C alkyl
1 2 group but do not both simultaneously represent a hydrogen atom, or R and R together represent a group -CH2ZCH2-; Z represents a bond, an oxygen or sulphur atom or a group CH2 or NR , and is preferably a bond; is O or 1; R represents a 5- to 10-membered unsaturated ring system which may comprise from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, nitro, cyano, NR8R9, CrC4 alkyl-C(O)NH-, NHR12C(O)-,
CrC4 alkyl-SO2-, CrC4 alkyl-SO2NH-, CrC4 alkyl-NHSO2-, CrC4 alkoxy, and
C;[-C4 alkyl optionally substituted by one or more fluorine atoms;
R represents a phenyl or pyridinyl group, each of which is substituted in an ortho position with a substituent selected from halogen, C^-Q^ alkoxy, 0^4 alkylthio, and
CrC4 alkyl optionally substituted by one or more fluorine atoms, the phenyl or pyridinyl group being optionally further substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, CrC4 alkylthio, CrC4 alkyl-NH-, NHR13-CrC4 alkyl-, CrC4 alkyl-SO2-, CrC4 alkyl-SO2NH-, CrC4 alkyl-NHSO2-, CrC4 alkyl-C(O)NH-, CrC4 alkyl-NHC(O)-, -D-G, CrQ4 alkoxy optionally substituted by -NR R or by R , and Ci -C4 alkyl optionally substituted by one or more fluorine atoms or by one or more hydroxyl groups, or R represents a 9- or 10-membered unsaturated bicyclic ring system which may comprise from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the bicyclic ring system being optionally substituted by one or more substituents independently selected from halogen, oxo, CrC4 alkyl, CrC4 alkoxy, Cι-C4 alkylthio and -NR10Rπ;
D represents an oxygen atom or a group (CH2)n or CH2NH; n is i, 2 or 3; G represents a piperazinyl, morpholinyl or 2,5-diazabicyclo[2.2.1]heptyl group, or G represents a piperidinyl group optionally substituted by amino (-NH2);
R represents a hydrogen atom, or a hydroxyl or C1-C4 alkoxy group;
R represents a hydrogen atom, or a cyano, nitro, hydroxyl, Cι-C4 alkyl or C1-C alkoxy group;
R 7 , R 8 and R 9 each independently represent a hydrogen atom or a CrC4 alkyl group;
R and R each independently represent a hydrogen atom or a CrC alkyl group, or R and R together with the nitrogen atom to which they are attached form a 5- or 6- membered saturated heterocyclic ring comprising one or two ring nitrogen atoms; R 12 represents a hydrogen atom, or a Ci -C4 alkyl group optionally substituted by amino (-NH2); R 13 represents a hydrogen atom, or a C C4 alkyl group optionally substituted by hydroxyl;
R and R each independently represent a hydrogen atom or a C C4 alkyl group optionally substituted by hydroxyl, or R 14 and R 15 together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprising one or two ring nitrogen atoms; and
R represents a l-(Cι-C4-alkyι)-piperidinyl group; with the proviso that when m is 0, X is N and Y is O, then R does not represent 2-benzothiazolyl; or a pharmaceutically acceptable salt or solvate thereof.
In the context ofthe present specification, unless otherwise indicated, an alkyl substituent or alkyl moiety in a substituent group may be linear or branched. In the present invention, an alkyl group or moiety may contain up to 4 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and t-butyl.
When the substituent group is NHR 13 -C1-C4 alkyl-, it should be appreciated that the NHR 13 moiety may be attached to a terminal or internal carbon atom ofthe alkyl moiety and when the substituent group is alkoxy substituted by -NR R , the alkoxy group will contain at least 2 carbon atoms and the group -NR R is not attached to the same carbon atom to which the oxygen atom is attached.
3 R represents a 5- to 10-membered unsaturated ring system which may comprise 1, 2, 3 or 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more (i.e. at least one), e.g. one, two or three, substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), nitro, cyano, NRδR9, CrC4 alkyl-C(O)NH- (e.g. CH3C(O)NH-), NHR12C(O)- (e.g. NH2C(O)-, NH(CH3)C(O)-, (CH3)2NC(O)-, NH2CH2CH2NHC(O)-), CrC4 alkyl- SO2- (e.g. CH3SO2-), CrC4 alkyl-SO2NH- (e.g. CH3SO2NH-), CrC4 alkyl-NHSO2- (e.g. CH3NHSO2-), CrC4, preferably CrC2, alkoxy, and CrC4, preferably ^-C^ alkyl optionally substituted by one or more (i.e. at least one), e.g. one, two, three or four, fluorine atoms (e.g. trifluoromethyl). Specific substituents that may be mentioned include: methyl, amino (-NH2), cyano, methoxy, chloro, nitro, NH2C(O)-, CH3C(O)NH-, CH3SO2-, CH3SO2NH- andNH2CH2CH2NHC(O)-.
The ring system may be monocyclic or poly cyclic. If polycyclic, e.g. bicyclic, the two rings may "be fused to one another or may be joined by a bond. If the ring system is bicyclic, it is preferred that the rings are fused to one another. Examples of ring systems that may be used include phenyl, pyridinyl, pyrimidinyl, naphthyl, furanyl, pyrryl, thieiryl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, quinolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, triazinyl, benzothiazolyl, benzooxazolyl, imidazopyrazinyl, triazolopyrazinyl, naphthyridinyl, furopyridinyl, ύuopyranopyrimidinyl, pyridazinyl, quinazolinyl, pteridinyl, triazolopyrimidinyl, triazolopyrazinyl, thiapurinyl, oxapurinyl, deazapurinyl, Mazolopyrimidinyl, indolinyl, benzooxadiazolyl, benzothiadiazolyl, tetrahydroisoquinilinyl, 2-(isoxazol-3-yl)thienyl, and thienopyrimidinyl. Preferred ring systems are phenyl, thienopyrimidinyl, purinyl, pyrimidinyl, thiazolopyrimidinyl, quinazolinyl, benzooxadiazolyl, benzothiadiazolyl, thienyl, imidazolyl, tetrahydroisoquinilinyl, isoquinolinyl, pyrazolyl, isoxazolyl, 2-(isoxazol-3-yl)thienyl and pyridinyl.
4 R may represent a phenyl or pyπdmyl group comprising at least one substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), Cι-C , preferably CrC2, alkoxy, CrC , preferably C1-C2, alkylthio or CrC4, preferably CrC2, alkyl optionally substituted by one or more (i.e. at least one) fluorine atoms (e.g. trifluoromethyl), which substituent is attached to the phenyl or pyridinyl group at a position ortho (*) with respect to the point of attachment of R to the rest ofthe molecule, for example as illustrated below. Examples of preferred ortho substituents include chloro, methyl and trifluoromethyl.
Figure imgf000006_0001
or
Figure imgf000006_0002
or
Figure imgf000007_0001
The phenyl or pyridinyl group may be optionally further substituted by one or more (i.e. at least one) (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, hydroxyl, Cι-C alkylthio (e.g. methylthio or ethylthio), -C4 alkyl-NH- (e.g. methylamino or ethylamino), NHR13-CrC4 alkyl-, CrC4, preferably CrC2, alkyl-SO2-, CrC4, preferably CrC2, alkyl-SO2NH-, CrC4, preferably CrC2, alkyl-NHSO2-, CrC4, preferably CrC2, alkyl-C(O)NH-, C,-C4, preferably CrC2, alkyl-NHC(O)-, -D-G, CrC4 alkoxy optionally substituted by -NR R or by R , and Cι-C4, preferably CrC2, alkyl optionally substituted by one or more (i.e. at least one) fluorine atoms (e.g. trifluoromethyl) or by one or more (i.e. at least one) hydroxyl groups (e.g. hydroxymethyl).
Alternatively, R may represent a 9- or 10-membered unsaturated fused bicyclic ring system which may comprise 1, 2, 3 or 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more (i.e. at least one) (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), oxo, C C4, preferably Cι-C2, alkyl, C'1-C4, preferably C C2, alkoxy, CrC , preferably Cι-C , alkylthio and NR R . Examples of suitable bicyclic ring systems include naphthyl, benzimidazolyl, quinolinyl, indolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, benzthiazolyl, benzoxazolyl and quinazolinyl. An example of an unsaturated fused bicyclic ring system substituted by an oxo group is oxindolyl. D represents an oxygen atom or a group (CH2)n or CH2NH (in that orientation), where n is 1, 2 or 3.
G represents a piperazinyl, morpholinyl or 2,5-diazabicyclo[2.2.1]heptyl group, or G represents a piperidinyl group optionally substituted by at least one amino group (e.g. 1 -piperidinyl, 4-piperidinyl, 1 -piperazinyl, 1 -morpholinyl or 4-amino-l -piperidinyl).
R represents a hydrogen atom, or a hydroxyl or Cι-C alkoxy group. In a preferred embodiment, R represents a hydrogen atom.
R represents a hydrogen atom, or a cyano, nitro, hydroxyl,
Figure imgf000008_0001
preferably C1-C2, alkyl or Cj- i, preferably Cj-02, alkoxy group.
R 7 , R 8 and R 9 each independently represent a hydrogen atom or a C C4, preferably C1-C2, alkyl group.
R and R each independently represent a hydrogen atom or a Cι-C , preferably C1-C2, alkyl group, or R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprismg one or two ring nitrogen atoms (e.g. pyrrolidinyl, piperidinyl or piperazinyl).
12
R represents a hydrogen atom, or a C1-C4, preferably Cι-C2, alkyl group optionally substituted by at least one amino group (-NH2).
13 R represents a hydrogen atom, or a CrC4, preferably CrC2, alkyl group optionally substituted by at least one hydroxyl group.
14 15
R and R each independently represent a hydrogen atom or a CrC4, preferably
C -C2, alkyl group optionally substituted by at least one hydroxyl group, or R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprising one or two ring nitrogen atoms (e.g. pyrrolidinyl, piperidinyl or piperazinyl).
R represents a l-(C1-C4-alkyl)-piperidinyl group, e.g. 1-methylpiperidinyl, specifically l-methylpiperidin-3-yl.
Preferred compounds ofthe invention include:
(+)-N-(2,6-Dimethylphenyl)-2-(3-methyl-4-(thieno[2,3-<flpyrimidin-4-yl)piperazin-l- yl)acetamide, cw-[2-(3,5-Dimethyl-4-(tMeno[2,3-^pyrimidin-4-yl)piperazin-l-yl)]-N-(2,6- dimethylρhenyl)acetamide,
(+)-2-[3-Methyl-4-(4-methylphenyl)piperazin-l-yl]-N-(2,6-dimethylphenyl) acetamide, cz5-N-[3-Hydroxymethyl-2-memylρhenyl]-2-(3,5-dime l-4-(thieno[2,3- ]pyrimidin-4-yl)piperazin- 1 -yl)acetamide,
(R)-2-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3-ethylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide, cz's-2-[3,5-Djmemyl-4-(thieno[2,3-βTlpyrimidin-4-yl)piperazin-l-yl]-N-(2- methylphenyl)acetamide, cw-N-(2-CUorophenyl)-2-[3,5-dimethyl-4-(tMeno[2,3- t pyrimidin-4-yl)ρiperazin- 1 - yl]acetamide, c -?-N-(2-Chlorophenyl)-2-[3,5-dimethyl-4-(9-methyl-9H-ρurin-6yl)piperazin-l- yl] acetamide, cw-2-(3,5-Dimeώyl-4-(tm^no[2,3--φyrir^ 5-yl)acetamide, c/5-2-(3,5-Dimemyl-4-thieno[2,3-ύTIpyrimidin-4-yl)piperazin-l-yl)-N-(quinolin-5- yl)acetamide, c^-2-(3,5-Dimethyl-4-(thieno[2,3-rf]pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- methylsulphonamidophenyl)acetamide, cw-2-(3,5-Dimethyl-4-(thieno[2,3- ]pyrimidin-4-yl)piperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide, ew-2-(3,5-Dimemyl-4-(tMeno[2,3-<^pyrimidin-4-yl)piperazin-l-yl)-N-(3- methylpyridin-2-yl)acetamide, cw-2-(3,5-Dimethyl-4-(thieno[2,3-c Ipyrimidin-4-yl)piperazin-l-yl)-N-(isoquinolin- l-yl)acetamide, cw-4-(4-Amino-5-cy-mopyrimidin-2-yl)-3,5-dimethylpiperazin-l-yl)-N-(2- chlorophenyl)acetamide, cϊ5-2-(4-Benzenesulphonyl-3,5-dimethylpiperazin-l-yl)-N-(2-chloro- phenyl)acetamide,
(+)-N-(2,6-Dimemylphenyl)-2-[(3-memyl-4-tWazolo(5,4-(^pyrimidin-7-yl)ρiperazin- l-yl]acetamide, ct-f-N-(2-Chlorophenyl)-2-[(3,5-dimethyl-4-quinazolin-4-yl)piperazin-l- yl] acetamide, N-(2-Chlorophenyl)-2-[(8-(thieno[2,3-(i]ρyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-
3-yl]acetamide,
N-(2-Methylphenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
2-[8-(9-Methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(quinolin-5- yl)acetamide, N-(Quinolin-5-yl)-2-[8-thiazolo[5,4- lpyrimidin-7-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
N-(2-Methylphenyl)-2-[(8-thiazolo[5,4-(i]pyrimidin-7-yl)-3,8-diazabicyclo[3.2.1]oct- 3-yl]acetamide, N-(2-Methyl-5-(methylsulphonyl)amidophenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3 , 8- diazabicyclo[3.2.1 ]oct-3-yl]acetamide,
N-[2-Memyl-5-(methylsulphonyl)amidophenyl]-2-[(8-thiazolo[5,4-(i]pyrimidin-7-yl)- 3,8-diazabicyclo[3.2.1]oct-3-yl]acetamide,
N-[2-Methyl-5-(memylsulphonyl)amidophenyl]-2-[4-(thieno[2,3-(i]pyrimidin-4-yl)- 3,8-diazabicyclo[3.2. l]oct-3-yl] acetamide, cw-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- (l-piperazinylmethyl)phenyl)acetamide, hydrochloride salt,
N-(2-Methylphenyl)-2-[(8-(thieno[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl]acetamide, 5 N-[5-(Methanesulphonylamido-2-methylphenyl)-2-[8-(thieno[2,3-d]pyrimidin-4-yl)-8- azabicyclo[3.2.1 ]oct-3-yl]acetamide,
N-(2-Methyl-5-(l-ρiperazinylmethyl)phenyl)-2-[(8-( ieno[2,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1 ]oct-3-yl]acetamide, cw-N-(5-(2-Aminoemoxy)-2-methyl-ρhenyl)-2-(3,5-dimethyl-4-(thieno[2,3- i o d]pyrimidin-4-yl)piperazin- 1 -yl)acetamide, hydrochloride salt, cz5-N-(5-(2-(N-Methylamino)e oxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4-(thieno[2,3- d]pyrimidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt, cz5-N-(5-(2-(N-Memylamino)ethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl)-3,5- dimethyl)piρerazin- 1 -yl)acetamide, is cz'5'-N-[5-(2-Aminoethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl-3,5- dimethyl)piρerazin- 1-yl] acetamide, hydrochloride salt,
N-(2-Oxo-2,3-dihydro-lH-indol-4-yl)-2-(8-thieno[2,3-d3pyrimidin-4-yl-3,8- diazabicyclo[3.2.1]oct-3-yl)acetamide
N-(3-Fluoro-2-methyl-phenyl)-2-((8-quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- 20 yl)acetamide,
>„ N-(2-Methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
N-(3-Fluoro-2-methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicycIo[3.2.1]oct-3- yl] acetamide, 25 cz5-N-(3-Fluoro-2-methyl-phenyl)-2-(4-benzenesulphonyl)-3,5-dimethyl)piperazin-l- yl)acetamide,
N-(2-Methylphenyl)-2-[8-(3-cyanobenzenesulphonyl)-3,8-diazabicyclo[3.2.1 ]oct-3- yl]acetamide,
2-[8-(3-Methoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- 30 methylphenyl)acetamide, 2-[8-(Benzo[l,2,5]oxadiazole-4-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyι)acetamide,
2-[8-(Benzo[l,2,5]thiadiazole-4-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, 2-[8-(5-Chlorothieno-2-yl)sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide,
2-[8-(2-Chlorobenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide,
2-[8-(5-Chloro-2-methoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide,
2-[8-(4-Acetylaminomethoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N- (2-methylphenyl)acetamide,
N-(2-Methylρhenyl)-2-[(8-(3-methylthieno[2,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1 ]oct-3-yl]acetamide, cw-2-(3,5-Dimethyl-4-(tMeno[2,3-d]pyrimidin-4-yl)piperazin-l-yl)-N-(l-methyl-lH- benzoimidazol-2-yl)acetamide, cώ-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- (4-piperidinyloxy)phenyl)acetamide, hydrochloride salt, cz5-2-(3,5-Dimethyl-4-benzenesulphonyl)piperazin-l-yl)-N-(2-methyl-5-(4- piperidinyloxy)phenyl)acetamide, cis-2-(3 ,5-Dimethyl-4-(quinazolin-4-yl)piperazin- 1 -yl)-N-(2-methyl-5-(4- piperidinyloxy)phenyl)acetamide, cis-2-(3 ,5-Dimethyl-4-(4-quinazolinyl)piperazin- 1 -yl)-N-(2-methyl-5-(piperazin-4- yl-methyl)phenyl)acetamide, cz5-2-(3,5-Dimethyl-4-(4-quinazolinyl)piperazin- 1 -yl)-N-(2-methyl-5-(2-(N- methylamino)ethoxy)phenyl)acetamide, cz -2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cw-N-(2-Methylphenyl)-2-[4-(3 -nitrobenzenesulphonyl)-3 ,5-dimethylpiperazin- 1 -yl]- acetamide, cz5-2-[4-(3-Aminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cw-2-(3,5-Dimethyl-4-(3-cyanobenzenesulphonyl)piperazin-l-yl)-N-(quinolin-5- yl)acetamide, cw-2-(3,5-Dimethyl-4-(4-cyanobenzenesulphonyl)piperazin-l-yl)-N-(quinolin-5- yl)acetamide, ct>s-2-(4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide, ew-2-(4-(4-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide, cι-?-2-[4-(3-Acetylaminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz*5,-2-[4-(3-Aπιmocarbonylbenzenesulphonyl)-3,5-dimemylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cw-2-[4-(3-Methanesulphonylaminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-
N-(2-methylphenyl)acetamide, cz'5'-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiρerazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide, c 5'-2-[4-(2-Melhanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3- fluoro-2-methylphenyl)acetamide, fis-2-[4-( 1 -Methylimidazol-4-sulphonyl-4-yl)-3 ,5-dimethylpiperazin- 1 -yl]-N- (quinolin-5-yl)acetamide, cz5-2-[4-( 1 -Methylimidazol-4-sulphonyl-4-yl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(3 - methoxy-2-methylphenyl)acetamide, cz'-?-2-[4-( 1 -Methylimidazol-4-sulphonyl-4-yl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(3- fluoro-2-methylphenyl)acetamide, czi'-2-[4-(3-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifiuoromethylphenyl)acetamide, cz'-?-2-[4-(2-Aminoethylaminocarbonylbenzenesulphonyl)-3,5-dimethylpiperazin-l- yl]-N-(2-methylphenyl)acetamide, cis-2-[4-( 1 , 1 ,2,2-Tetrahydroisoquinilin-7-sulphonyl-7-yl)-3 ,5-dimethylpiperazin- 1 - yl]-N-(2,6-dimethylphenyl)acetamide, ezi"-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2,6- dimethylρhenyl)acetamide, ezi,-2-[4-(4-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz5-2-[4-(2-Cyanobenzenesulphonyl)-355-dimethylpiperazin-l-yl]-N-(2,6- dimethylphenyl)acetamide, hydrochloride salt, cz's-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- chlorophenyl)acetamide,
2-[8-(Isquinolin-l-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, cw-2-[4-(4-Acetamidobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz'5'-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methanesulphonamidophenyl)acetamide,
2-[8-(4-Benzenesulphonyl)-3,8-diazabicyclo[3.2.1 ]oct-3-yl]-N-(2- methylphenyl)acetamide,
-„ 2-[8-(2-Benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, cz5-2-[4-(l,2-Dimethylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N- (quinolin-5-yl)acetamide, cz5-2-[4-(5-CMoro-l,3-dimemylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl]-N-(3-methoxy-2-methylphenyl)acetamide,
2-[8-(2-(Isoxazol-3-yl)thiophen-5-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N- (2- methylphenyl)acetamide,
2-[8-(l,l,2,2-Tetrahydroisoquinilin-7-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N- (2-methylphenyl)acetamide, cw-2-[4-(5-Chloro- 1 ,3-dimethylpyrazole-4-sulphonyl-4-yl)-3 ,5-dimethylpiperazin- 1 - yl] -N-(2-methylphenyl)acetamide, eZ5-2-[4-(3,5-Dimethylisoxazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cis-2- [4-(2-Methanesulphonylbenzenesulphonyl)-3 ,5 -dimethylpiperazin- 1 -yl] -N-(2- methylphenyl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3-methoxy-2- methylphenyl)acetamide, cw-2-[4-(4-Methanesulρhonylbenzenesulphonyl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(2- methylphenyl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-cyano-2- methylphenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-acetamido-2- methylphenyl)acetamide, (R)-2-[4-(4-Cyanobenzenesulphonyl)-3-methylpiperazin- 1 -yl]-N-(quinolin-5- yl)acetamide,
(S)-2-[4-(4-Cyanobenzenesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methanesulphonylphenyl)acetamide,
* czs-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- amino- 1 -piperidinyl)methyl)phenyl]acetamide,
(R)-2-[4-(4-Methanesulphonylbenzenesulphonyl)-3-methylpiperazin- 1 -yfJ-N- (quinolin-5-yl)acetamide, (R)-2-[4-(4-Acetamidobenzenesulphonyl)-3 -methylpiperazin- 1 -yl]-N-(quinolin-5- yl)acetamide, ct-?-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- piperazinylmethyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulρhonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- piperidinylamino)methyl)ρhenyl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- morpholinyl)methyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(2- hydroxyethylamino)methyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-
(S,S)-(2,5-diazabicyclo[2.2.1 ]hept-2-yl)methyl)phenyl)acetamide,
(R)-2-[4-(2-Pyridinesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5-yl)acetamide, cz -2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(4- amino- 1 -piperidinyl)methyl)phenyl] acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(4- piperidinylamino)methyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(l- piperazinylmethyl)phenyl)acetamide, cz'5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3- (S,S)-(2,5-diazabicyclo[2.2.1 ]hept-2-yl)methyl)phenyl)acetamide, cz'5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3-(l- morpholinyl)methyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3-(2- (l-pyrrolidinyl)ethoxy)phenyl)acetamide, (±) cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-
3-(l ?methylpiρeridin-3-yl)methoxy)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-4-(2- ( 1 -pyrrolidinyl)ethoxy)phenyl)acetamide,
(±) cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 4-( 1 -methylpiperidin-3 -yl)methoxy)phenyl)acetamide,
(±) cz'i'-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 5 -( 1 -methylpiperidin-3 -yl)methoxy)phenyl)acetamide,
(±) c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 6-(l -methylpiρeridin-3-yl)methoxy)phenyl)acetamide, and cz5-2-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-((2- methyl-3 -(2-( 1 -pyrrolidinyl)ethoxy)phenyl)acetaπιide, and their pharmaceutically acceptable salts and solvates.
The present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises: (a) reacting a compound of general formula
Figure imgf000017_0001
wherein X, Y, R , R and R are as defined in formula (I), with a compound of general formula (III), R 3 -(SO2)m-L 1 , wherein L 1 represents a leaving group (e.g. a halogen atom
3 or triflate) and m and R are as defined in formula (I); or
(b) when X represents a nitrogen atom and Y represents an oxygen atom, reacting a compound of general formula
Figure imgf000017_0002
wherein m, R 1 , R2 and R 3 are as defined in formula (I), with a compound of general fdrmula
Figure imgf000017_0003
wherein L 2 represents a leaving group such as a halogen atom and R 4 • is as defined in formula (I); or
(c) reacting a compound of general formula
Figure imgf000018_0001
3 wherein L represents a leaving group such as a halogen atom or hydroxyl group and m, X,
Y, R 1 , R2 and R 3 are as defined in formula (I), with a compound of general formula (Nil), H2Ν - R , wherein R is as defined in formula (I);
and optionally after (a), (b) or (c) converting the compound of formula (I) obtained to a pharmaceutically acceptable salt or solvate thereof.
Processes (a) and (b) are conveniently carried out in the presence of a base, e.g. a metal carbonate such as potassium or caesium carbonate or a trialkylamine such as triethylamine, preferably N,N-diisopropylethylamine, and in the presence of a polar solvent (e.g. l-methyl-2-pyrrolidinone, dimethylformamide, ethanol, tetrahydrofuran or 1,4-dioxane).
Process (c) is conveniently carried out in the presence of a base and a polar solvent as described above for processes (a) and (b). In addition, a coupling reagent is suitably used, for Example, l,r-carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide or bromo-tris-oxy- tripyrrolidinophosphonium hexafluorophosphate.
Compounds of formulae (II), (III), (IN), (N), (NI) and (Nil) are either commercially available, are well known in the literature or may be prepared easily using known techniques.
It will be appreciated by those skilled in the art that in the processes ofthe present invention certain functional groups such as hydroxyl, carboxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation ofthe compounds of formula (I) may involve at a certain stage the removal of one or more protecting groups.
The protection and deprotection of functional groups is described in 'Protective
Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1991).
It will be appreciated that certain compounds of formula (I) may be converted to further compounds of formula (I) by techniques known in the art such as alkylation, hydrolysis, amide bond formation, esterification or reductive amination.
The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, furnarate, maleate, tartrate, citrate, oxalate, methanesulphonate or jp-toluenesulphonate, or an alkali metal salt such as a sodium or potassium salt.
Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will±ie understood that the invention encompasses all geometric and optical isomers ofthe compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect ofthe present invention.
The compounds of the present invention are advantageous in that they possess pharmacological activity and have utility as modulators of P2X7 receptor activity. They are therefore indicated as pharmaceuticals for use in the treatment or prevention of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, hyperresponsiveness ofthe airway, chronic obstructive pulmonary disease (COPD), bronchitis, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, neurodegenerative disease, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke, peripheral vascular disease and varicose veins.
Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
In the context ofthe present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.
Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history ofthe disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
The invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis, psoriasis, pulmonary disease, e.g. COPD or bronchitis, or diseases ofthe central nervous system, e.g. Alzheimer's disease or stroke) which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined to a patient. For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disease or condition indicated. For effecting immunosuppression, the daily dosage of the compound of formula (I) will typically be in the range from 0.001 mg/kg to 30 mg/kg.
The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.
Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
The invention further provides a process for the preparation of a pharmaceutical composition ofthe invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical composition ofthe invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.
The present invention will now be further explained by reference to the following illustrative examples.
Example 1
(+)-N-(2,6-DimethyIphenyl)-2-(3-methyI-4-(thieno[2,3-ιiIpyrimidin-4-yl)piperazin-l- yl)acetamide
Figure imgf000022_0001
i) (+)-l,l-Dimethylethyl, 3-methyI-4-(thieno[2,3-</]pyrimidin-4-yl)piperazine-l- carboxylate
A solution of 4-ctøoro-thieno[2,3- ]pyrimidine (0.2g) and (+)- 1,1-dimethylethyl, 3-methylpiperazine-l-carboxylate (J. Med. Chem., 1993, 36, 690-698) (0.23g) in ethanol (50ml) was heated under reflux for 24 hours. The solvent was evaporated and the residue purified by flash column chromatography eluting with ethyl acetate/iyσhexane (3:7) to give the subtitle compound as a yellow gum. Yield 0.33g.
MS: APCI(+ve) 335 (M+l, 100%)
ii) (+)-2-Methyl-l-(thieno[2,3-(flpyrimidine-4-yl)piperazine, trifluoroacetic acid salt
A mixture ofthe product from step (i) (0.33g) and trifluoroacetic acid (4 ml) in dichloromethane (5 ml) was stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure. Toluene (20 ml) was added to the residue and then evaporated under reduced pressure to give the crude subtitle compound as a gum. The product was used without further purification in the next step. MS: APCI(+ve) 235 (M+l, 100%)
iii) (+)-N-(2,6-Dimethylphenyl)-2-(3-methyl-4-(thieno [2,3-d] pyrimidin-4-yl)piperazin- l-yl)acetamide
A mixture ofthe product from step (ii) (0.23g), N,N-diisopropylethylamine (0.65g) and 2-chloro-N-(2,6-dimethylphenyl)acetamide (0.2g) in dimethylformamide (4ml) was heated at 80°C for 18 hours. The reaction mixture was cooled and diluted with ethyl acetate. The organic solution was washed with a small volume of water and the solvent evaporated under reduced pressure. The residue was purified by flash cliromatography eluting with ethyl acetate/tsohexane (6:4) to give the product as a gum. The gum was further purified by reverse phase high pressure liquid chromatography (methanol / 0.1% aqueous ammonium acetate, gradient elution 15% to 85% organic phase) to give the title product, after freeze drying, as a beige solid. Yield 0.095g.
MS: APCI(+ve) 396 (M+l ,100%) lK NMR: δ (CDC13) 8.5(2H, s); 7.32(2H, q); 7.13(3H, m); 4.98(1H, bs); 4.60(1H, bd);
3.59(1H, dt); 3.25(2H,q); 3.12(1H, bd); 2.98(1H, d); 2.72(1H, dd); 2.55(1H, dt); 2.28(6H, s); 1.53(3H, d). MP: 184-185 °C
Example 2 ci5-[2-(3,5-Di ethyl-4-(thieno[2,3-ιi]pyriιαidin-4-yl)piperazin-l-yl)]-N-(2,6- dimethylphenyl)acetamide
Figure imgf000023_0001
i) c&-l,l-DimethyIethyl, 3,5-dimethyI-4-(thieno [2,3-d] pyrimidine-4-yl)piperazin-l- carboxylate
A solution of 4-chloro-thieno[2,3-<i]pyrimidine (4.0g), cis- 1,1-dimethylethyl, 3,5- dimethylpiperazine-1 -carboxylate (J. Med. Chem., 1999, 4(7), 1123-1114) (12g) and N,N-diisopropylethylamine (10ml) in l-methyl-2-pyrrolidinone (30ml) was heated at 120 °C for 5 days under nitrogen. The reaction mixture was cooled and diluted with ethyl acetate. The organic solution was washed with water, dried (MgSO4) and the solvent evaporated under reduced pressure. The residue was purified by flash column chromatography eluting with ethyl acetate/zsohexane (2:8) to give the subtitle compound as a beige solid. Yield 5.5g.
MS: APCI(+ve) 349 (M+l, 100%)
ii) α 2,6-Dimethyl-l-(thieno[2,3-rflpyriιnidin-4-yl)piperazine, trifluoroacetic acid salt The subtitle compound was prepared from the product of step (i) (0.15g) by the method of Example 1 step (ii) as a gum. This was used without purification in the next step.
MS: APCI(+ve) 249 (M+1,100%). ) cz5-[2-(3,5-Dimethyl-4-(thieno[2,3-^pyrimidin-4-yl)piperazin-l-yl)]-N-(2,6- dimethylphenyl)acetamide
A mixture ofthe product from step (ii), N,N-diisopropylethylamine (0.37ml) and 2-chloro- N-(2,6-dimethylphenyl)acetamide (0.08g) in l-methyl-2-pyrrolidinone (5ml) was heated at 100°C for 24 hours. The reaction mixture was cooled and diluted with ethyl acetate. The organic solution was washed with a small volume of water, dried (MgSO4) and the solvent evaporated under reduced pressure. The residual red oil was purified by reverse phase high pressure liquid chromatography (acetonitrile / 0.1% aqueous ammonium acetate, gradient elution 20% to 80% organic phase) to give the title product, after freeze drying, as a cream solid. Yield 0.05g. MS: APCI(+ve) 410 (M+l, 100%)
^ NMR: δ (CDC13) 8.5(2H, s); 7.38(1H, d); 7.26(1H, d); 7.14(3H, m); 5.10(2H, bs);
3.29(2H, s); 3.01(2H,d); 2.65(2H, dd); 2.30(6H, s); 1.56(6H, d).
MP: 186-189 °C
Example 3 (+)-2-[3-Methyl-4-(4-methylphenyl)piperazin-l-yl]-N-(2,6-dimethylphenyl) acetamide
Figure imgf000025_0001
The title compound was prepared from (+)-3-methyl-4-(4-methylphenyl)ρiperazine (0.1 g) and 2-chloro-N-(2,6-dimethylphenyl)acetamide (0.1 g) by the method of Example 1 step (iii) as a white solid. Yield 0.056g.
MS: APCI(+ve) 352 (M+1,100%).
^ NMR: δ (CDCI3) 8.63(1H, s); 7.09(5H, m); 6.87(2H, d); 3.78(1H, bm); 3.24(2H, d); 3.17(2H, m); 2.95(1H, m); 2.88(1H, dd); 2.72(2H, m); 2.29(3H, s); 2.26(6H, s); 1.08(3H, d).
Example 4 αs-N-[3-Hydroxymethyl-2-methylphenyl]-2-(3,5-^ 4-yl)piperazin-l-yl)acetamide
Figure imgf000025_0002
i) s-N-[3 (l,l-Dimet yl)-l-dimethylethyl)silyloxymethyl-2-methylphenyl]-2-(3,5- dimethyl-4-(thieno[2,3-^pyrimidjm-4-yl)piperazin-l-yl)acetamide The subtitle compound was prepared from N-(3-((l,l-dimethyl-l- dimethylethyl)silyloxymethyl)-2-methylphenyl)-2-chloroacetamide (Chem. Abs., 1997, 765311) (O.lg) and the product from Example 2 step (ii) (O.lg) by the method of Example 2 step (iii) as a red oil. This was used directly in the next step without further purification.
ii) 5-N-[3-Hydroxymethyl-2-methylphenyl]-2-(3,5-dimethyl-4-(thieno[2,3- < ]pyrimidin-4-yl)piperazin-l-yl)acetamide
The subtitle product from step (i) (0.15g) in anhydrous tetrahydrofuran was treated with a 1M solution of tetrabutyl ammonium fluoride in tetrahydrofiαran (0.31ml) and the mixture stirred at room temperature for 1 hour. The solvent was removed under reduced pressure and the residue purified by high pressure liquid chromatography (acetonitrile / 0.1% aqueous ammonium acetate, gradient elution 20% to 80% organic phase) to give the title compound as a white solid. Yield 0.025g.
MS: APCI(+ve) 426 (M+l, 100%)
^ NMR: δ (CDCI3/DMSO) 8.97(lH,s), 8.49(lH,s), 7.89(lH,d), 7.32(1H, d), 7.26(3H, m),
5.09(2H, bs), 4.74(2H, s), 3.27(2H, s), 2.96(2H, d), 2.63(2H, dd), 2.36(3H, s), 1.58(6H, bs) MP: 203-204°C
Example 5
(R)^-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3-ethylpiperazm-l-yl]-N-(qumolin-5- yl)acetamide
Figure imgf000026_0001
i) (R)-3-Eth l-l -(phenylmethyl)-2,5-piperazinedione To a stirred solution of (R)-N-BOC-2-aminobutyric acid (3.36g) and ethyl N-benzylglycine (4.52g) in dichloromethane (50ml) at 15 °C was added dicyclohexylcarbodiimide (3.59g). The temperature was maintained at 10-15 °C for a further 2h and then allowed to stir at ambient temperature for a further 16h. The mixture was filtered and the mother liquor collected and solvent evaporated under reduced pressure. The residue was re-dissolved in dichloromethane (20ml) and hydrogen chloride gas passed through the mixture for 20 minutes. The mixture was quenched with aq. saturated sodium bicarbonate solution and extracted with ethyl acetate, collected, dried (MgSO4) and solvent evaporated under reduced pressure to leave a colourless oil. This was purified by crystallisation from ether/iso-hexane mixtures to give the subtitle compound as a white solid. Yield: 1.35g
Η NMR δ (DMSO) 8.30(s, IH), 7.24-7.39(m, 5H), 4.60(d, IH), 4.44(d, IH), 3.92(t, IH), 3.78(d, 3H), 1.75(m, 2H), 0.84(t, 3H)
ϋ) (R)-3-Ethyl-l-phenylmethylpiperazine
A stirred solution ofthe product from step (i) (6.0g) in tetrahydrofuran (250ml) at 0 °C was treated with lithium aluminium hydride (3.44g). The mixture was allowed to stir at ambient temperature for 24h and then set at reflux for 4h. The mixture was carefully quenched with 10% aq. sodium hydroxide solution (10ml). After stirring for 30 minutes the mixture was filtered and the mother liquor partitioned between ethyl acetate and brine. The organic layer collected, dried (MgSO4) and solvent evaporated under reduced pressure to give the subtitle compound as a pale yellow oil. Yield: 5.8g
lH NMR δ (CDC13) 7.32(s, 5H), 3.50(dd, 2H), 2.62-3.0(m, 5H), 2.00(m, IH), 1.70(t, IH), 1.57(s, IH), 1.27(m, 2H), 0.90(t, 3H)
iii) (R)-l -(1 -Methylimidazol-4-sulphonyl-4-yI)-2-ethyl-4-phenylmetIιyl)piper azine
The subtitle compond was prepared from the product of step (ii) (0.5g) and 1- methylimidazole-4-sulphonyl chloride (0.5g) by the method of Example 80 step (i) as a pale yellow solid. Yield: 0.53g Η NMR δ (CDCI3) 7.46(s, IH), 7.38(s, IH), 7.29(m, 5H), 3.80(s, 2H), 3.47(d, IH), 3.3(d+m, 2H), 2.64(4 2H), 2.08(m, 2H), 1.79(m, 2H), 0.82(t, 3H)
iv) (R)-l-(l-Methylimidazol-4-sulphonyl-4-yl)-2-ethyl)piperazine
The subtitle compound was prepared from the product of step (iii) (0.49g) by the method of Example 80 step (ii) as a pale yellow solid. Yield: 0.32g
Η NMR δ (CDCI3) 7.6(d, 2H), 7.5(m, 4H), 4.05(s, IH), 3.73(s, 3H), 3.42(4 IH), 3.04(4 2H), 2.87(m, IH), 2.32(m, IH), 1.87(m, 2H), 0.91(t, 3H)
v) (R)-2-[4-(l-Methyljimidazol-4-sulphonyl-4-yl)-3-ethylpiperaz -l-yl]-N-(qum yl)acetamide
The title compound was prepared from the product of step (iv) (0.23g) and 2-chloro-N- (quinolin-5-yl)acetamide (0.21 g)) (J. Indian Chem Soc, 1940, 17, 619-621 ) by the method of Example 80 step (iii) as a cream solid. Yield: 21mg
MS: APCI (+ve) 443 (M+l)
Η NMR δ (CD3OD) 9.16(d, IH), 9.07(4 IH), 8.10(s, 3H), 7.97(t, IH), 7.81(4 IH), 7.70(t, IH), 7.50(dd, IH), 4.29(m, 2H), 4.10(m, 2H), 3.81(s, 3H), 3.69(m, 2H), 3.32(m, 2H), 3Λ5j(m, 2H), 1.84(m, 2H), 0.99(t, 3H)
Example 6 c/5-2-[3,5-Dimethyl-4-(thieno[2,3-ciIpyriιnidin-4-yl)piperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000028_0001
The title compound was prepared from the product of Example 9 step (ii) (0.316g) and 2-methylaniline (0.09g) by the method of Example 8 step (v) as a white solid. Yield 0.202g
MS : APCI(+ve) 396 (M+l , 100%)
11Λ NMR: δ (DMSO) 9.25(1H, s), 8.40(1H, d), 7.60-7.67(3H,m), 7.26(2H, m),
7.10(1H, ), 5.01(2H, bs), 3.23(2H, s), 2.96(2H, d), 2.45(2H, m), 2.29(3H, s), 1.50(6H, m) MP: 174-175 °C
Example 7 ds-N-(2-Chlorophenyl)-2-[3,5-dimethyl-4-(thieno[2,3-^pyrjinιidm-4-yl)piperaziιι-l- yl] acetamide
Figure imgf000029_0001
The title compound was prepared from the product of Example 8 step (ii) (0.316g) and 2-chloroaniline (0.107g) by the method of Example 1 step (iii) as a white solid. Yield 0.119g.
MSr APCI(+ve) 416(M+1, 100%) H NMR: δ(DMSO) 9.70(1H, s), 8.55(1H, d), 7.27-7.42(3H, m), 7.26(2H, s), 7.08(1H, t), 5t,08(2H, bs), 3.26(2H, s), 2.94(2H, d), 2.60(2H, m), 1.63(6H, d) MP: 206-207 °C
Example 8 5-N-(2-Chlorophenyl)-2-[3,5-dimethyl-4-(9-methyl-9H-purin-6yl)piperazin-l- yl] acetamide
Figure imgf000030_0001
i) 5-l,l-Dimethylethyl, 3,5-dimet yl-4-(9-methyl-9H-purin-6-yl)piperazine-l- carboxylate
The subtitle compound was prepared from 6-chloro-9-methyl-9H-purine (J. Org. Chem., 1983, 48(6), 850-5) (2g) and cis- 1,1-dimethylethyl, 3,5-dimethylpiperazine-l-carboxylate (2.74g) by the method of Example 2 step (i) as beige solid. Yield 0.2g. H NMR: δ (CDCL3) 8.40(1H, S), 7.73(1H, S), 4.20-4.00(3H, BRM), 3.30-3.00(3H, BRM), 1.5(9H, S), 1.40(6H, D)
ii) c/5~2,6-Dimethyl-l-(9-methyl-9H-purm-6-yl)piperazme, trifluoroacetic acid salt
The subtitle compound was prepared from the product of step (i) (0.2g) by the method of Example 1 step (ii) as a red gum. This was used directly in the next step.
MS: APCI(+ve) 247 (M+l,100%)
iii) c/s-l,l-Dimethylethyl, 2-(3,5-dimethyl-4-(9-methyl-9H-purin-6-yl)piperazin-l- yl)aeetate
A mixture ofthe product from step (ii) (0.34g), tert-butyl bromoacetate (0.13g) and sodium bicarbonate (0.8g) in acetone was heated at 45°C for 18 hours. The reaction mixture was filtered and the filtrate evaporated under reduced pressure. The residual brown gum was purified by flash chromatography eluting with ethyl acetate/z'-rohexane/ triethylamine (7:2.5:0.5) to give the subtitle compound as a pale yellow gum. Yield 0.12g.
MS: APCI(+ve) 361 (M+l , 100%) iv) c s-2-(3,5-Dimethyl-4(9-methyl-9H-purin-6-yl)piperazm-l-yl)acetic cid, hydrochloride salt
The product from step (iii) (0.12g) in dichloromethane was treated with 1M hydrogen chloride in diethyl ether (12 ml). The mixture was stirred at room temperature for 18 hours. The solvent was evaporated under reduced pressure to give the subtitle product as a pale yellow solid. Yield 0.15g.
MS: APCI(+ve) 305 (M+l, 100%)
v) c/5-N-(2-Chlorophenyl)-2-[3,5-dimethyl-4-(9-methyl-9H-purin-6yl)piperazin-l- yl] acetamide
Bromo-tris-oxy-tripyrrolidinophosphonium hexafluorophosphate (known as PyBroP) (0.18g) was added to a stirred solution ofthe product from step (iv) (0.14g), 2-chloroaniline (0.05g) and N,N-diisopropylethylamine (0.3g) in anhydrous dimethylformamide (6ml). After stirring for 4 hours a further aliquot of 2-chloroaniline (0.1ml) and PyBroP (0.18g) were added and the mixture further stirred at room temperature for four days. Water was added and the precipitate filtered to give the crude product as a brown solid (0.07g). This was purified by high pressure liquid chromatography (acetonitrile / 0.1% aqueous ammonium acetate, gradient elution 25% to 75% organic phase) to give the title product as a white solid. Yield 0.04g.
MS: APCI(+ve) 414/416 (M+l, 100%) H NMR: δ (CDCI3/DMSO) 9.76(lH,s), 8.52(1H, dd), 8.39(1H, s), 7.78(1H, s), 7.40(1H, dd), 7.31(1H, dt), 7.07(1H, dt), 5.50(2H, bs), 3.83(3H, s), 3.26(2H, s), 2.94(2H, d), 2.59(2H, m), 1.58(6H, d) MP: 221-222 °C
Example 9 c/5-2-(3,5-Dimethyl-4-(thieno[2,3-ι jpyrimidm-4-yl)piperazm-l-yl)-N-(isoqumolin-5- yl)acetamide
Figure imgf000032_0001
i) c 5-l,l-Dimethylethyl, 2-(3,5-dimethyl-4-(thieno[2,3-< ]pyrimidin-4-yl)piperaziιι-l- yl)acetate
The subtitle compound was prepared from the product of Example 2 step (ii) (3.0g) and tert-butyl bromoacetate (1.15g) by the method of Example 8 step (iii) as a white solid. Yield l.Og.
MS: APCI(+ve) 363 (M+l, 100%)
ii) c 5-2-(3,5-Dmιethyl-4-(thieno[2,3-^pyrimidi-4-yl)piperazin-l-yl)acetic acid, hydrochloride salt
The product from step (i) (1.0g) in 1,4-dioxane was treated with 4M hydrogen chloride in 1,4-dioxane (40 ml). The mixture was stirred at room temperature for 18 hours. The solvent was evaporated under reduced pressure to give the subtitle compound as a white solid. Yield 1.9g.
MS APCI(+ve) 307 (M+l, 100%)
iii) cw-2-(3,5-Dimethyl-4-(thieno[2,3-^pyriιm^in-4-yl)piperazm-l-yl)-N-(isoqumolin- 5-yl)acetamide
The title product was prepared from the product of step (ii) (0.2g) and 5-aminoisoquinoline (0.084g) by the method of Example 8 step (v) as a white solid. Yield 0.1 lg.
MS: APCI(+ve) 433 (M+l, 100%) LH NMR: δ (CDCI3 ) 9.62(lH,bs), 9.30(1H, s), 8.59(1H, d), 8.51(1H, s), 8.46(1H, d), 7.85(lH,d), 7.68(2H, m), 7.38(1H, d), 7.28(1H, m), 5.13(2H, bs), 3.38(2H, s), 3.03(2H, d), 2.70(2H, dd), 1.65(6H, d) MP: 213-216 °C
Example 10 c 5-2-(3,5-Dmιethyl-4-thieno[2,3-^pyrimidm-4-yl)piperazm-l-yl)-N-(quinolin-5- yl)acetamide
Figure imgf000033_0001
The title compound was prepared from the product of Example 9 step (ii) (0.207g) and 5-aminoquinoline (0.072g) by the method of Example 8 step (v) as a white solid. Yield 0.1 lg.
MS: APCI(+ve) 433 (M+l, 100%) H NMR: δ (CDC13) 9.53(lH,s), 8.97(1H, s), 8.51(lH,s), 8.28(lH,s). 8.00(1H, s), 7.77(lH,t), 7.47(1H, m), 7.42(lH,d), 7.37(1H, d), 5.13(2H,s), 3.38(2H,s), 3.03(2H,d), 2.7l(2H,d), 2.29(3H,s), 1.63(6H,d) MP: 194-195 °C
Example 11 c 5-2-(3,5-Dimethyl-4-(thieno[2,3-rfJpyrimidin-4-yl)piperazm-l-yl)-N-(2-methyl-5- methylsulphonamidophenyl)acetamide
Figure imgf000033_0002
i) 2-Methyl-5-bis(methylsulphonyl)amido-l-nitrobenzene
To a mixture of 5-nitro-4-methylaniline (3.04g) and N,N-diisopropylethylamine (5.2ml) in dichloromethane (40ml) was added dropwise a solution of methanesulphonyl chloride (2.29g) in dichloromethane (10ml) over 40mins. After stirring for 16 hours the mixture was poured into 2% aq. HCl. The organic phase collected and further washed with brine, dried (NajSO and solvent evaporated under reduced pressure to leave the crude product. This was purified by silica-gel chromatography eluting with dichloromethane to give the subtitle compound as a pale yellow solid. Yield 4.46g. This was used directly in the next step.
u) 2-Methyl-5-bis(methylsulphonyl)amido-l-aniline
A mixture ofthe product from step (i) (3.8g), ammonium chloride (3.8g), reduced iron powder (3.8g) in ethanol (30ml) and water (10ml) were stirred at 80 °C for 5 minutes. The mixture was filtered through Celite and further washed with ethanol and dichloromethane. The filtrate was concentrated to a quarter ofthe volume and then water added to give a brown precipitate. This was filtered to give the subtitle compound as a brown solid. Yield 1.25g. The mother liquor was further partitioned between water and ethyl acetate. The organic phase collected, dried (Na^O^ and evaporated to give a second batch ofthe subtitle compound as an orange solid. Yield l.lg.
!H NMR: δ (DMSO) 6.98 (IH, d), 6.65 (IH, s), 6.56 (IH, d), 2.50 (6H, s), 2.06 (3H, s)
iii) c/s-2-(3,5-Dimethyl-4-(thieno[2,3-^pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- bis(methylsulphonyl)amidophenyl)acetamide The subtitle product was prepared from the product of Example 9 step (ii) (0.318g) and the product of step (ii) (0.172g) by the method of Example 8 step (v) as a white solid. Yield 0.2 lg. This product was used directly in the next step without further purification. iv) czs-2-(3,5-Dimethyl-4-(thieno [2,3-d] pyrimidin-4-yl)piperazm-l -yl)-N-(2-methyl-5- methylsulphonamidophenyl)acetamide
A mixture ofthe product from step (iii) (0.2 lg) and potassium carbonate (0.5g) was stirred in methanol (20ml) and water (10ml) over 24 hours at room temperature. The solid product was filtered and purified by reverse phase HPLC to give the title compound as white solid. Yield 0.058g.
MS: APCI(+ve) 489(M+1, 100%)
Ti NMR: δ (DMSQ) 9.66(lH,s), 9.23(lH,s), 8.40(lH,s), 7.60(3H,s),7.17(lH,d), 6.94(lH,d),4.50(2H,bs),3.22(2H,s),2.93(2H,s),2.43(2H,m),2.22(3H,s),1.49(6H,d)
Example 12 c s-2-(3,5-Dmιethyl-4-(thieno[2,3-^pyrimidiιι-4-yl)piperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide
Figure imgf000035_0001
i) c 5-2-(3,5-Dimethyl-4-(thieno[2,3-^pyrimidin-4-yl)piperazin-l-yl)acetyl chloride, hydrochloride salt
A mixture ofthe product from Example 9 step (ii) (1.15g) and oxalyl chloride (1.2ml) in dichloromethane (100 ml) was treated with 2 drops of dimethylformamide. After 24 hours at room temperature a further aliquot of oxalyl chloride (3.6ml) was added and the mixture heated under reflux for 48 hours. The solvent was evaporated under reduced pressure. Toluene was added to the residue and then evaporated under reduced pressure to give the subtitle product as a yellow oil (0.95g).
MS : (methanol added to give the methyl ester) : APCI(+ve) 320 (M(methyl ester)+l , 100%) ii) c s-2-(3,5-DimethyI-4-(thieno[2,3-^pyrimidin-4-yl)piperazin-l-yI]-N-(2- trifluoromethylphenyl)acetamide
A mixture ofthe product from step (i) (0.2g), 2-trifluoromethylaniline (0.1 lg) and N,N-diisopropylethylamine in 1,4-dioxane (5ml) was heated at 80°C forlδ hours. LC mass spectrum analysis showed cz' -(3,5-dimethyl-4-(thieno[2,3-ύ ]pyrimidin-4-yl)piperazin- 1 - yljacetic acid present. PyBroP (0.18g) and 4-dimethylaminopyridine (0.05g) were added and the mixture further stirred at room temperature for 18 hours. The solvent was evaporated under reduced pressure and the residue purified by high pressure liquid chromatography (acetonitrile / 0.1% aqueous ammonium acetate, gradient elution 25% to 75% organic phase) to give the title product as a white solid. Yield 0.08g.
MS: APCI(+ve) 450 (M+l, 100%) H NMR: δ (CDC13 ) 9.41(lH,bs), 8.49(1H, s), 8.34(1H, d), 7.65(1H, d), 7.60(1H, t), 7.37(1H, d), 7.27(2H, m), 5.06(2H, bs), 3.24(2H, s), 2.92(2H, d), 2.59(2H,dd), 1.55(6H, d) MP: 154-155 °C
Example 13 -2-(3,5-Dimethyl-4-(thieno[2,3-^ρyriιmdin-4-yl)piperazin-l-yl)-N-(3- methylpyridin-2-yl)acetamide
Figure imgf000036_0001
The title compound was prepared by from the product of Example 12 step (i) (0.2g) and 2-amino-3-methylpyridine (0.076g) by the method of Example 12 step (ii) as a cream solid. Yield 0.025g.
MS: APCI(+ve) 397 (M+l, 100%) ϊ NMR: δ (CDCI3 ) 9.13(lH,s), 8.47(1H, s), 8.31(1H, d), 7.60(1H, d), 7.40(1H, m), 7.27(1H, d), 7.13(1H, m), 5.09(2H, bs), 3.28(2H, s), 2.91(2H, d), 2.61(2H, m), 2.3(3H, s), 1.60(6H, d) MP: 157-159 °C
Example 14 c 5-2-(3,5-Dimethyl-4-(thieno[2,3-^pyriιnidm-4-yl)piperazm-l-yl)-N-(isoqumolin-l- yl)acetamide
Figure imgf000037_0001
The title product was prepared by from the product of Example 12 step (i) (0.2g) and isoquinolin-1-ylamine (O.lg) by the method of Example 12 step (ii) as a cream solid. Yield 0.055g.
MS : APCI(+ve) 433 (M+l, 100%) lR NMR: δ (CDC13 ) 9.65(1H, bs); 8.49(1H, s); 8.37(1H, bs); 8.05(1H, bd); 7.72(1H, t);
7.60(2H, t); 7.39(1H, d); 7.26(1H, m); 5.12(2H, bs); 3.39(2H, s); 3.07(2H, d);
2.6?(2H, dd); 1.63(6H, d).
MP: 206-207 °C
Example 15 c/5-2-(4-(4-Am o-5-cyanopyrimidin-2-yl)-3,5-dimethyl-piperazin-l-yl)-N-(2- chlorophenyl) acetamide
Figure imgf000037_0002
i) 2-Chloro-N-(2-chlorophenyl)acetamide
2-Chloroaniline (5g) was dissolved in dichloromethane (100ml) and chloroacetyl chloride (3.1 lml) and N,N-diisopropylethylamine (13.65ml) were added at 0 °C under a nitrogen atmosphere. The mixture was stirred for 1 hour at 0 °C and 12 hours at room temperature, then quenched with water. The product was extracted with dichloromethane. The organic layer was washed with water, brine, dried (MgSO4) and concentrated under reduced pressure to leave the subtitle product as a beige solid. Yield 7.5g. This was used in the next step without further purification.
MS: ES(-ve) 203 (M-1, 100%)
ii) cis-N-(2-Chlorophenyl)-2-(3,5-dimethylpiperazin-l-yl)acetamide
The product of step (i) (5.9g) was dissolved in ethanol (50ml) and cz5-2,6-dimethylpiperazine (3g) and sodium hydrogencarbonate (6.63g) were added at room temperature under a nitrogen atmosphere. The mixture was heated under reflux for 24 hours and the cooled solution was filtered and the filtrate was evaporated under reduced pressure. The residue was dissolved in 1M HCl (22ml) and washed with dichloromethane. The aqueous solution was then basified to pH13 with a solution of sodium hydroxide and the product was extracted with dichloromethane. The organic layer was washed with water, brine, collected, dried (MgSO4) and concentrated under reduced pressure to give the subtitle compound as a beige solid. Yield 4g.
MS: ES(+ve) 282(M+1,100%)
iii) c s-2-(4-(4-Ammo-5-cyanopyriπύdm-2-yl)-3,5-dimethylpiperazin-l-yl)-N-(2- chlorophenyl)acetamide
A mixture ofthe product from step (ii) (0.5g), 4-amino-2-chloro-5-cyanopyrimidine (0.275g) and N,N-diisopropylethylamine (1.55ml) in l-methyl-2-pyrrolidinone (5ml) was heated under nitrogen at 120 °C for 3 days. The cooled mixture was partitioned between ethyl acetate and water. The organic phase collected was dried (MgSO4) and the solvent evaporated. The crude product purified by silica-gel chromatography eluting with 2% ethyl acetate in z'sohexane to give the title compound as white solid. Yield O.lg.
MS: APCI (+ve) 400 (M+l, 100%) lH NMR: δ (DMSO) 9.67(1H, s), 8.32(1H, dd), 8.29(1H, s), 7.53(1H, dd), 7.37(1H, t),
7.23(2H, brs), 7.15(1H, t), 4.76-4.72(2H, m), 3.23(2H, s), 2.86(2H, d), 2.38(2H, dd), 1.36(6H, d)
Example 16 c s-2-(4-Benzenesulphonyl-3,5-dimethylpiperazin-l-yl)-N-(2-chloro-phenyl)acetamide
Figure imgf000039_0001
Benzenesulphonyl chloride (0.124g) was added to a solution ofthe product from Example 15 step (ii) (0.2g) in pyridine (2ml). The mixture was stirred at room temperature for 16 hours and then the solvent was evaporated under reduced pressure. The residue was purified by flash silica-gel chromatography eluting with 1% EtOH, 1% Et3N, 98%CH2C12 followed by trituration with ethyl acetate to give the title compound. Yield 0.03 g.
MS; APCI(+ve) 422 (M+l, 100%)
^ MR: δ (CDC13) 9.49 (brs, IH), 8.48 (dd,lH), 7.82 (dd,2H), 7.60-7.50 (m,3H), 7.37 (dd,lH), 7.30 (m,lH), 7.05 (dt,lH), 4.17 (quin,2H), 3.07 (s,2H), 2.65 (d,2H), 2.15 (dd,2H), 1.55 (s,6H). M.P: 182-3°C
Example 17 (+)-N-(2,6-Dimethylphenyl)-2-[(3-methyl-4-thiazolo(5,4-^pyrimidin-7-yl)piperazin-l- yl] acetamide
Figure imgf000040_0001
i) (+)-N-(2,6-Dimethylphenyl)-2-(3-methylpiperazin-l-yl)acetamide
The subtitle compound was prepared from 2-chloro-N-(2,6-dimethylphenyl)acetamide (7g) and (+)-2-methyl-piperazine (3.55g) by the method of Example 15 step (ii) as a white solid, s Yield 7g.
MS: ES(+ve) 262(M+1,100%)
u) (+)-Ν-(2,6-Dimethylphenyl)-2-[(3-methyl-4-thiazolo(5,4-ιi)pyrimidin-7-o yl)piperazin-l-yl] acetamide
The title compound was prepared from the product of step (i) (0.38 lg) and 7-chloro- thiazolo[5,4,d]pyrimidine (Chem. Pharm. Bull. 1968, (16(4), 750-755) (0.25g) by the method of Example 15 step (iii) as a beige solid. Yield 0.0 lg. s MS: ES(+ve) 397(M+1, 100%)
^ NMR: δ (CDC13) 8.84(1H, s), 8.77(1H, s), 8.48(1H, s), 7.18-7.06(3H, m), 3.14(2H, s), 3.88-2.68(7H, br ), 2.26(6H, s), 1.25(3H, m)
Example 18 0 α>-N-(2-Chlorophenyl)-2-[(3,5-dimethyl-4-quinazolin-4-yl)piperazin-l-yl]acetamide
Figure imgf000040_0002
A mixture ofthe product from Example 15 step (ii) (2.1g), 4-chloroquinazoline (1.23g) (J. Chem. Soc, 1944, 619-623) and N,N-diisopropylethylamine (6.15ml) in l-methyl-2- pyrrolidinone (14ml) under nitrogen was heated at 120 °C for 4 days. The cooled mixture was partitioned between ethyl acetate and water. The organic layer was further washed with water, brine, dried (MgSO4) and concentrated under reduced pressure. The residue was purified by silica-gel chromatography eluting with ethyl acetate/ isohexane (4:6) to give the title compound as a white solid. Yield 0.08g.
MS: ES(+ve) 410(M+1,100%), ES(-ve) 408(M-1,100%)
!H NMR: δ (DMSO) 9.81(1H, s), 8.82(1H, brs), 8.30(1H, dd), 8.18(1H, d), 7.87(2H, d), 7.63-7.58(lH, m), 7.55(1H, dd), 7.38(1H, t), 7.17(1H, t), 4.38(2H, brs), 3.26(2H, s), 2.69(4H, brs), 1.30-1.15(6H, m)
Example 19
N-(2-Chlorophenyl)-2-[(8-(thieno[2,3-^pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000041_0001
i) 1,1-Dimethylethyl, 3-[(2-chlorophenylcarbamoyI)methyl]-3,8-diaza- bicy clo [3.2.1] octane-8-car b oxylate
A mixture of 1,1-dimethylethyl, 3,8-diaza-bicyclo[3.2.1]octane-8-carboxylate (0.048g) (J. Med. Chem., 1998, 41(5), 674-681), sodium bicarbonate (0.058g), potassium iodide (Q.003g) and the product of Example 15 step (i) (0.05 lg) in ethanol (0.5ml) was heated at 70°C for 3 hours. The cooled mixture was partitioned between ethyl acetate and water and the organic phase was washed with water and brine, dried (MgSO4) and the solvent evaporated under reduced pressure. Purification was by flash silica-gel chromatography eluting with 2%EtOH, l%Et3N, 97%CH2C12. Yield 0.068g.
MS: ES(+ve) 380 (M+l, 100%) ii) N-(2-Chlorophenyl)-2-(3,8-diaza-bicyclo [3.2.1] oct-3-yl)acetamide trifluoroacetic acid salt
The subtitle compound was prepared from the product of step (i) (0.068g) by the method of Example 1 step (ii) as a white solid. Yield 0.06 lg.
MS: ES(+ve) 280 (M+l, 100%)
iϋ) N-(2-Chlorophenyl)-2-[(8-(thieno[2,3-ιi]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct- 3-yl] acetamide
The title compound was prepared from the product of step (ii) (0.06 lg) by the method of Example 15 step (iii), with heating for 1 hour only, as a white solid. Yield 0.04g.
MS: APCI(+ve) 414 (M+l, 100%) LH NMR: δ (CDC13) 9.65 (s,lH), 8.53 (dd,lH), 8.49 (s,lH), 7.41 (dd,lH),7.33-7.28
(m,3H), 7.07 (t,lH), 5.02 (brs,lH), 3.18 (s,2H), 2.95 (d,2H), 2.77 (d,2H), 2.32 (m,2H),
2.12 (m,2H).
M.P: 164 °C
Example 20
N-(2-Methylphenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000042_0001
i) 1,1-Dimethylethyl, 3-phenylmethyl-3,8-diazabicyclo[3.2.1]oct-8-carboxylate 3-Phenylmethyl-3,8-diazabicyclo[3.2.1]octane hydrochloride salt (1.15g) was dissolved in dichloromethane (16ml) and water (16ml) and sodium hydrogencarbonate (1.61g) were added. The mixture was stirred rapidly for 10 minutes at room temperature and then di-tert-butyl dicarbonate (1.15g) was added in portions. The mixture was stirred rapidly for an additional 2 hours. The organic layer was separated, dried over magnesium sulphate, filtered and concentrated to afford a white crystalline solid. Yield 1.45g.
MS: ES(+ve) 303 (M+l, 100%)
ii) 1,1-Dimethylethyl, 3,8-diazabicyclo[3.2.1]oct-8-carboxylate hydrochloride salt
A solution ofthe product from step (i) (1.45g) was dissolved in ethyl acetate (12ml) and cooled at -10 °C under a nitrogen atmosphere. IM HCl in diethyl ether (4.81ml) was added dropwise, causing the salt to precipitate out of solution. The mixture was stirred an additional 1 hour and the crystalline product was collected by filtration and dried in a vacuum oven. This white solid was dissolved in methanol (18ml) and 10% palladium on carbon (0. lg) added under a nitrogen atmosphere. The mixture was then stirred vigorously under an hydrogen atmosphere for 12 hours. After completion ofthe reaction, the mixture was filtered through Celite and the mother liquor concentrated to afford the subtitle compound as a white crystalline solid. Yield 1.18g. H NMR: δ (CDC13) 4.34(2H, brs), 3.16(4H, brs), 2.27-2.09(4H, m), 1.47 (9H, s)
iii) X,l-Dimethylethyl, 3-[(2-methylphenylcarbamoyl)methyl]-3,8-diaza- bicyclo[3.2.1]octane-8-carboxylate
A mixture ofthe product from step (ii) (0.16g), 2-chloro-N-(2-methyl)acetamide (Synthesis, 1982, (9), 795-796) (0.13g), sodium hydrogencarbonate (0.16g), and potassium iodide (8mg) in ethanol (2ml) under a nitrogen atmosphere was heated at 70 °C for 4 hours. The reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with water, brine, dried (MgSO4) and concentrated under reduced pressure. The residue was purified by silica-gel chromatography eluting with 2% ethanol 1% triethylamine in dichloromethane to give the subtitle compound as beige solid. Yield 0.23g. MS: ES(+ve) 360 (M+l, 100%)
iv) N-(2-Methylphenyl)-2-[3,8-diazabicyclo[3.2.1]oct-3-yl] acetamide, trifluoroacetic acid salt
A mixture ofthe product from step (iii) (0.23g) in dichloromethane (30ml) and trifluoroacetic acid (1.80ml) under a nitrogen at room temperature was stirred for 24 hours. The mixture was concentrated under reduced pressure to leave brown gum. This was used in the next step without further purification.
MS: ES(+ve) 260 (M+l, 100%)
v) N-(2-Methylphenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide A mixture ofthe product from step (iv) (0.12g), 6-chloro-9-methylpurine (0.06g) (J. Org. Chem., 1983, 48(6), 850-855), and N,N-disopropylethylamine (1ml) in 1,4-dioxane (5ml) were heated together at reflux for 5 hours. The volatiles were removed under reduced pressure and the residue purified by reverse phase HPLC eluting with a gradient from 5% acetonitrile in aqueous 1% ammonium acetate to 75% over 7min. The title product was obtained, by freeze drying, as a white solid. Yield: 0.027g.
MS: APCI(+ve) 392 (M+l, 100%)
^ NMR: δ (DMSO); 9.16(s, IH), 8.27(s, IH), 8.15(s, IH), 7.75(d, IH), 7.10(t, IH),
7.08(t, IH), 3.74(s, 3H), 5.70(bs, IH), 5.00(bs, IH), 3.74(s, 3H), 3.07(s, 2H), 2.90(m, 2H), 2.50-1.80(m, 6H), 2.30(s, 3H)
Example 21
2-[8-(9-Methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(quinoliιι-5- yl)acetamide
Figure imgf000045_0001
i) 1,1-Dimethlethyl, 3-[(quinolin-5-ylcarbamoyl)methyl]-3,8-diaza- bicyclo [3.2.1] octane-8-carboxylate
The subtitle compound was prepared from the product of Example 20 step (ii) (0.24g) and 2-chloro-N-(quinolin-5-yl)acetamide (J. Indian Chem. Soc, 1940, 17, 619-621) (0.234g) by the method of Example 20 step (iii) as a pale yellow solid. Yield 0.38g.
MS: ES(+ve) 397 (M+l, 100%)
ii) 2-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-Ν-(qumoIin-5-yl)acetamide, trifluroacetic acid salt
The subtitle compound was prepared from the product of step (i) (0.38g) by the method Example 20 step of step (iv) as a pale yellow gum. This was used directly in the next step.
MS: ES(+ve) 297 (M+l , 100%) ) 2-[8-(9-Methyl-9H-purm-6-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(qumolin-5- yl)acetamide
A mixture ofthe product from step (ii) (0.20g), 6-chloro-9-methylpurine (O.lg) (J. Org. Chem., 1983, 48(6), 850-855), and N,N-disopropylethylamine (1ml) in 1,4-dioxane (5ml) were heated together at reflux for 4 hours. The volatiles were removed under reduced pressure and the residue purified by reverse phase HPLC eluting with a gradient from 5% acetonitrile in aqueous 1% ammonium acetate to 75% over 7min. The title product was obtained, by freeze drying, as a white solid. Yield: 0.047g.
MS: APCI(+ve) 429(M+100%), APCI(-ve) 427(M-1,100%) !H NMR: δ (DMSO); 9.9(bs, IH), 8.90(m, IH), 8.40(4 IH), 8.30(s, IH), 8.18(s, IH), 7.90(d, IH), 7.80(d, IH), 7.75(t, IH), 7.60(m, IH), 5.78(bs, IH), 5.00(bs, IH), 3.78(s, 3H), 3.30(s, 2H), 2.90(m, 2H), 2.70-1.80(m, 6H).
Example 22
N-(Qumol -5-yl)-2-[8-thiazolo[5,4-^pyrimidm-7-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000046_0001
The title compound was prepared from the product Example 21 step (ii) (O.lg) and 7-chlorothiazolo[5,4-u pyrimidine (Chem. Pharm. Bull, 1968, 16(4), 750-755) (0.06g) by the method of Example 21 step (iii) as a pale yellow solid. Yield O.lg.
MS: ES(+ve) 432 (M+l, 100%) H NMR: δ (CDC13) 9.62(1H, s), 8.99-8.98(lH, m), 8.77(1H, s), 8.50(1H, s), 8.26(1H, d), 8.16(1H, d), 7.99(1H, d), 7.75(1H, t), 7.52-7.49(lH, m), 6.04(1H, brs), 5.29(1H, brs), 3.27(2H, s), 3.03(2H, d), 2.83(2H, brs), 2.22(2H, brs), 1.70(1H, brs), 1.45(1H, dd)
Example 23
N-(2-Methylphenyl)-2-[(8-thiazolo[5,4- t]pyrimidin-7-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000046_0002
The title compound was prepared from the product of Example 20 step (iv) (O.lg) and 7-chlorothiazolo[5,4- ]pyrimidine (Chem. Pharm. Bull, 1968, 16(4), 750-755) (0.06g) by the method of Example 21 step (iii) as a white solid. Yield 0.06g.
MS: ES(+ve) 395 (M+l , 100%) H NMR: δ (CDClj) 8.99(1H, s), 8.75(1H, s), 8.48(1H, s), 8.08(1H, d), 7.27-7.21(2H, m), 7.08(1H, t), 6.00(1H, brs), 5.29(1H, brs), 3.15(2H, s), 2.95(2H, d), 2.74(2H, brs), 2.38(3H, s), 2.27-2.07(4H, m)
Example 24
N-(2-Methyl-5-(methylsulphonyl)amidophenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3,8- diazabicyclo [3.2.1] oct-3-yl] acetamide
Figure imgf000047_0001
i) 2-Chloro-N-(5-bis(methylsulphonyl)amido-2-methylphenyl)acetamide A mixture ofthe product from step (ii) (0.62g) and N,N-diisopropylethylamine (1.04ml) in dichloromethane (40ml) at 10 °C was treated with chloroacetyl chloride (0.19ml) dropwise. After stirring for 4 hours the mixture was poured into saturated sodium bicarbonate solution and the organic phase collected and further washed with brine, collected, dried (CaCl2) and solvent evaporated under reduced pressure to leave a yellow gum. This was purified by silica-gel chromatography eluting with 10% diethyl ether in dichloromethane to give the subtitle product as a white solid. Yield 0.7 lg.
MS: APCI (-ve) 353 (M-1, 100%)
ii) 1,1-Dimethylethyl, 3-[(5-bis(methylsulphonyI)amido-2-methyl phenylcarbamoyl)methyl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate The subtitle compound was prepared from the product of step (i) (0.266$) and the product from Example 20 step (ii) (0.2g) by the method of Example 20 step (iii) as a white solid. Yield 0.45g.
MS : ES(+ve) 531 (M+l , 100%)
ϋi) 2-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-N-[5-bis(methylsulphonyl)amido-2- methylphenyl] acetamide, trifluoroacetic acid salt
The subtitle compound was prepared from the product of step (ii) (0.45 g) by the method of Example 20 step (iv) as a white solid. Yield 0.42g.
MS: ES(+ve) 431 (M+l, 100%)
iv) N-[5-Bis(methylsulphonyl)amido-2-methylphenyl]-2-[8-(9-methyl-9H-purm-6-yl)- 3,8-diazabicyclo[3.2.1]oct-3-yl]acetamide
The subtitle compound was prepared from the product of step (iii) (0.2g) and 6-chloro-9- methylpurine (J. Org. Chem., 1983, 48(6), 850-855) (O.lg) by the method of Example 20 step (v) as white solid. Yield O.lg.
MS: ES(+ve) 563 (M+l , 100%)
v) N 2-Methyl-5-(methylsulphonyl)amidophenyl)-2-[8-(9-methyl-9 T-purin-6-yl)-3,8- diazabicyclo[3.2.1]oct-3-yl]acetamide
A mixture ofthe product from step (iv) (O.lg) and sodium bicarbonate (0.05g) in wet ethanol (2ml) was heated at reflux for 1.5 hours, cooled and filtered. Purification was by flash silica-gel chromatography eluting with 2.5% EtOH, l%aq. NH3, 96.5% CH2C12 followed by trituration with ethyl acetate to give the title product as a white solid. Yield 0.066g.
MS: AP(+ve) 485 (M+l, 100%) !H NMR: δ (CDCI3): 9.19 (s,lH), 8.40 (s,lH), 8.14 (d,lH), 7.74 (s,lH), 7.20 (d,lH), 7.12 (dd,lH), 7.08 (s,lH), 3.84 (s,3H), 3.17 (s,2H), 2.97 (s,3H), 2.90 (d,2H), 2.75 (d,2H), 2.37 (s,3H), 2.15 (brm, 4H). M.P: 216-217°C
Example 25
N-[2-Methyl-5-(methylsulphonyl)aιnidophenyl]-2-[(8-thiazolo[5,4-^pyrimidin-7-yl)-
3,8-diazabicyclo[3.2.1]oct-3-yl]acetamide
Figure imgf000049_0001
i) N-[5-Bis(methylsulphonyl)amido-2-methylphenyl]-2-[(8-thiazolo[5,4- |pyrimidm-7- yl)-3,8-diazabicyclo [3.2.1] oct-3-yl] acetamide
The subtitle compound was prepared from the product of Example 24 step (iii) (0.2 lg) and 7-chloro-thiazolo[5,4-d]pyrimidine (Chem. Pharm. Bull, 1968, 16(4), 750-755) (0.069g) by the method of Example 20 step (v) as a white solid. Yield 0.113g.
MS: APCI(+ve) 566 (M+l, 100%)
u) N-[2-Methyl-5-(methylsulphonyl)amidophenyl]-2-[(8-thiazolo[5,4-flpyrimidin-7- yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]acetamide The title compound was prepared from the product of step (i) (0.113g) by the method of Example 24 step (v) as a white solid. Yield 0.085g.
MS: APCI(+ve) 488 (M+l, 100%)
LH NMR: δ (CDCI3) 9.18 (s,lH), 8.76 (s,lH), 8.48 (s,lH), 8.17 (d,lH), 7.31 (s,lH), 7.20 (d,lH), 7.13 (dd,lH), 3.21 (s,2H), 2.95 (s,3H), 2.92 (m,2H), 2.76 (m,2H), 2.38 (s,3H), 2.17(br m, 4H). MP: 145-187 °C
Example 26
N-[2-Methyl-5-(methylsulphonyl)amidophenyl]-2-[4-(thieno[2,3-^pyrimidin-4-yl)- 3,8-diazabicyclo [3.2.1] oct-3-yl] acetamide
Figure imgf000050_0001
i) N-[(5-Bis(methylsulphonyl)a)mido-2-methylphenyl]-2-[4-(thieno[2,3-^pyriιnidin-4- yl)-3,8-diazabicyclo [3.2.1] oct-3-yl] acetamide
The subtitle compound was prepared from the product of Example 24 step (iii) (0.216g) and 4-chlorothieno[2,3--f]pyrimidine (0.056g) by the method of Example 20 step (v) as a white solid. Yield 0.13g.
MS: ESI (+ve) 565 (M+l, 100%)
ϋ) N-[2-Methyl-5-(methylsulphonyl)amidophenyl]-2-[4-(thieno[2,3-^pyrimidm-4-yl)- 3,8-diazabicyclo[3.2.1]oct-3-yl] acetamide
The title compound was prepared from the product of step (i) (0.130g) by the method of Example 24 step (v) as a white solid. Yield 0.025g.
MS : APCI(+ve) 487 (M+l , 100%) lE NMR: δ (DMSO) 9.18(1H, s), 8.38(1H, s), 7.71-7.62(3H, m), 7.17(1H, d),
6.93(1H, dd), 5.04(2H, brs), 3.12(2H, s), 2.93(3H, s), 2.90(2H, d), 2.58(2H, d), 2.23(3H, s),
2.13(2H, d), 1.98-1.95(2H, m) Example 27
C 5-2-(3,5-Dimethyl-4-(thieno[2,3-</Jpyrimidm-4-yl)piperazin-l-yl)-N-(2-methyl-5-(l- piperazinylmethyl)phenyl)acetamide, hydrochloride salt
Figure imgf000051_0001
i) 1,1-Dimethylethyl, 4-((4-methyl-3-nitrophenyl)methyl)piperazine-l-carboxylate
A mixture of 4-methyl-3-nitrobenzyl chloride (5.55g), 1,1-dimethylethyl, piperazine-1- carboxylate (5.6g), N,N-diisopropylethylamine (5ml) in N,N-dimethylformamide (25ml) were heated at 110 °C for 3h. After cooling to ambient temperature the mixture was partitioned between dichloromethane and water. The organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure to leave the subtitle compound as a pale yellow oil. Yield: 9.6g
MS: APCI(+ve) 336 (M+l)
ϋ) 1,1-Dimethylethyl, 4-((3-amino-4-methylphenyl)methyl)piperaziιιe-l-carboxylate
The product from step (i) (9.6g), 10% palladium on charcoal (lOOmg) in ethanol (100ml) was stirred under an atmosphere of hydrogen gas for 24h. The catalyst was filtered through celite and the mother liquor collected and solvent evaporated under reduced pressure to give the subtitle compound as a pale yellow oil. Yield. 9g
MS: APCI(+ve) 322 (M+l)
iii) c/s-2-(3,5-Dimethyl-4-(thieno [2,3-d\ pyrimidin-4-yl)piperazin-l-yl-N-(2-methyl-5- ((4-(l,l-dimethylethyloxycarbonyl)piperazin-l-yl)methyl)phenyl)acetamide The product from Example 9 step (ii) (0.21g), the product from step (ii) (0.15g), benzotriazol-l-yl-pxy-tripyrrolidinophosphonium hexfluorophosphate (PyBrop) (0.24g), N,N-diisopropylethylamine (0.36ml) in dry N.N-dimethylformamide were stirred together under nitrogen for 20h. The mixture was poured into water and the resulting precipitate filtered as an off white solid. Purification was by silica gel chromatography eluting with ethyl acetate to give the subtitle compound as a white solid. Yield: 0.2 lg
MS: APCI (+ve) 594 (M+l)
iv) C/5-2-(3,5-Dimethyl-4-(thieno [2,3-d] pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- (l-piperazinylmethyl)phenyl)acetamide, hydrochloride salt
The product from step (iii) (0.17mg) was dissolved in 4M hydrogen chloride in 1,4- dioxane (2ml). After 48h the solvents were evaporated under reduced pressure to leave the title compound as a white solid. Yield: 0.16g
MS: APCI (+ve) 494(M+1)
'H NMR: δ (DMSO) 8.50(s, IH), 7.78(s, IH), 7.65(4 IH), 7.58(4 IH), 7.39(4 IH), 7.31(d, IH), 5.25(m, IH), 5.05(bs, 2H), 4.23(s, 2H), 3.77(bs, 2H), 3.43(s, 4H), 3.18(m, 6H), 3.04(m, 2H), 2.71(s, IH), 2.30(s, 3H), 1.47(d, 6H)
Example 28
N-(2-Methylphenyl)-2-[(8-(thieno[2,3-< Jpyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000053_0001
The title compound was prepared from the product of Example 20 step (iv) (0.45g) and 4- chloro-thieno[2,3-cfjpyrimidine by the method of Example 1 step (i). Yield: 0.22g.
MS: APCI(+ve) 394 (M+l)
!H NMR: δ (DMSO) 9.17 (IH, brs), 8.39 (IH, s), 7.73-7.62 (3H,m), 7.25-7.15 (2H,m),
7.07 (lH,m), 5.05 (2H,brs), 3.12 (2H,s), 2.92 (2H,d), 2.58 (2H,d), 2.28 (3H,s), 2.15 (2H,m), 1.97 (2H,m).
Example 29
N-[5-(Methanesulphonylamido-2-methylphenyl)-2-[8-(thieno[2,3-^pyriπύdin-4-yl)-8- azabicyclo[3.2.1]oct-3-yl]acetamide
Figure imgf000053_0002
i) Ethyl, 2-(8-(thieno[2,3-έ lpyrimidin-4-yl)-8-azabicyclo[3.2.1]oct-3-yl)ethanoate
Ethyl, 2-(8-azabicyclo[3.2.1]oct-3-yl)ethanoate (0.64g) (Arch. Pharm., 1976, 309(6), 447. Arch. Pharm., 1975, 308(5), 365), 4-chlorotωeno[2,3-φyrimidine (0.55g), N,N- diisopropylethylamine (1.7ml) in 1,4-dioxane (10ml) were heated at 105 °C for 4h. The precipitate was filtered and the mother liquor collected, the solvent evaporated under reduced pressure to leave a brown oil. Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane (3:7) to give the subtitle compound as a colourless oil. Yield: 0.35g. MS: APCI(+ve) 332 (M+l)
u) 2-(8-(Thieno[2,3-rf|pyrmιidin-4-yl)-8-azabicyclo[3.2.1]oct-3-yl)ethanoic acid
The product from step (i) (0.14g) in ethanol (0.3ml) was treated with IN sodium hydroxide (0.6ml) at ambient temperature for 48h. The mixture was acidified to pH4 with 2N hydrochloric acid and the solvents evaporated under reduced pressure. The residue was treated with ethanol (5ml) and inorganic salts filtered. The mother liquor collected and solvent evaporated under reduced pressure to leave a gummy residue. Purification was by trituration with diethyl ether. Yield: 0.097g
MS: APCI(+ve) 304 (M+l)
iu) N-[5-bis((Methanesulphonyl)aιmdo-2-methylphenyl)-2-[8-(thieno[2,3-^pyrimidm- 4-yl)-8-azabicyclo[3.2.1]oct-3-yl]acetamide The product from step (ii) (0.097g), the product from Example 11 step (ii) (0.089g), benzotriazol-1-yl-oxy-triρyrrolidinoρhosphonium hexfluorophosphate (PyBrop) (0.16g), 4-N,N-dimethylaminopyridine (0.04g), N,N-diisopropylethylamine (0.28ml) in dichloromethane (10ml) were stirred at ambient temperature for 48h. The mixture was partitioned between water and dichloromethane. The organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure. Purification was by reverse phase HPLC eluting with 1% aq. ammonium acetate/acetonitrile (90% to 50%) to give the subtitle compound as a white solid. Yield: O.lg
MS: APCI (+ve) 564 (M+l)
iv) N-[5-(Methanesulphonylaιnido-2-methyIphenyl)-2-[8-(thieno[2,3-^pyrimidin-4- yl)-8-azabicyclo[3.2.1]oct-3-yi]acetamide
The product from step (iii) (O.lg), potassium carbonate (0.14g), water (5ml) and 1,4- dioxane (5ml) were heated at 110 °C for Ih. The mixture was treated with acetic acid (2ml) and solvents evaporated under reduced pressure. Purification was by silica gel chromatography eluting with ethyl acetate to give the title compound as a white solid. Yield: 0.01 lg
MS: APCI (+ve) 486 (M+l) 'H NMR: δ (DMSO) 9.33(bs, IH), 9.16(bs, IH), 8.38(2xs, IH), 7.6(m, 3H), 7.30(m, IH), 7.15(t, IH), 6.90(m, IH), 5.0(bm, 2H), 2.90(s, 3H), 2.30-1.89(bm, 4H), 2.10(s, 3H), 1.5- 0.9(bm, 2H)
Example 30 N-(2-Methyl-5-(l-piperazmylmethyl)phenyl)-2-[(8-(thieno[2,3-( |pyrimidin-4-yl)-3,8- diazabicyclo[3.2.1]oct-3-yl]acetamide
Figure imgf000055_0001
i) Methyl, 2-(8-(l,l-dimethylethyloxycarbonyl)-3,8-diazabiyclo[3.2.1]oct-3-yl)acetate A mixture of 1,1-dimethylethyl, 3,8-diazabicyclo[3.2.1]oct-8-carboxylate (0.35g), sodium bicarbonate (84mg), potassium iodide (20mg) and methyl bromoacetate (355mg) in ethanol (5ml) were heated at 70 °C for 6h. The reaction mixture was partitioned between ethyl acetate and water. The organic phase collected, dried (MgSO4) and the solvent evaporated under reduced pressure to leave the subtitle compound as a pale yellow solid. Yield: 380mg
Η NMR: δ (DMSO) 4.01 (bs, 2H), 3.58 (s, 2H), 3.29 (s, 3H), 2.62-2.49 (m, 4H), 1.82- 1.64(m, 4H), 1.40 (s, 9H)
ϋ) Methyl, 2-(3,8-diazabiyclo[3.2.1]oct-3-yl)acetate, trifluoroacetic acid salt
The subtitle compound was prepared from the product of step (i) (380mg) by the method of Example 1 step (ii). The product was used without further purification directly in next step. iii) Methyl, 2-(8-(thieno[2,3-rf]pyrimidin-4-yl)-(3,8-diazabiyclo[3.2.1]oct-3-yl)acetate
The subtitle compound was prepared from the product of step (ii) (400mg) and 4-chloro- thieno[2,3-< ]pyrimidine (288mg), N,N-diisopropylethylamine (232ul) in 1,4-dioxane at 100 °C for 48h. Solvent was evaporated under reduced pressure. Purification was by silica gel chromatography eluting with 2% ethanol in dichloromethane to give the subtitle compound as a beige solid. Yield: 170mg.
MS: APCI (+ve) 319 (M+l, 100%)
iv) 2-(8-(Thieno[2,3-< |pyrimidin-4-yl)-(3,8-diazabiyclo[3.2.1]oct-3-yl)acetic acid
The product from step (iii) (170mg) was dissolved in ethanol (1ml) and treated with IN sodium hydroxide solution (0.8ml) at room ambient temperature. After 3h the mixture was acidified with 2M hydrochloric acid to pH4. The solvents were then evaporated under reduced pressure and the residue treated with ethanol and filtered to remove inorganic salts. The mother liquor was collected and evaporated under reduced pressure to leave the subtitle compound as a white solid. Yield: 160mg.
MS: APCI(+ve) 305 (M+l)
v) N-(5-(4-(l,l-Dimethylethyloxycarbonyl)piperazin-l-yhnethyl)-2-methyl)phenyl)-2- [(8-(thieno[2,3-^pyrimidm-4-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]acetamide
The product of step (iv) (83mg), the product of Example 27 step (ii) (92mg), benzotriazol- 1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (PyBrop) (153mg) and N,N- diisopropylethylamine (95ul) were stirred in N,N-dimethylformamide (5ml) at ambient temperature for 12h. The solvents were evaporated under reduced pressure and purification was by silica gel chromatography eluting with iso-hexane/acetone (7:3) containing 1% triethylamine to give the subtitle compound as a white solid. Yield: 40mg. 'H NMR δ (DMSO) 9.15(s, IH), 8.38(s, IH), 7.67-7.66(m, 2H), 7.17(d, IH), 7.00(4 IH), 5.04(bs, 2H), 3.41 (s, 2H), 3.29(s, 4H), 3.1 l(s, 2H), 2.90(4 2H), 2.29(t, 4H), 2.24(s, 3H), 2.14(d, 2H), 2.00-1.93(m, 2H), 1.38(s, 9H)
vi) N-(2-Methyl-5-(l-piperazinylmethyl)phenyl)-2-[(8-(thieno [2,3-f jpyrimidm-4-yl)- 3,8-diazabicyclo[3.2.1]oct-3-yI]acetamide
The title compound was prepared from the product of step (v) (35mg) by the method of Example 8 step (iv) as a white solid. Yield: 35mg
MS: APCI(+ve) 492 (M+l)
'H NMR: δ (DMSO) 9.66(bs, IH), 8.53(s, 1H),"7.75 (s, 2H), 7.63(bs, IH), 7.42(4 IH), 7.33(d, IH), 5.21(bs, 2H), 4.33 (bs, 2H), 3.79-3.13(bm, 10H), 2.40-2.26(bm, 4H), 2.23(s, 3H), 2.20-2.10(bm, 4H).
Example 31
C5-N-(5-(2-Aminoethoxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4-(thieno[2,3- ^pyrimidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt
Figure imgf000057_0001
i) 1,1-Dimethylethyl, 2-(4-methyl-3-nitro-phenoxy)ethylammo-l-carboxylate The subtitle compound was prepared from 4-methyl-3-nitrophenol (2g) and 1,1- dimethylethyl, 2-hydroxyethylamino-l -carboxylate (2.5g) by the method of Example 50 step (i) as a beige solid. Yield: 3g
Ti NMR δ (CDClj) 7.50(s, IH), 7.22(4 IH), 7.05(dd, IH), 4.96(bs, IH), 4.07(t, 2H), 3.56(q, 2H), 2.52(s, 3H), 1.46(s, 9H) ii) 1,1-Dimethylethyl, 2-(3-amino-4-methyl-phenoxy)ethylamino-l-carboxylate
The subtitle compound was prepared from the product of step (i) (lg) by the method of Example 50 step (ii) as an off white solid. Yield: 0.9g
s MS: APCI (+ve) 267 (M+l)
iii) cis-N-(5-(2-(l,l-Dimethylethyloxycarbonylaminoethoxy))-2-methyl-phenyl)-2-(3,5- dimethyl-4-(thieno[2,3-ήfjpyrimidin-4-yl)piperazin-l-yl)acetamide
The product of Example 9 step (ii) (0.54g), the product from step (ii) (0.35g), benzotriazol-0 1-yl-oxy-tripyrrolidinophosphonium hexafluorophosphate (PyBrop) (0.59g), N,N- diisopropylethylamine (0.8ml) in dry N,N-dimethylformamide (15ml) were stirred together under nitrogen for 24h. The mixture was poured onto water (50ml) and the resulting precipitate filtered as a pale yellow solid. Purification was by silica gel chromatography eluting with diethyl ether/ethyl acetate (9:1) as eluant to give the subtitle compound as as white solid. Yield: 0.5 lg
MS: APCI(+ve) 555 (M+l)
iv) C5-N-(5-(2-Aminoethoxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4-(thieno[2,3-0 ^pyriιnidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt
Thβ title compound was prepared from the product of step (iii) (0.42g) according to the method of Example 27 step (iv) as a white solid. Yield: 0.36g
MS: APCI(+ve) 455 (M+l) 5 'HNMR δ (DMSO) 9.57(bs, IH), 8.50(s, IH), 8.15(bs, 2H), 7.65(d, IH), 7.57(d, IH),
7.37(s, IH), 7.15(d, IH), 6.75(dd, IH), 5.05(bs, 2H), 4.17(t, 2H), 3.77(bs, 2H), 3.27(d, 2H), 3.19(4 2H), 3.00(bs, 2H), 2.22(s, 3H), 1.48(d, 6H) Example 32
C5-N-(5-(2-(N-Methylamino)ethoxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4-(thieno[2,3- ^pyrinιidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt
Figure imgf000059_0001
i) 1,1-Dimethylethyl, 2-(4-methyl-3-nitro-phenoxy)ethyl(N-methylaιnino)-l- carboxylate
The subtitle compound was prepared from 4-methyl-3-nitrophenol (0.5g) and 1,1- dimethylethyl, 2-hydroxyethyl-(N-methylamino)-l -carboxylate (0.69g) by the method of Example 50 step (i) as a beige solid. Yield: 0.67g
'H NMR δ (CDCI3) 7.5(s, IH), 7.24(4 IH), 7.61(dd, IH), 4.12(bs, 2H), 3.64(t, 2H), 2.98(s, 3H), 2.53(s, 3H), 1.46(s, 9H)
ii) 1,1-Dimethylethyl, 2-(3-aniino-4-methyl-phenoxy)ethyl(N-methylammo)-l- carboxylate
The subtitle compound was prepared from the product of step (i) (lg) by the method of Example 50 step (ii) as an off white solid. Yield: 0.95g
MS: APCI (+ve) 281 (M+l)
jiu) N-(5-(2-(l,l-Dimethylethoxycarbonyl(N-methylarjtύno)ethoxy))-2-methyl-phenyl)- 2-(3,5-dimethyl-4-(thieno[2,3-ti]pyriijrύdin-4-yl)piperazin-l-yl)acetamide
The subtitle compound was prepared from the product of Example 9 step (ii) (0.26g), the product of step (ii) (0.175g) by the method of Example 31 step (iii). Purification was by silica gel chromatography eluting with diethyl ether/ethyl acetate (9:1) as eluant to give the subtitle compound as a white solid. Yield: 0.25g MS: APCI(+ve) 569 (M+l)
iv) cis-N-(5-(2-(N-Methylamino)ethoxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4- (thieno[2,3-rf]pyrimidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt The title compound was prepared from the product of step (iii) (0.189g) by the method of Example 27 step (iv) as a white solid. Yield: 0.077g
MS: APCI(+ve) 469 (M+l)
'HNMR δ (DMSO ) 9.50(bs, IH), 9.00(bs, IH), 8.49(s, IH), 7.64(4 IH), 7.57(d, IH), 7.39(s, IH), 7.17(d, IH), 6.76(4 IH), 5.05(bs, 2H), 4.24(s, 2H), 3.22-3.30(m, 4H), 2.95(bs, 2H), 2.62(s, 2H), 2.22(s, 3H), 1.48(4 6H)
Example 33
Cw-N-(5-(2-(N-Methylamiαo)ethoxy)-2-methyl-phenyl)-2-(4-benzenesuIphonyl)-3,5- dimethyl)piperazin-l-yl)acetamide
Figure imgf000060_0001
i) cis-l,l-DimethyIethyl, (4-benzenesuIphonyl-3,5-dimethyI)piperazine-l -carboxylate
A of solution of cir- 1,1 -dimethyl, 3,5-dimethylpiperazine-l -carboxylate (5g) in pyridine (60ml) was treated with benzene sulphonyl chloride (3ml). After 48h the solvent was evaporated under reduced pressure and purification ofthe residue was by silica gel chromatography eluting with ethyl acetate containing 1% triethylamine to give the subtitle compound as a yellow solid. Yield: 5g
MS: APCI(+ve) 255 (M-99)
ii) "s-l-Benzenesulphonyl-3,5-dimethylpiperazine, trifluoroacetic acid salt The subtitle compound was prepared from the product of step (i) (5g) by the method Example 1 step (ii). Purification was by recrystallisation from ethanol. Yield: 2g
MS: APCI(+ve) 255 (M+l)
iii) C5-2-chloro-N-[5-(2-(l,l-dimethylethoxycarbonyl)-N-methylamino)ethoxy)-2- methyl-phenyl] acetamide
A solution ofthe product from Example 32 step (ii) (0.65g), N,N-diisopropylethylamine (lml) in dichloromethane (30ml) at 0 °C under nitrogen was treated with chloroacetyl chloride (202ul). After 2h the mixture was partitioned with water and the product extracted into dichloromethane. The organic phase collected, dried (MgSO4) and solvent removed under reduced pressure to give the subtitle compound as a beige foam. Yield: 0.9g
MS: APCI (-ve) 355 (M-1)
iv) C/5-N-(5-(2-((l,l-dimethylethoxycarbonyl)-N-methylamino)ethoxy)-2-methyl- phenyI)-2-(4-benzenesulphonyl)-3,5-dimethyl)piperazin-l-yl)acetamide
The product of step (ii) (lOOmg), sodium bicarbonate (99mg), potassium iodide (5mg) in ethanol (6ml) was treated with the product of step (iii) at 70 °C for 12h. The mixture was partitioned between ethyl acetate and water. The organic phase collected, dried (MgSO4) and Solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with iso-hexane/acetone (7:3) containing 1% triethylamine to give the subtitle compound as a white solid. Yield: 126mg
MS: APCI(+ve) 575 (M+l), APCI(-ve) 573 (M-1)
v) C5-N-(5-(2-(N-Methylamino)ethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl)-3,5- dimethyl)piperazin-l-yl)acetamide, hydrochloride salt
The title compound was prepared from the product of step (iv) (120mg) by the method of Example 27 step (ii) as a white solid. Yield: 107mg MS: APCI(+ve) 475 (M+l), APCI (-ve) 473 (M-1)
'H NMR δ (DMSO) 9.01(bs, 2H), 7.85(4 2H), 7.69(t, IH), 7.62(t, 2H), 7.30(bs,lH), 7.15(d, IH), 6.74(dd, IH), 4.18(t,4H), 4.01(bs,2H), 3.56(s, 2H), 3.31-3.25(m, 2H), 2.61- s 2.58(m,3H), 2.50 (m, 2H), 2.15(s, 3H), 1.44 (d, 6H)
Example 34 N-[5-(2-Amiιιoethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl-3,5- dimethyl)piperazin-l-yl]acetamide, hydrochloride salt
Figure imgf000062_0001
i) Ci5-2-chloro-N-[5-(2-(l,l-dimethylethyloxycarbonyl)amino)ethoxy-2-methyl- phenyl] acetamide
The subtitle compound is prepared from the product of Example 31 step (ii) (650mg) and chloroacetyl chloride (213ul) by the method of Example 33 step (iii) as a beige foam,s Yield: 900mg
MS: APCI(-ve) 341 (M-1)
ii) Cw-N-[5-(2-(l,l-Dimethylethoxycarbonyl)amino)ethoxy-2-methyl-phenyl)-2-(4-0 bjfenzenesulphonyl-3,5-dimethyI)piperazin-l-yl] acetamide
The subtitle compound was prepared from the product of step (i) (148mg) and the product of Example 33 step (ii) by the method of Example 33 step (iv) as a pale yellow solid. Yield: 150mg. 5 MS: APCI(+ve) 561 (M+l), APCI (-ve) 559 (M-1) iii) Cs-N-[5-(2-(Aminoethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl-3,5- dimethyl)piperazin- 1-yl] acetamide, hydrochloride salt
The title compound was prepared from the product of step (ii) (150mg) by the method Example 27 step (iv) as a white solid. Yield: 150mg
MS: APCI (+ve) 461 (M+l), APCI (-ve) 459 (M-1)
Η NMR δ (DMSO) 8.13(bs, 2H), 7.85(d, 2H), 7.70-7.59(m, 3H), 7.32(bs,lH), 7.14(d, IH), 6.73(dd, IH), 4.16(bs, 2H), 4.10(t, 2H), 3.56(s, 2H), 3.19(4 2H), 3.10-3.03(m, 2H), 2.50(m, 2H), 2.15(s, 3H), 1.43 (d, 6H)
Example 35
N-(2-Oxo-2,3-d ydro-lH-mdol-4-yl)-2-(8-thieno[2,3-^pyrimidin-4-yl-3,8- diazabicyclo [3.2.1] oct-3-yl) acetamide
Figure imgf000063_0001
i) 2-ChIoro-N-(2-oxo-2,3-dihydro-lJy-indol-4-yl)acetamide
The subtitle compound was prepared from 4-amino-oxindole (0.19g) (J. Org. Chem., 1983, 48 (15), 2468-72) and chloroacetyl chloride (0.1ml) by the method of Example 15 step (i). Yield: 0.25g
MS: ES(-ve) 223 (M-l)
u) 3-[(2-Oxo-2,3-dihydro-lJH-indol-4ylcarbamoyl)-methyl]-3,8- diazabicyclo[3.2.1]octane-8-carboxylic acid, 1,1-dimethylethyl ester
The subtitle compound was prepared from the product of step (i) (0.24g) and 1,1 -dimethyl, 3,8-diaza-bicyclo[3.2. l]octane-8-carboxylate (0.26g) by the method of Example 19 step (i) Yield: 0.8g
!H NMR: δ (DMSO) 10.45 (lH,s), 9.26 (lH,s), 7.39 (lH,d), 7.15 (lH,t), 6.62 (lH,d), 4.06 (2H,brs), 3.45 (2H,s), 3.10 (2H,s), 2.72 (2H,d), 2.38 (2H,d), 1.95 (2H,d), 1.79 (2H,m), 1.41 (9H,s).
m) 2-(3,8-Diazabicyc!o[3.2.1]oct-3-yI)-N-(2-oxo-2,3-d ydro-liϊ-indol-4-yl)acetamide, hydrochloride salt
The product of step (ii) (0.8g) was dissolved in 2M hydrogen chloride in 1,4-dioxane (10ml), 1,4-dioxane (10ml), methanol (10ml) and the reaction mixture was stirred at ambient temperature for 2 hours. The solvents evaporated under reduced pressure to dryness. Yield: 0.8g
MS: ES(+ve) 301 (M+l)
iv) N-(2-Oxo-2,3-d ydro-l/r-mdol-4-yl)-2-(8-thieno[2,3-ci]pyrimidin-4-yl-3,8- diazabicycIo[3.2.1]oct-3-yI)acetamide
The title compound was prepared from the product of step (iii) (0.8g) by the method of Example 1 step (i). Yield: O.lg
MS-; ES(+ve) 435 (M+l)
2H NMR: δ (DMSO) 10.43 (lH,s), 9.27 (lH,s), 8.39 (lH,s), 7.66 (lH,d), 7.62 (lH,d), 7.40
(JH,d), 7.15 (lH,t), 6.62 (lH,d), 5.04 (2H,brs), 3.47 (2H,s), 3.12 (2H,s), 2.87 (2H,d), 2.57 (2H,d), 2.15 (2H,m), 1.97 (2H,m). M.P. 265°C decomp.
Example 36
N-(3-Fluoro-2-methyl-phenyl)-2-((8-quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl)acetamide
Figure imgf000065_0001
i) 2-ChIoro-N-(3-fluoro-2-methyl-phenyl)acetamide
The subtitle compound was prepared from 3-fluoro-2-methylaniline (0.232g) and chloroacetyl chloride (0.164ml) by the method of Example 33 step (iii) as a beige solid. 5 Yield: 0.3g
MS: APCI(-ve) 200 (M-1)
ii) N-(3-Fluoro-2-methyl-phenyl)-2-(l,l-dimethylethyloxycarbonyl)-3,8- l o diazabicyclo [3.2.1 ] oct-3-yl] acetamide
The subtitle compound was prepared from the product of step (i) (179mg) and 1,1- dimethyl-3,8-diaza-bicyclo[3.2.1]octane-8-carboxylate (0.2g) by the method of Example 33 step (iv) as a white solid. Yield: 305mg
is MS: APCI (+ve) 378 (M+l)
iii) V-(3-Fluoro-2-methyl-phenyl)-2-(3,8-diazabicyclo[3.2.l]oct-3-yl)acetamide, hydrochloride salt
The subtitle compound was prepared from the product of step (ii) (303mg) by the method 20 of Example 27 step (iv) as a white solid. Yield: 305mg
MS: APCI(+ve) 278 (M+l), APCI (-ve) 276 (M-1)
iv) N-(3-Fluoro-2-methyl-phenyl)-2-((8-quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- 25 yl)acetamide The title compound was preapred from the product of step (iii) (223mg) and 4- chloroquinazoline (133mg) by the method of Example 2 step (i) as a white solid. Yield: 120mg
MS: APCI(+ve) 406 (M+l)
Η NMR δ (DMSO) 9.34 (s, IH), 8.57(s, IH), 8.09(d, IH), 7.84-7.77(m, 2H), 7.60-7.53(m, 2H), 7.22(q, IH), 6.99(t, IH), 4.87(bs, 2H), 3.24(s, 2H), 2.97(dd, 2H), 2.77(dd, 2H), 2.17(s, 3H), 2.12-2.04(m, 2H), 1.91-1.85(m, 2H)
Example 37
N-(2-Methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000066_0001
The trifluoroacetate salt of Example 20 step (iv) was converted to the free base by use of aqueous 2N NaOH solution followed by extraction with ethyl acetate. The extracts were dried (MgSO4), filtered and evaporated to dryness, leaving an oil which crystallised on standing.
MS: ES(+ve) 260 (M+l, 100%)
The amine free base (0.075g) was stirred in acetone (15ml) and a solution of K2CO3 (0.08g) in water (0.5ml) was added, followed by benzenesulphonyl chloride (0.047g) dissolved in acetone (5.0ml). The solution was stirred for 1 hour, quenched with water and the white solid was collected by filtration, washed with water and dried in vacuo, to give the title compound. Yield 0.037g. MS: APCI(+ve) 487 (M+l, 100%)
!H NMR: δ (CDC13) 1.55 (s, H2O), 1.70 (2H, m), 1.85(2H, m), 2.26(3H, s), 2.67 (2H, m),
2.85(2H, d of d), 3.18(2H, s), 7.05(2H, m), 7.2(2H, m), 7.52(2H, m), 7.6(1H, m), 7.9(2H, d) MP: 169-170 °C
Example 38
N-(3-Fluoro-2-methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide
Figure imgf000067_0001
i) Methyl, (3,8-Diazabicyclo [3.2.1] oct-3-yl)acetate, hydrochloride salt
A mixture ofthe product from Example 30 step (i), 2M HCl in 1,4-dioxane (10ml) and methanol (10ml) was stirred at ambient temperature for 2 hours and evaporated to dryness. Yield 0.54g. Used directly in the next step.
ii) Methyl, (8-benzenesulphonyl-3,8-diazabicyclo [3.2.1] oct-3-yl)acetate
A mixture ofthe product of step (i) (0.53g), potassium carbonate (0.66g) and benzenesulphonyl chloride (0.32ml) in acetone (10ml) and 1,4-dioxane (10ml) was stirred at ambient temperature for 4 hours. The mixture was partitioned between ethyl acetate and water. The organic phase was washed with water, saturated sodium bicarbonate and brine, dried (MgSO4) and evaporated. The product was purified by silica gel chromatography eluting with 0.5% ethanol in dichloromethane. Yield 0.29g.
lU NMR: δ (DMSO) 7.86 (2H,d), 7.69 (lH,m), 7.59 (2H,m), 4.13 (2H,brs), 3.59 (3H,s), 3.29 (2H,s), 2.67 (2H,dd), 2.57 (2H,d), 1.59 (2H,q), 1.13 (2H,m). iii) (8-Benzenesulphonyl-3,8-diazabicyclo[3.2.1]oct-3-yl)acetic acid
A solution ofthe product of step (ii) (0.29g) in ethanol (5ml) was treated with 1ml of IN sodium hydroxide solution. After 1 hour at ambient temperature the reaction mixture was acidified with 2N hydrochloric acid to pH4 and evaporated to dryness to give a white solid. This was dried at 40° C in vacuo over phosphorous pentoxide for 2 hours and used directly in the next step.
iy N-(3-Fluoro-2-methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct- 3-yl] acetamide A mixture ofthe product of step (iii) (0.45mmol), 2-fluoro-2-methylaniline (60μl), PyBroP (0.25g), NN-dimethylaminopyridine (54mg) and NN-diisopropylethylamine (0.23ml) in Ν,Ν-dimethylformamide (5ml) was stirred at ambient temperature for 16 hours. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried (MgSO4) and evaporated. The residue was purified by flash chromatography eluting with 1% ethanol in dichloromethane followed by further chromatography with 20% ethyl acetate /iso-hexane to give the title compound as a white solid. Yield: 30mg.
MS: AP (+ve) 418 (M+l) lH NMR: δ (DMSO) 9.20 (lH,s), 7.88 (2H,d), 7.70 (lH,m), 7.60 (2H,m), 7.49 (lH,d), 7.20
(lH-q), 6.97 (lH,t), 4.17 (2H,brs), 3.17 (2H,s), 2.81 (2H,dd), 2.50 (2H,d), 2.09 (3H,s), 1.78 (2H,m), 1.20 (2H,m). M.P. 168-9°C
Example 39
C5-N-(3-Fluoro-2-methyl-phenyl)-2-(4-benzenesulphonyl)-3,5-dimethyl)piperazin-l- yl) acetamide
Figure imgf000069_0001
i) Cis-N-(3-Fluoro-2-methyI))phenyl)-2-(4-benzenesulphonyl)-3,5-dimethyl)piperazin- l-yl)acetamide
The title compound was prepared from the product of Example 33 step (ii) (152mg) and the product of Example 36 step (i) (132mg) by the method of Example 33 step (iv) as a white solid. Purification was by silica gel chromatography eluting with iso-hexane/acetone (7:3). Yield: 58mg.
MS: APCI(+ve) 420 (M+l) 'H NMR δ (DMSO) 9.23(s, IH), 7.83(d, 2H), 7.69-7.58(m, 3H), 7.34(d, IH), 7.20(q, IH), 6.99(t, 1H)„ 4.06-3.99(m, 2H), 3.03(s, 2H), 2.64(d, 2H), 2.08(s, 3H), 1.90(dd, 2H), 1.42(d, 6H)
Example 40 N-(2-Methylphenyl)-2-[8-(3-cyanobenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct- 3-yl] acetamide
Figure imgf000069_0002
The title compound was prepared from the product of Example 20 step (iv) and 3- cyanobenzenesulphonyl chloride by the method of Example 37 as a white solid. Yield O. lOlg.
MS: APCI(+ve) 425 (M+l, 100%) !H NMR: δ (CDCI3) 1.76(2H, m), 1.92(2H, m), 2.27(3H, s), 2.64(2H, d), 2.85(2H, m), 3.20(2H, s), 4.26(2H, s), 7.06(1H, m), 7.20(2H, m), 7.68(1H, m), 7.87(1H, ), 8.02(1H, d), 8.13(1H, m), 8.18(1H, s), 8.68(1H, s) MP: 166-8 °C
Example 41
2-[8-(3-Methoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000070_0001
The title compound was prepared from the product of Example 20 step (iv) and 3- methoxybenzenesulphonyl chloride by the method of Example 37 as a white solid Yield 0.095g.
MS: APCI(+ve) 430 (M+l, 100%)
!H NMR: δ (CDCI3) 1.75(2H, m), 1.82(2H, m), 2.26(3H, s), 2.65(2H, d), 2.82(2H, d of d),
3.18(2H, s), 3.86(3H, s), 4.25(2H, br s), 7.02-7.25(4H, m), 7.40-7.50(3H, m),
8.02(lH, d), 8.75(lH, br s)
MP: 163-5 °C
Example 42
2-[8-(Benzo[l,2,5]oxadiazole-4-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000071_0001
The title compound was prepared from the product of Example 20 step (iv) by the method of Example 37 as a white solid. Yield: 0.088g.
MS: APCI(+ve) 442 (M+l, 100%)
!H NMR: δ (CDC13) 1.90-2.02(4H, m), 2.28(3H, s), 2.65(2H, m), 2.90(2H, m),
3.16(2H, s), 4.55(2H, s), 7.06(1H, m), 7.19(2H, m), 7.54(1H, m), 8.08(3H, d),
8.75(1H, br s)
MP: 167-8 °C
Example 43
2-[8-(Benzo[l,2,5]thiadiazole-4-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000071_0002
The title compound was prepared from, the product of Example 20 step (iv) by the method of Example 37 as a white solid. Yield 0.108g.
MS: APCI(+ve) 458 (M+l, 100%) lU NMR: δ (CDCI3) 1.75(2H, m), 1.93(2H, m), 2.27(3H, s), 2.62(2H, m), 2.85(2H, d of d), 3.14(2H, s), 4.61(2H, br s), 7.05(1H, m), 7.20(2H, m), 7.70(1H, m), 8.02(1H, d), 8.26(2H, d of d), 8.77(1H, br s) MP: 169-70 °C Example 44
2-[8-(5-ChIorothieno-2-yl)sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000072_0001
The title compound was prepared from the product of Example 20 step (iv) and 2-chloro-5- chlorosulphonyl-thiophene by the method of Example 37 as a white solid. Yield 0.108g.
MS: APCI(+ve) 440 (M+l, 100%) !H NMR: δ (CDC13) 1.90(4H, m), 2.28(3H, s), 2.70(2H, d), 2.86(2H, m), 3.21(2H, s), 4.27(2H, br s), 6.94(1H, d), 7.05(1H, m), 7.20(2H, m), 7.42(1H, d), 8.04(1H, d), 8.73(1H, br s) MP: 150-2 °C
Example 45
2-[8-(2-ChlorobenzenesuIphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000072_0002
The title compound was prepared from the product of Example 20 step (iv) and 2- chlorobenzenesulphonyl chloride by the method of Example 37 as a white solid. Yield 0.085g.
MS: APCI(+ve) 434 (M+l, 100%) lB NMR: δ (CDCI3) 2.07(4H, m), 2.31(3H, s), 2.66(2H, d), 2.82(2H, m), 3.18(2H, s), 4.31(2H, br s), 7.05(1H, m), 7.22(2H, ), 7.40(1H, m), 7.53(2H, m), 8.05(1H, d), 8.12(1H, d ofd), 8.80(lH, br s) MP: 170-1 °C
Example 46
2-[8-(5-Chloro-2-methoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000073_0001
The title compound was prepared from the product of Example 20 step (iv) and 3-chloro-6- methoxybenzenesulphonyl chloride by the method of Example 37 as a white solid Yield 0.105g.
MS: APCI(+ve) 464 (M+l, 100%) H NMR: δ (CDC13) 1.93(4H, m), 2.30(3H, s), 2.62(2H, m), 2.85(2H, m), 3.17(2H, s),
3.95(3H, s), 4.35(2H, br s), 6.95(1H, d), 7.05(1H, ), 7.20(2H, m), 7.46(1H, d of d), 7.91(1H, d), 8.05(1H, d), 8.80(1H, br s) MP', 180-1 °C
Example 47
2-[8-(4-Acetylammomethoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000074_0001
The title compound was prepared from the product of Example 20 step (iv) and 4- acetylamidobenzenesulphonyl chloride by the method of Example 37 as a white solid. Yield 0.108g.
MS: APCI(+ve) 457 (M+l, 100%)
*H NMR: δ (CDC13) 1.60(2H, m), 1.82(2H, m), 2.18(3H, s), 2.26(3H, s), 2.65(2H, d),
2.80(2H, d of d), 3.18(2H, s), 4.20(2H, br s), 7.05(1H, m), 7.18(2H, m), 7.78(4H, s), 8.00(1H, d), 8.77(1H, br s), 9.64(1H, s) MP: 205-6 °C
Example 48
N-(2-Methylphenyl)-2-[(8-(3-methylthieno[2,3-< ]pyrimidm-4-yl)-3,8- diazabicyclo[3.2.1]oct-3-yl]acetamide
Figure imgf000074_0002
The trifluoroacetate salt of Example 20 step (iv) was converted to the free base by use of aqueous 2N NaOH solution followed by extraction with ethyl acetate. The extracts were dried (MgSO4), filtered and evaporated to dryness, leaving an oil which crystallised on standing. MS: ES(+ve) 260 (M+l , 100%)
A mixture ofthe amine free base (0.13g), N,N-disopropylethylamine (0.5ml), 4- dimethylatninopyrimidine (0.06g) and 4-chloro-3-methylthieno[2,3-d]pyrimidine was heated in N-methylpyrrolidin-2-one (5.0ml) at 100 °C for 5 hours. The solvent was evaporated under high vacuum and the residue was slurried with water, filtered and dried. Purification was by chromatography on silica gel eluting with dichloromethane containing ethanol (1%) to give the title compound as a white solid. Yield (0.053g).
MS: APCI(+ve) 408 (M+l, 100%) lR NMR: δ (CDC13) 1.98(4H, m), 2.35(3H, s), 2.62(3H, s), 2.95(4H, m), 3.26(2H, s),
4.46(2H, br s), 7.00(1H, s), 7.10(1H, m), 7.20(2H, m), 8.10(1H, d), 8.53(1H, s), 8.96(1H, br s) MP: 199-200 °C
Example 49 c s-2-(3,5-Dimethyl-4-(thieno[2,3-« lpyrimidm-4-yl)piperazin-l-yl)-N-(l-methyl-lJH- benzoimidazol-2-yl)acetamide
Figure imgf000075_0001
The title compound was prepared from the product of Example 9 step (ii) (0.2g) and 2- amino- 1-methyl-benzimidazole (0.14g) by the method of Example 38 step (iv). Purification was, by silica gel chromatography followed by recrystallisation from methanol. Yield 45mg.
MS: APCI (+ve) 436 (M+l)
!H NMR: δ (CDCI3) 8.47 (lH,s), 7.41 (lH,d), 7.26 (3H,m), 5.01 (2H,brs), 3.68 (3H,s),
3.40 (2H,s), 3.05 (2H,d), 2.50 (2H,d), 1.61 (6H,s).
M.P. 200°C
Example 50 C5-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrinιidm-4-yl)piperazin-l-yl)-N-(2-methyl-5-(4- piperidmyloxy)phenyl)acetamide, hydrochloride salt
Figure imgf000076_0001
i) 1,1-Dimethylethyl, 4-(4-methyI-3-nitro)phenoxypiperidme-l-carboxylate
A solution of 4-methy 1-3 -nitrophenol (2g), 1,1-dimethylethyl, 4-hydroxypiperidine-l- carboxylate (2.6g), triphenylphosphine (4.11 g) in tetrahydrofuran (40ml) under nitrogen at 0 °C was treated with diethylazidodicarboxylate (2.3ml) over 1 minute. The cooling bath was removed and the mixture allowed to stir at ambient temperature for 48h. The solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane containing 1% triethylamine to give the subtitle product as a pale yellow oil. Yield: 3.46g
'H NMR δ (CDC13) 7.52(dd, IH), 7.21(dd, IH), 7.08(dd, IH), 4.50(m, IH), 3.70(m, 2H), 3.55(m, 2H), 2.50(s, 3H), 2.0-1. (m, 4H), 1.5 (s,9H)
ϋ) 1,1-Dimethylethyl, 4-(3-aιnino-4-methyl)phenoxypiperidine-l-carboxylate
A solution ofthe product from step (i) (2g), 10% Palladium on charcoal (300mg) were stirred under a lbar atmosphere of hydrogen at ambient temperature. The mixture was filtered through celite and solvent removed under reduced pressure to leave the subtitle product as a beige solid. Yield: 1.88g
'H NMR δ (CDCI3) 6.9(d, IH), 6.3(m, 2H), 4.4(m, IH), 3.7(m, 2H), 3.6(bs, 2H), 3.3(m, 2H), 2.10(s, 3H), 1.9-1.6(m, 4H), 1.50(s, 9H)
iϋ) 2-Chloro-N-5-(l-(l,l-dimethylethoxycarbonyl)-4-piperidmyloxy)-4-methyl-5- nitro) acetamide A solution ofthe product from step (ii) (1.4g), N,N-diisopropylethylamine (2ml) in dichloromethane( 30ml) under nitrogen at 0 °C was treated with chloroacetylchloride (0.4ml). After 4h the reaction mixture was partitioned between water and dichloromethane. The organic phase collected, dried (MgSO4) and solvent reduced under reduced pressure to leave the subtitle compound as a brown oil. Yield: 1.8g This was used directly in the next step.
iv) C5-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrimidm-4-yl)piperazin-l-yl)-N-(2-methyl-5- (l-(l,l-dimethylethoxycarbonyl)-4-piperidinyloxy)phenyl)acetamide The subtitle compound was prepared from the product of Example 2 step (ii) (0.4g) and the product of step (iii) (0.56g) by the method of Example 33 step (iv) as a pale yellow gum. Yield: 0.25g
MS: APCI(+ve) 595 (M+l), APCI(-ve) 593(M-1)
v) C s-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrimidm-4-yl)piperazin-l-yl)-N-(2-methyl-5- (4-piperidinyloxy)phenyl)acetamide, hydrochloride salt
The title compound was prepared from the product of step (iv) (0.24g) by the method of Example 27 step (iv) as a white solid. Purification was by reverse phase HPLC eluting with aq. l%ammonium acetate/acetonitrile (95% to 60%). Yield. 80mg
MS: APCI(+ve) 495(M+1), APCI(-ve) 493 (M-1)
'HNMR δ (DMSO) 8.97(bs, IH), 8.52(s, IH), 7.7(d, IH), 7.62(d, IH), 7.26(s, IH), 7.18(d, IH), 6.84(d, IH), 5.30(bs, 2H), 4.60(bs, IH), 3.30-3.00(2xbs, 4H), 2.20(s, 3H), 2.15- 1.80(m, 4H), 1.60(d, 6H)
Example 51
C5-2-(3,5-Dimethyl-4-benzenesulphonyl)piperazin-l-yl)-N-(2-methyl-5-(4- piperidiαyloxy)phenyl)acetamide
Figure imgf000078_0001
i) C s-2-(3,5-Dimethyl-4-benzenesulphonyl)pip dimethylethoxycarbonyl)4-piperidinyloxy)phenyl)acetamide
The subtitle compound was prepared from the product of Example 33 step (ii) (0.42g) and the product of Example 50 step (iii) (0.55g) by the method of Example 33 step (iv). Purification was by silica gel chromatography eluting with dichloromethane/ethyl acetate (95:5) to give the subtitle compound as colourles gum. Yield: 0.23g
MS: APCI(+ve) 601 (M+l), APCI(-ve) 599 (M-1)
ii) C5-2-(3,5-Dimethyl-4-benzenesulphonyI)piperazin-l-yl)-N-(2-methyl-5-(4- piperidinyloxy)phenyl)acetamide
The title compound was prepared from the product of step (i) (0.2g) by the method of Example 27 step (iv) as a white solid after purification by reverse phase HPLC eluting with 1% aq. ammonium acetate/acetonitrile (95% to 60%). Yield: 50mg
MS: APCI(+ve) 501 (M+l), APCI(-ve) 499 (M-1)
'HNMR δ (DMSO) 8.8(bs, IH), 7.8(d, 2H), 7.7(m, 3H), 7.25(s, IH), 7.15(d, IH), 6.75(d, IH), 4.60(m, IH), 4.2-4.0(bs, 2H), 3.3-3.0(2xm, 4H), 2.2(s, 3H), 2.15-1.70(m, 4H), 1.5(d, 6H)
Example 52
Cs'-2-(3,5-Djlmethyl-4-(qumazojun-4-yl)piperazin-l-yl)-N-(2-methyl-5-(4- piperidinyloxy)phenyl)acetamide
Figure imgf000079_0001
i) 1,1-Dimethylethyl, 4-(4-quinazoliιιyl)-3,5-dimethylpiperazine-l-carboxylate
4-Chloroquinazoline (6g), cis- 1,1 -diethyl ethyl, 3,5-dimethylpiperazine-l -carboxylate (7.8g), N,N-diisopropylethylamine (32ml) in l-methyl-2-pyrrolidinone (70ml) were heated at 120 °C for 6 days under nitrogen. The mixture was partitioned between ethyl acetate and brine. The organic phase collected and further washed with brine (x2), collected, dried (MgSO4) and solvent evaporated under reduced pressure to leave a pale brown solid. Purification was by silica gel chromatograpy eluting with ethyl acetate/iso-hexane (3:7) to give the subtitle compound as a pale yellow oil. Yield: l.lg
MS: APCI(+ve) 343 (M+l)
ii) c 5-4-(4-Quinazolinyl)-2,6-dimethylpiperazine, hydrochloride salt
The subtitle compound was prepared from the product of step (i) (lg) by the method of Example 27 step (iv) as cream solid. Yield: 1.8g
MS: APCI(+ve) 243 (M+l)
iii) C5-2-(3,5-Dimethyl-4-(4-quinazolinyl)piperazin-l-yl)-N-(2-methyl-5-(l-(l,l- dimethylethoxycarbonyl)4-piperidinyloxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (ii) (0.56g) and the product of Example 50 step (iii) (0.37g) by the method of Example 33 step (iv). Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane (9:1) to give the subtitle compound as a white solid. Yield. 0.18g
MS: APCI(+ve) 589 (M+l) iv) C/5-2-(3,5-Dimethyl-4-(qumazojlin-4-yl)piperazin-l-yl)-N-(2-methyl-5-(4- piperadinyloxy)phenyl)acetamide
The title compound was prepared from the product of step (iii) (0.18g) by the method of Example 27 step (iv). Purification was by reverse phase HPLC eluting qith 1% aq. ammonium acetate/acetonitrile (99% to 50%) to give the title compound as a white solid. Yield: 0.079g
MS: APCI(+ve) 489 (M+l)
'H NMR δ (CDC13) 9.26(bs, IH), 9.08(bs, IH), 8.35(4 IH), 8.00(d, IH), 7.95(s, IH), 7.90(t, IH), 7.60(t, IH), 7.10(4 IH), 6.61(4 IH), 4.57(m, IH), 3.25(m+s, 4H), 3.05(m, 2H), 2.90(d, 2H), 2.60(m, 2H), 2.30(s, 3H), 2.10(m, 2H), 2.0(m, 2H), 1.0(4 6H)
Example 53
C/ 2-(3,5-Dimethyl-4-(4-qumazojlmyl)piperazin-l-yl)-N-(2-methyl-5-(piperazm-4-yl- methyl)phenyl)acetamide
Figure imgf000080_0001
i) 2-Chloro-N-5-((l-(l,l-dimethylethyloxycarbonyl)piperazin-4-yI)methyl)phenyl-2- methyl)acetamide
The subtitle compound was prepared from the product of Example 27 step (ii) (O.lg) by the method of Example 33 step (iii) as a beige foam. Yield:0.15g
MS: APCI(+ve) 382 (M+l)
ύ Cw-2-(3,5-Dimethyl-4-(4-quinazolinyl)piperazin-l-yl)-N-(2-methyl-5-(l-(l,l- dimethylethyloxycarbonyl)piperazin-4-yl-methyl)phenyl)acetamide
The subtitle compound was prepared from the product of Example 52 step (ii) (0.2g) and the product of step (i) (0.21g) by the method of Example 33 step (iv). Purification was by silica gel chromatography eluting with ethyl acetate/iso-hexane (9:1) to give the subtitle compound as a white solid. Yield. 0.068g
MS: APCI(+ve) 588 (M+l)
iii) C5-2-(3,5-Dimethyl-4-(4-qumazojlmyl)piperazin-l-yl)-N-(2-methyl-5-(piperazin-4- yl-methyl)phenyl)acetamide
The title compound was prepared from the product of step (ii) (0.069g) by the method of Example 27 step (iv). Purification was by reverse phase HPLC eluting with 1% aq. ammonium acetate/acetonitrile (99% to 50%) to give the title compound as a white solid. Yield: 0.072g
MS: APCI(+ve) 488 (M+l)
'H NMR δ (CDCI3) 8.58(bs, IH), 8.25(bs, IH), 7.63(4 IH), 7.20(m, 2H), 6.95(t, IH), 6.50(d, IH), 6.35(d, IH), 3.60(bs, 2H), 2.80(s, IH), 2.60(s, IH), 2.30(bs, 3H), 2.20(d, IH), 2.0(m, IH), 1.90(bs, 2H), 1.70(s, 2H), 1.30(bd, 6H)
Example 54
Cs-2-(3,5-Dimethyl-4-(4-qumazolinyl)piperazin-l-yl)-N-(2-methyl-5-(2-(N- methylamino)ethoxy)phenyl)acetamide
Figure imgf000081_0001
i) Cis-2-(3,5-Dimethyl-4-(4-quiιιazolinyl)piperazin-l-yl)-N-(2-methyl-5-(2-(l,l- dimethylethyloxycarbonyI-N-methylaminoethoxy)phenyl)acetamide
The subtitle compound was prepared from the product of Example 52 step (ii) (0.64g) and the product from Example 33 step (iii) (0.59g) by the method of Example 33 step (iv). Yield. 0.45g MS: APCI(+ve) 563 (M+l), APCI(-ve) 561 (M-1)
H) Cz5-2-(3,5-Dimethyl-4-(4-quinazolinyl)piperazin-l-yl)-N-(2-methyl-5-(2-(N- methylamino)ethoxy)phenyl)acetamide The title compound was prepared from the product of step (i) (0.4g) by the method of Example 27 step (iv). Purification was by reverse phase HPLC eluting with 1% aq. ammonium acetate/acetonitrile (99% to 50%) to give the title compound as a white solid. Yield: 0.25g
MS: APCI(+ve) 463 (M+l)
'H NMR δ (CDC13) 9.30(bs, IH), 9.12(bs, IH), 8.39(, IH), 8.05(d, IH), 7.95(m, 2H), 7.60(t, IH), 7.10(4 IH), 6.70(d, IH), 4.20(m, 2H), 4.0(bs, 2H), 3.30(s, 2H), 3.20(m, 2H), 2.90(m, 2H), 2.60(m+s, 5H), 2.35(s, 3H), 1.0(bs, 6H)
Example 55 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000082_0001
i) cts-2-(3,5-Dimethylpiperazin-l-yl-N-(2-methylphenyl)acetamide
A mixture of 2-chloro-N-(2-methylphenyl)acetamide (1.83g), N,N-disopropylethylamine (5.0ml), sodium iodide (0.020g) and ets-2,6-dimethylpiperazine 1.14g) in ethanol (50ml) was heated at reflux for 2.5 hours. The solvent was removed and the residue was crystallised from ethanol as white needles. It was dissolved in water and the solution was made basic with 2N aqueous NaOH, extracted with dichloromethane and the extracts were dried (MgSO4), filtered and evaporated to dryness, leaving an oil which crystallised on standing. Yield l.lg. H NMR: δ (CDCI3) 1.08(6H, d), 1.40(1H br s) 1.94(2H, t), 2.27(3H, s), 2.83(2H, m), 2.98(2H, m) 3.14(2H, s), 7.03(1H, m), 7.20(2H, m), 8.18(1H, d), 9.32(1H, br s) MP: 105-6 °C
ii) c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide The product of step (i) (0.60g), 4-dimethylaminopyridine (0.14g) in pyridine (2.0ml) was stirred while 3-cyanobenzenesulphonyl chloride (0.46g) was added. The mixture was stirred for 10 minutes after which it solidified. After 1 hour the solid was triturated with water and filtered off. It was purified by chromatography on silica eluting with ethyl acetate/iso-hexane (1:1) to give the title compound as a pale yellow solid. Yield: 0.22g.
MS: APCI(+ve) 427 (M+l, 100%) H NMR: δ (CDCI3) 1.55(6H, d), 2.17(2H, d of d), 2.32(3H, s), 2.73(2H, d), 3.10(2H, s),
4.13(2H, m), 7.10(1H, m), 7.20(2H, m), 7.67(1H, m), 7.85(1H, m), 7.95(1H, m), 8.05(1H, m), 8.12(1H, m), 8.67(1H, br s). MP: 152-3 °C
Example 56 c s-N-(2-Methylphenyl)-2-[4-(3-nitrobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]- acetamide
Figure imgf000083_0001
The title compound was prepared from the product of Example 55 step (i) and 3- nitrobenzenesulphonyl chloride by the method of Example 55 step (ii) as an off white solid. Yield: 3.06g
MS: APCI(+ve) 447 (M+l, 100%)
!H NMR: δ (CDC13) 1.59(6H, d), 2.20(2H, d of d), 2.30(3H, s), 2.74(2H, d), 3.10(2H, s), 4.16(2H, m), 7.05(1H, m), 7.20(2H, m), 7.75(1H, t), 7.96(1H, d), 8.16(1H, d of d), 8.43(1H, d of d), 8.67(2H, br s). MP: 163-4 °C
Example 57 c s-2-[4-(3-Aminobenzenesulphonyl)-3,5-dimethylpiperazύι-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000084_0001
To a stirred solution ofthe product of Example 56 (3.0g) in ethanol (1500ml) was added 5%,palladium on charcoal (1.5g) followed by dropwise addition of hydrazine hydrate (20ml). The mixture was stirred for 1 hour, filtered through 'hyflo' and the filtrate was evaporated to dryness. The solid residue was crystallised from ethanol to give the title compound as a white solid. Yield 1.6g.
MS: APCI(+ve) 417 (M+l, 100%)
^ NMR: δ (CDCI3) 1.54(6H, d), 2.18(2H, d of d), 2.30(3H, s), 2.65(2H, d), 3.07(2H, s), 3.90(2H, s), 4.15(2H, m), 6.82(1H, d of d), 7.05-7.20(6H, m), 7.99(1H, d), 8.75(1H, s). MP: 202-3 °C Example 58
C5-2-(3,5-Dimethyl-4-(3-cyanobeιιzenesulphonyl)piperazm-l-yl)-N-(qumolin-5- yl)acetamide
Figure imgf000085_0001
i) C/5-2-(3,5-Dimethyl-piperazm-l-yl)-N-(quinolin-5-yl)acetamide
A mixture of 2-chloro-N-(quinolin-5-yl)acetamide (7.76g) (J. Indian Chem Soc, 1940, 17, 619-621), cis-2,6-dimethylpiperazine (4.42g), sodium bicarbonate (8.9g) in ethanol (100ml) was heated at reflux for 4h. The solvent was removed under reduced pressure, The residue was partitioned between chloroform and brine. The organic phase collected and the aqeuous phase further extracted (x6 ) with chloroform. The combined extracts dried (MgSO4) and solvent removed under reduced pressure. Yield: 6.8g
MS: APCI(+ve) 299 (M+l)
ii) Ct 2-(3,5-Dimethyl-4-(3-cyanobenzenesulphonyl)piperazm-l-yl)-N-(quinolin-5- yl)acetamide
The product from step (i) (150mg), 4-N,N-dimethylaminopyridine (31mg) in pyridine (0.5ml) was treated in one portion with 3-cyanobenzenesuphonyl chloride (leq) and then immediately heated for 30 minutes. The mixture was partitioned between dichloromethane and water. The organic phase collected, dried (MgSO4) and solvent removed under reduced pressure. The reisdue was purified by reverse phase HPLC eluting with 0.1% aq. ammonium acetate/acetontrile (95%> to 50%) as eluant to give the title compound as a white solid. Yield: 8mg
MS: APCI(+ve) 464 (M+l) 'HNMR δ (CD3OD) 9.87(d, IH), 8.4(4 IH), 8.3(4 IH), 8.2(m, 2H), 8.0(m 2H), 7.78(m, 2H), 7.6(m, IH), 4.2(m, 2H), 3.24(s, 2H), 2.82(d, 2H), 2.1(dd, 2H), 1.57(d, 6H)
Example 59 C/5-2-(3,5-Dimethyl-4-(4-cyanobenzenesulphonyl)piperazin-l-yl)-N-(quinolm-5- yl)acetamide
Figure imgf000086_0001
The title compound was prepared from the product of Example 58 step (i) (0.503 mmol) and 4-cyanobenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 4mg
MS: APCI(+ve) 464 (M+l)
'HNMR δ (CD3OD) 8.9(d, IH), 8.4(d, IH), 8.1(d, 2H), 7.93-7.96(m, 2H), 7.8(m, 2H),
7.6(m, IH), 4.2(m, 2H), 3.24(s, 2H), 2.81(d, 2H), 2.1(dd, 2H), 1.57(d, 6H)
Example 60
Cw-2-(4-(3-cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide
Figure imgf000086_0002
i) c s-(3,5-Dimethylpiperazin-l-yl)-N-(2-methyl-3-fluorophenyl)acetamide The subtitle compound was prepared from the product of Example 36 step (i) (14.5g) and cz's-2,6-dimethylpiperazine (9.0g) by the method of Example 58 step (i) as cream solid. Yield: 11.48g
MS: APCI(+ve) 280 (M+l)
ii) C/s-2-(4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide
The title compound was prepared from the product of step (i) (0.503mmol) and 3- cyanobenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 44mg
MS: APCI(+ve) 445 (M+l)
'H NMR δ (CD3OD) 8.24(d, IH), 8.14(4 IH), 7.98(4 IH), 7.76(t, IH), 7.36(4 IH), 7.1(q, IH), 6.93(t, IH), 4.14-4.16(m, 2H), 3.10(s, 2H), 2.73(4 2H), 2.16(d, 3H), 2.04(dd, 2H), 1.53(4 6H)
Example 61
Cis-2-(4-(4-Cyanobenzenesulphonyl)-3,5-dimethyipiperazin-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide
Figure imgf000087_0001
The title compound was prepared from the product of Example 60 step (i) (0.503mmol) and 4-cyanobenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 4mg
MS: APCI(+ve) 445 (M+l) 'H NNMR δ (CD3OD) 8.24(d, IH), 8.14(4 IH), 7.98(4 IH), 7.76(t, IH), 7.36(4 IH), 7.1 (q, IH), 6.93(t, IH), 4.14-4.16(m, 2H), 3.10(s, 2H), 2.73(4 2H), 2.16(d, 3H), 2.04(dd, 2H), 1.53(d, 6H)
Example 62 c/s-2-[4-(3-Acetylaminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000088_0001
A solution ofthe product from Example 57 (0.2g) and N,N-diisopropylethylamine (0.3ml) in dichloromethane (10ml) was rapidly stirred whilst a solution of acetyl chloride (0.055g) in dichloromethane (2.0ml) was added. After 3 hours a further amount of acetyl chloride (0.022g) was added, the mixture was stirred 3 hours more then evaporated to dryness. The residue was triturated with water, filtered and dried in vacuo, to give the title compound as a white solid. Yield 0.17g.
MS: APCI(+ve) 459 (M+l, 100%) H NMR: δ (CDCI3+DMSO) 1.53(6H, d), 2.17(3H, s), 2.26(2H, m), 2.30(3H, s),
2.66*(2H,d), 3.08(2H, s), 4.14(2H, m), 7.07(113, m), 7.20(2H, m), 7.42(1H, m), 7.48(1H, m), 7.82(1H, d), 7.95(1H, d), 8.16(1H, s), 8.77(1H, s), 9.49(1H, s) MP: 236-8 °C
Example 63 c 5-2-[4-(3-Am ocarbonylbeιιzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000089_0001
Hydrgen chloride gas was bubbled through a solution ofthe product of Example 55 step (ii) (0.2 lg), in methanol (50ml) at 0 °C for 4 hours. The mixture was evaporated to dryness, the residue was dissolved in methanol and ethylenediamine (0.18g) was added. After 3 hours LC/MS indicated mainly amide. After 18 hours the mixture was evaporated to dryness, the residue was triturated with ether/ethanol, filtered and the solid was purified by chromatography on silica gel eluting with dichloromethane containing ethanol (2.5-5%) to give the title compound as a white solid. Yield 0.08g.
MS: APCI(+ve) 445 (M+l, 100%) H NMR: δ (CDCI3+DMSO) 1.54(6H, d), 2.13(2H, ), 2.29(3H, s), 2.70(2H,d),
3.06(2H, s), 4.14(2H, ), 6.24(1H, br s), 7.07(1H, m), 7.21(2H, m), 7.60(1H, t), 7.68(lH, br s), 7.93(2H, d), 8.15(1H, d), 8.41(1H, s), 8.74(1H, s) MP: 124-5 °C
Example 64 c 5-2-[4-(3-Methanesulphonylanιinobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-
(2-methylphenyl)acetamide
Figure imgf000089_0002
The title compound was prepared from the product of Example 57 and methane sulphonyl chloride by the method of Example 62. The solid obtained at the end ofthe reaction was suspended in ethanol (50ml) to which a solution of K2CO3 (0.2g) in water (10ml) was added, and stirred for 18 hours, in order to hydrolyse any bis-sulphonamide. The ethanol was removed, water (50ml) was added and the pH was adjusted to 5.0. The solid was filtered off, washed with water and ether and dried in vacuo to give the title compound as a white solid. Yield 0.13g.
MS : APCI(+ve) 495 (M+ 1 , 100%)
!H NMR: δ (CDC13) 1.54(6H, d), 2.20(2H, m), 2.30(3H, s), 2.68(2H,d), 3.06(3H, s), 3.09(2H, s), 4.13(2H, m), 7.07(1H, m), 7.20(2H, m), 7.25(1H, s), 7.40(1H, d of d), 7.48(1H, t), 7.60(1H, d), 7.68(1H, m), 7.95(1H, d), 8.73(1H, s) MP: 102-3 °C
Example 65 cis-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide
Figure imgf000090_0001
i) c s-[3,5-Dimethylpiperazm-l-yl]-N-(3-methoxy-2-methylphenyl)acetamide
The subtitle compound was prepared from 2-chloro-N-(3-methoxy-2- methylphenyl)acetamide (10.72g) and cts-2,6-dimethylpiperazine (6.29g) by the method of Example 58 step (i) as a tan solid. Yield: 13.13g
'H NMR δ (CDCI3) 9.32(bs, IH), 7.79(d, IH), 7.18(t, IH), 6.68(d, IH), 3.83(s, 3H), 3.14(s, 2H), 2.93-3.04(m, 2H), 2.81-2.85(m, 2H), 2.14(s, 3H), 1.92(t, 2H), 1.10(d, 6H)
ϋ) cw-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide The title compound was prepared from the product of step (i) (0.503mmol) and 2- methanesulphonylbenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 6mg
MS: APCI(+ve) 510(M+1)
'H NMR δ (CD3OD) 8.4(m, IH), 8.3(m, IH), 7.91-7.89(m, 2H), 7.16-7.18(m, 2H), 6.8(t, IH), 4.2(m, 2H), 3.84(s, 3H), 3.43(s, 3H), 3.14(s, 2H), 2.74(d, 2H), 2.33(dd, 2H), 2.14(s, 3H), 1.61(d, 6H)
Example 66 cfs-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3- fluoro-2-methylphenyi)acetamide
Figure imgf000091_0001
The title compound was prepared from the product of Example 60 step (i) (0.503mmol) and 2-methanesulphonylbenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 17mg
MS: APCI(+ve) 498 (M+l)
'H NMR δ (CD3OD) 8.4(m, IH), 8.3(m, IH), 7.89-7.91(m, 2H), 7.4(d, IH), 7.1(q, IH), 6.'9(t, IH), 4.2(m, 2H), 3.44(s, 3H), 3.16(s, 2H), 2.74(4 2H), 2.3(dd, IH), 2.20(d, 2H), 1.62(d, 6H)
Example 67 cw-2-[4-(l-MethyUjmidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazm-l-yl]-N-(qumojlin- 5-yl)acetamide
Figure imgf000092_0001
The title compond was prepared from the product of Example 58 step (i) (0.503mmol) and l-methylimidazole-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 16mg
MS: APCI(+ve) 443 (M+l)
Η NMR δ (CD3OD) 8.90(d, IH), 4.45(d, IH), 7.97(t, IH), 7.82(s, IH), 7.80(4 IH), 7.68(s, IH), 7.58-7.63(m, IH), 4.17-2.21(m, 2H), 3.79(s, 3H), 3.26(s, 2H), 2.80(4 2H), 2.25(dd, 2H), 1.58(d, 6H)
Example 68 s-2-[4-(l-MethyUmidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide
Figure imgf000092_0002
The title compound was prepared from the product of Example 65 step (i) (0.503mmol) and l-methylimidazol-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 3 lmg
MS APCI(+ve) 436 (M+l) 'H NMR δ (CD3OD) 7.77 (s, IH), 7.67(s, IH), 7.16-7.18(m, 2H), 6.82-6.85(m, IH), 4.14- 4.18(m, 2H), 3.84(s, 3H), 3.79(s, 3H), 3.10(s, 2H), 2.72(d, 2H), 2.20(dd, 2H), 2.13(s, 3H), 1.53(d, 6H)
Example 69 c/s-2-[4-(l-MethyUιmdazoϊ-4-sulphonyl-4-yl)-3,5-dimethyIpiperazin-l-yl]-N-(3-fluoro- 2-methylphenyl)acetamide
Figure imgf000093_0001
The title compound was prepared from the product of Example 60 step (i) (0.503mmol) and l-methylimidazol-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 21mg
MS: APCI(+ve) 424 (M+l)
'H NMR δ (CD3OD) 7.77 (s, IH), 7.67 (s, IH), 7.43 (d, IH), 7.20(q, IH), 6.95(t, IH), 4.12- 4.20(m, 2H), 3.79(s, 3H), 3.12(s, 2H), 2.72(d, 2H), 2.17-2.23(m, 5H), 1.54(d, 6H)
Example 70 c/s-2-[4-(3-Methanesulphonylbenzeuesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide
Figure imgf000093_0002
i) 2-Chloro-N-(2-trifluoromethylphenyl)acetamide The subtitle compound was prepared from 2-trifluoromethylaniline(10.5g) and chloroacetyl chloride (6.8ml) by the method of Example 33 step (iii) as a white solid. Yield: 13.7g
MS: APCI(-ve) 236 (M-1)
ii) cw-3,5-Dimethylpiperazm-l-yl]-N-(2-trifluoromethylphenyl)acetamide
The subtitle compound was prepared from the product of step (i) (7.6g ) and cis-2,6- dimethylpiperazine (3.53g) by the method of Example 58 step (i) as a white solid. Yield: 8.57g
MS: APCI(+ve) 316 (M+l)
iii) cts-2-[4-(3-MethanesuIphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide
The product of step (iii) (0.25g) and 3-methanesulphonylbenzenesulphonyl chloride (0.606g), potassium carbonate (0.275g) in 2,6-lutidine(0.5ml) were heated in a lOOWatt microwave oven at 120 °C for lOmin. The mixture was then partitioned between dichloromethane and water. The organic phase collected, dried (MgSO4), and the solvent evaporated under reduced pressure. Purification was by revese phase HPLC eluting with l%tøq. ammonium acetate/acetonitrile (95% to 60%) to give the title compound as a white solid. Yield: O.lg
MS: APCI(+ve) 534 (M+l) 'H NMR δ (CDC13) 9.16(bs, IH), 8.41 (s, IH), 8.30(4 IH), 8.20(d, IH), 7.58(t, IH), 7.26(d, IH), 4.15(m, 2H)
Example 71 ew-2-[4-(2-AniinoethylammocarbouyIbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]- N-(2-methylphenyl)acetamide
Figure imgf000095_0001
The title compound was prepared from the product of Example 55 by the method of Example 63 followed by addition of ethylenediamine, the mixture was heated at reflux for 5 hours, evaporated to dryness and the residue was crystallised from ethanol to give the title compound as a white solid. Yield 0.15g
MS: APCI(+ve) 488 (M+l, 100%) lH NMR: δ (CDC13) 1.56(8H, m), 2.17(2H, m), 2.29(3H, s), 2.68(2H, d), 2.98(2H, t), 3.06(2H, s), 3.51(2H, m), 4.14(2H, m), 6.97(1H, br t), 7.07(1H, m), 7.20(2H, m), 7.60(1H, t), 7.9(3H, m), 8.25(1H, m), 8.71 (IH, br s) MP: 90-2 °C
Example 72 c/5-2-[4-(l,l,2,2-Tetrahydroisoqumj in-7-sulphonyl-7-yl)-3,5-dimethylpiperazm-l-yl]- N-(2,6-dimethylphenyl)acetamide
Figure imgf000095_0002
i) cw-3,5-Dimethylpiperazin-l-yl]-N-(2,6-dimethylphenyl)acetamide The subtitle compound was prepared from 2-chloro-N-(2,6-dimethylphenyl)acetamide (6.54g) and cz -2,6-dimethylpiperazine (3.78'g) by the method of Example 58 step (i) as a white solid. Yield:7.85g MS: APCI(+ve): 276(M+1)
ϋ) c s-2-[4-(N-Trifluoroacetyl(l,l,2,2-tetrahydroisoqumilin)-7-sulphonyl-7-yl)-3,5- dimethylpiperazin-l-yl]-N-(2,6-dimethylphenyl)acetamide
The subtitle compound was prepared from the product of step (i) (0.165g) and N-trifluoroacetyl(l,l,2,2-tetrahydroisoquinolin)-7-sulphonyl chloride (0.39g) by the method of Example 58 step (ii) as a white solid. Yield: 96mg
MS: APCI(+ve) 567 (M+l)
iu) α5-2-[4-(l,l,2,2-Tetrahydroisoqumilm-7-sulphonyl-7-yl)-3,5-dimethylpiperazin-l- yl]-N-(2,6-dimethylphenyl)acetamide
The product from step (ii) (90mg), potassium carbonate (200mg) in water (10ml) and methanol (15ml) were heated at reflux for 2h. Water (50ml) was added and the mixture extracted with ethyl acetate. The organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure to give the title compound as a white solid. Yield: 55mg
MS: APCI(+ve) 471 (M+l) 'H NMR δ (CDC13) 8.29(s, IH), 7.55(d, IH), 7.50(s, IH), 7.17(d, IH), 7.1 l(m, 3H),
4.14(m, 2H), 4.06(s, 2H), 3.48(q, IH), 3.17(t, IH), 3.12(s, 2H), 2.87(t, 2H), 2.72(d, 2H), 2.25(d, IH), 2.22(s, 6H), 2.05(s, IH), 1.69(bs, IH), 1.51(4 6H), 1.19-1.28(m, 4H)
Example 73 c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2,6- dimethylphenyl)acetamide
Figure imgf000097_0001
The title compound was prepared from the product of Example 72 step (i) (0.165g) and 3- cyanobenzenesulphonyl chloride (0.15g) by the method of Example 58 step (ii) as a white solid. Yield: 40mg
MS: APCI(+ve) 441 (M+l)
'H NMR δ (CDC13) 8.22 (s, IH), 8.13(s, IH), 8.05(4 IH), 7.86(4 IH), 7.67(t, IH),
7.12(m, 3H), 4.15(m, 2H), 3.14(s, 2H), 2.78(4 2H), 2.22(s, 8H), 1.54(4 6H)
Example 74 c/s-2-[4-(4-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000097_0002
4-Cyanobenzenesulphonyl chloride (0.36g) was added to a stirred mixture ofthe product of Example 55 step (i) (0.5g) and potassium carbonate (0.62g) in l-methyl-2-pyrrolidinone (3ml). After 20 min the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried (MgSO4) and evaporated under reduced pressure. Purification was by flash chromatography eluting with 1% ethanol in dichloromethane followed by trituration with methanol to givethe title compound as a white crystalline solid. Yield 55mg.
MS: ES (+ve) 427 (M+l) H NMR: δ (CDCI3) 8.67 (lH,brs), 7.99-7.93 (3H,m), 7.83 (2H,d), 7.21 (2H,m), 7.08 (lH,m), 4.14 (2H,m), 3.10 (2H,s), 2.73 (2H,d), 2.30 (3H,s), 2.18 (2H,dd), 1.57 (3H,s), 1.54 (3H,s).
Example 75 cis-2-[4-(2-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2,6- dimethylphenyl)acetamide, hydrochloride salt
Figure imgf000098_0001
The free base ofthe title compound was prepared from the product of Example 72 step (i) (0.165g) and 2-cyanobenzenesulphonyl chloride (0.15g) by the method of Example 58 step (ii). The title compound was prepared by adding IM hydrogen chloride in diethyl ether to a solution ofthe free base to produce a white precipitate. This was filtered and further washed with diethyl ether to give the title compound as a white solid. Yield: 20mg
MS: APCI(+ve) 441 (M+l)
'H NMR δ (CDCI3) 8.19(bs, IH), 7.91(bs, IH), 7.78(bs, 2H), 7.10(m, 3H), 4.40(bs, 2H),
4.20(bs, 2H), 3.50(m, 3H), 2.20(s, 6H), 2.00-1.40(m, 6H)
Example 76 cis-2-[4-(3-CyanobenzenesuIphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- chlorophenyl)acetamide
Figure imgf000099_0001
The title compound was prepared from the product of Example 15 step (ii) (0.2g) and 3- cyanobenzenesulphonyl chloride (0.28g) by the method of Example 74 as a white solid. Yield 8mg.
MS: APCI (+ve) 447 (M+l) H NMR: δ (CDC13) 9.45 (lH,brs), 8.49 (lH,dd), 8.13 (lH,s), 8.05 (lH,d), 7.87 (lH,d), 7.68 (lH,t), 7.38 (lH,d), 7.29 (lH,m), 7.06 (lH,t), 4.14 (2H,m), 3.11 (2H,s), 2.72 (2H,d), 2.18 (lH,dd), 1.60 (3H,s), 1.58 (3H,s).
Example 77 2-[8-(Isqumolin-l-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2-methylphenyl)acetamide
Figure imgf000099_0002
The title compound was prepared from the product Example 20 step (iv) (0.32g) and 1- chloroisoquinoline (0.14g) by the method of Example 52 step (i) as a beige solid. Yield: 40mg
MS: ESI(+ve) 387 (M+l) 'H NMR δ (DMSO) 9.21(bs, IH), 8.20(4 IH), 8.00(4 IH), 7.93(d, 2H), 7.70(t, IH),
7.60(t, IH), 7.35(d, IH), 7.20(m, 2H), 7.06(t, IH), 4.40(bs, 2H), 2.98(4 2H), 2.85(4 2H), 2.30(s, 3H), 2.00(d, 2H), 1.90(m, 2H) Example 78 α5-2-[4-(4-Acetamidobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000100_0001
2,6-Lutidine (0.3ml) was added to a mixture of 4-acetamidobenzenesulphonyl chloride (0.25g), potassium carbonate (0.18g) and the product of Example 55 step (i) (0.14g). The reaction mixture was heated at 100°C for 5 minutes in a 100 Watt microwave oven, allowed to cool and partitioned between dichloromethane and water. The organic phase was washed with brine, dried (MgSO4) and evaporated under reduced pressure. Purification was by reverse phase HPLC (acetonitrile/ 1% aq.ammonium acetate). Yield 15mg.
MS: AP (+ve) 459 (M+l) H NMR: δ (DMSO) 10.35 (lH,s), 7.76 (4H,q), 7.55 (lH,d), 7.22-7.14 (2H,m), 7.07 (lH,m), 4.00 (2H,m), 3.02 (2H,s), 2.64 (2H,d), 2.20 (3H,s), 2.09 (3H,s), 1.92 (2H,dd), 1.42 (3H,s), 1.40 (3H,s)
Example 79 cts-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide
Figure imgf000100_0002
The title compound was prepared from the product of Example 70 step (i) (0.189g) and 3- cyanobenzenesulphonyl chloride (0.15g) by the method of Example 58 step (ii) as a white solid. Yield: 17mg
MS: APCI(+ve) 481 (M+l)
'H NMR δ (DMSO) 8.98(bs, IH), 8.1 l(m, 2H), 7.93(m, 2H), 7.05(m, 4H), 4.10(m, 2H), 3.30(s, 2H), 2.90(d, 2H), 2.40(bd, 2H), 1.50(d, 6H)
Example 80 c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methauesuIphonamidophenyl)acetamide
Figure imgf000101_0001
i) c 5-l-(3-Cyanobenzenesulphonyl)-2,6-dimethyl-4-phenyhτιethylpiperazme
A solution of cz5-4-benzyl-2,6-dimethylpiperazine (lg), 4-N,N- dimethylaminopyridine(0.54g), 3 -cyanobenzenesulphonyl chloride (2.13g) in pyridine (3ml) were stirred at ambient temperature. After lh the mixture was partitioned between dichloromethane and water. The organic phase further washed with brine, collected, dried, (MgSO4) and solvent evaporated under reduced pressure to leave the subtitle compound as an orange gum. Yield: lg
MS: APCI(+ve) 370 (M+l)
ii) c s-l-(3-Cyanobenzenesulphonyl)-2,6-dimethylpiperazine
A solution ofthe product from step (i) (lg) in 1,2-dichloroethane (10ml) was treated with 1-chloroethyl chlorofoimate (0.44ml). The mixture was heated at 80 °C for 16h.
The solvents were then evaporated under reduced pressure and the residue dissolved in methanol (50ml). The mixture then heated at 50 °C for lh. The solvents were then evaporated under reduced pressure. Purification was by trituration with ethyl acetate and filtration to give the subtitle compound as a white solid. Yield: 0.85g
MS: APCI(+ve) 279 (M+l)
iii) c/s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- bis(methanesulphonyl)amidophenyl)acetamide
A solution ofthe product from step (ii) (0.5g) and the product of Example 24 step (i) (0.8g), N,N-diisopropylethylamine (0.6ml), potassium iodide (2mg) in l-methyl-2- pyrrolidinone (10ml) were heated at 90 °C for 3h. The mixture was then partitioned dichloromethane and water. The organic phase collected, further washed with brine, dried (MgSO4) and solvent evaporated under reduced pressure to give the subtitle compound as a brown foam. Yield: 1.04g
MS: APCI(+ve) 597 (M+l)
iv) c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methanesuIphonamidophenyl)acetamide The product from step (iii) (lg), potassium carbonate (lg), water (10ml) and tetrahydrofuran (20ml) were stirred at ambient temperamre for 16h then heated at 90 °C for 6h. The mixture partitioned between dichloromethane and water. The organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with iso-hexane/ethyl acetate (1 :9) to give the title compound as a white solid. Yield: 0.5g
MS: APCI(+ve) 520(M+1), APCI(-ve) 518 (M-1)
'HNMR δ (CDC13) 8.9(bs, IH), 8.13(2xs, 2H), 8.05(d, IH), 7.90(d, IH), 7.70(t, IH), 7.40(bs, IH), 7.10(m, 2H), 4.10(m, 2H), 3.10(s, 2H), 2.95(s, 3H), 2.70(d, 2H), 2.30(s, 3H), 2.20(m, 2H), 1.60(d, 6H) Example 81
2-[8-(4-Benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000103_0001
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 4-cyanobenzenesulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: lOmg
MS: ESI(+ve) 425 (M+l)
'H NMR δ (CDC13) 8.68(bs, IH), 8.05(m, 3H), 7.83(4 2H), 7.23-7.17(m, 2H), 7.07(m, IH), 4.26(m, 2H), 3.19(s, 2H), 2.86(dd, 2H), 2.65(4 2H), 2.27(s, 3H), 1.94(m, 2H), 1.74(m, 2H)
Example 82
2-[8-(2-Benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000103_0002
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 2-cyanobenzenesulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: 8mg MS: APCI(+ve) 425 (M+l)
'H NMR δ (CDC13) 8.77(bs, IH), 8.15(dd, IH), 8.03(4 IH), 7.88(ss, IH), 7.78-7.69(m, 2H), 7.25-7.18(m, 2H), 7.07(t, IH), 4.36(m, 2H), 3.20(s, 3H), 2.85(dd, IH), 2.74(d, IH), 2.30(s, 3H), 2.07-1.99 (m, 4H)
Example 83 c s-2-[4-(l,2-DimethyIimidazol-4-suIphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-
(quinolin-5-yl)acetamide
Figure imgf000104_0001
The title compound was prepared from the product of Example 58 step (i) (0.503mmol) and l,2-dimethylimidazole-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 20mg
MS: APCI(+ve) 457 (M+l) Η NMR δ (CD3OD) 8.88-8.89(m, IH), 8.44(4 IH), 7.97-7.94(m, IH), 7.76-7.81(m, 2H), 7.56-7.60(m, 2H), 4.19-4.13(m, 2H), 3.65(s, 3H), 3.25(s, 2H), 2.79(4 2H), 2.38(s, 3H), 2.54(dd, 2H), 1.55(d, 6H)
Example 84 c 5-2-[4-(5-Chloro-l,3-dimethylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl]-N-(3-methoxy-2-methylphenyl)acetamide
Figure imgf000105_0001
The title compound was prepared from the product of Example 65 step (i) (0.503mmol) and 5-chloro-l,3-dimethyl-4-sulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 6mg
MS: APCI(+ve) 485 (M+l)
'H NMR δ (CD3OD) 7.15-7.16(m, 2H), 6.81-6.84(m, IH), 4.07-4.10(m ,2H), 3.83(s, 3H),
3.82(s, 3H), 3.15(s, 2H), 2.79(4 2H), 2.37(s, 3H), 2.56(dd, 2H), 2.12(s, 3H), 1.54(4 6H)
Example 85
2-[8-(2-(Isoxazol-3-yl)thiophen-5-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N- (2- methylphenyl)acetamide
Figure imgf000105_0002
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 2-(isoxazol-3-yl)thiophenesulphonyl chloride (0.34mmol) as a white solid. Yield: lOmg
MS: ESI(+ve) 473 (M+l) Η NMR δ (CDCI3) 8.72(bs, IH), 8.05(4 IH), 7.61(4 IH), 7.46(4 IH), 7.23(4 2H), 7.06(t, IH), 6.53(d, IH), 4.33(m, 2H), 3.22(s, 2H), 2.89(dd, 2H), 2.73(4 2H), 2.28(s, 3H), 1.94(m, 2H), 1.87(m, 2H)
Example 86
2-[8-(l,l,2,2-Tetrahydroisoqumilin-7-suIphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide
Figure imgf000106_0001
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and N-trifluoroacetyl-l,l,2,2-tetrahydroisoquinoline-7-sulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) followed by the method of Example 72 step (iii) as a white solid. Yield: 26mg
MS: ESI(+ve) 551 (M+l)
Η NMR δ (CDCI3) 8.73(bs, IH), 8.04(4 IH), 7.77-7.68(m, 2H), 7.33(t, IH), 7.25-7.17(m, 2H), 7.06(t, IH), 4.83(d, 2H), 4.24(m, 2H), 3.92(dt, 2H), 3.19(s, 2H), 3.05(m, 2H), 2.85"(dd, 2H), 2.66(4 2H), 2.27(s, 3H), 1.90(m, 2H), 1.76(4 2H)
Example 87 c 5-2-[4-(5-Chloro-l,3-dimethylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl] -N-(2-methylphenyl)acetamide
Figure imgf000106_0002
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 5-chloro-l,3-dimethylpyrazole-4-sulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: 12mg
MS: ESI (+ve) 452 (M+l)
'H NMR δ (CDC13) 8.77(bs, IH), 8.04(d, IH), 7.23-7.18(m, 2H), 7.07(t, IH), 4.25(m, 2H), 3.83(s, 3H), 3.19(s, 2H), 2.85(dd, 2H), 2.65(d, 2H), 2.43(s, 3H), 2.30(s, 3H), 1.95(s, 4H)
Example 88 c s-2-[4-(3,5-Dimethylisoxazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000107_0001
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 3,5-dimethylisoxazol-4-sulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: 5.6mg
MS; ESI (+ve) 419 (M+l)
Η NMR δ (CDCI3) 8.72(bs, IH), 8.04(4 IH), 7.21(t, 2H), 7.08(t, IH), 4.18(m, 2H),
3.20(s, 2H), 2.88(dd, 2H), 2.66(s, 3H), 2.61(4 2H), 2.44(s, 3H), 2.3 l(s, 3H), 2.03(m, 4H)
Example 89 c 5-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000108_0001
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 2-methanesulphonylbenzenesulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: 13mg
MS: ESI (+ve) 478 (M+l)
'H NMR δ (CDC13) 8.81(bs, IH), 8.40(m, IH), 8.28(m, IH), 8.03(4 IH), 7.80(m, 2H), 7.25-7.17(m, 2H), 7.06(t, IH), 4.48(m, 2H), 3.46(s, 3H), 3.16(s, 2H), 2.82(dd, 2H), 2.68(d, 2H), 2.29(s, 3H), 1.95(d, 4H)
Example 90 c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3-methoxy-2- methylphenyl)acetamide
Figure imgf000108_0002
T ie title compound was prepared from the product of Example 65 step (i) (0.503mmol) and 3-cyanobenzenesulphonyl chloride (0.503mmol) by the method of Example 58 step (ii) as a white solid. Yield: 21mg
MS: ESI (+ve) 424 (M+l) 'H NMR δ (CD3OD) 7.77(s, IH), 7.67(s, IH), 7.43(4 IH), 7.20(q, IH), 6.95(t, IH), 4.12- 4.20(m, 2H), 3.78(s, 3H), 3.12(s, 2H), 2.72(4 2H), 2.17-2.23(m, 5H), 1.54(4 6H) Example 91 '5-2-[4-(4-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide
Figure imgf000109_0001
The title compound was prepared from the product of Example 20 step (iv) (0.34mmol) and 4-methanesulphonylbenzenesulphonyl chloride (0.34mmol) by the method of Example 58 step (ii) as a white solid. Yield: 25mg
MS: ESI (+ve) 478 (M+l)
'H NMR δ (CDC13) 8.69(bs, IH), 8.10(q, 4H), 8.04(4 IH), 7.25-7.17(m, 2H), 7.07(t, IH), 4.28(m, 2H), 3.20(s, 2H), 3.1 l(s, 3H), 2.87(dd, 2H), 2.67(4 2H), 2.27(s, 3H), 1.93(m, 2H), 1.74(m, 2H)
Example 92 ct5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-cyano-2- methylphenyl)acetamide
Figure imgf000109_0002
i) 2-Chloro-N-(5-cyano-2-methylphenyl)acetamide The subtitle compound was prepared from 5-cyano-2-methylaniline (1.6g) and chloroacetyl chloride (1.1ml) by the method of Example 33 step (iii) as a white solid. Yield: 1.85g
MS: APCI (-ve) 207 (M-1) ii) cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-cyano-2- methylphenyl)acetamide
The title compound was prepared from the product of step (i) (0.19g) and the product from Example 80 step (ii) (0.2g) by the method of Example 80 step (iii) as a white solid. Yield: 0.25g
MS: APCI(+ve) 452 (M+l)
'H NMR δ (CDC13) 8.81(bs, IH), 8.49(s, IH), 8.13(s, IH), 8.05(4 IH), 7.90(4 IH), 7.70(t, IH), 7.29(d, IH), 7.27(d. IH), 4.20(m, 2H), 3.10(s, 2H), 2.70(4 2H), 2.36(s, 3H), 2.20(m, 2H), 1.60(d, 6H)
Example 93 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-acetamido-2- methylphenyl)acetamide
Figure imgf000110_0001
i) ct*5-2-Chloro-N-(5-acetamido-2-methylphenyl)acetamide
Ther subtitle compound was prepared from 5-acetamido-2-methylaniline (0.5g) and chloroacetyl chloride (0.27ml) by the method of Example 33 step (iii) as a beige solid. Yield: 0.55g
MS: APCI(+ve) 241 (M+l)
ii) c 5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(5-acetamido-2- methylphenyl)acetamide
The title compound was prepared from the product of step (i) (0.22g) and the product of Example 80 step (ii) (0.2g) by the method of Example 80 step (iii) as a white solid. Yield: 0.1 lg
MS: APCI(+ve) 468 (M+l)
'H NMR δ (CDC13) 9.60(bs, IH), 8.78(bs, IH), 8.19(s, IH), 8.17(d, IH), 8.05(s, IH), 7.98(d, IH), 8.77(t, IH), 7.75(s, IH), 7.50(4 IH), 7.10(4 IH), 4.10(m, 2H), 2.75(4 2H), 2.25(s, 3H), 2.16(m, 2H), 2.10(s, 3H), 1.50(4 6H)
Example 94
(R)-2-[4-(4-Cyanobenzenesulphonyl)-3-methyIpiperazm-l-yl]-N-(qumolin-5- yl)acetamide
Figure imgf000111_0001
i) (R)-2-(3-Methylpiperazin-l-yl)-N-(quinolin-5-yl)acetamide
The subtitle compound was prepared from 2-chloro-N-(quinolin-5-yl)acetamide (lg) (J Indian Chem Soc, 1940, 17, 619-621) and (R)-2-methylpiperazine (0.5g) by the method of Example 58 step (i) as a white solid. Yield: 1.4g
MS; APCI(+ve) 285 (M+l)
ii) (R)-2- [4-(4-Cy anobenzenesulphonyl)-3-methylpiperazin-l -yl] -N-(quinolin-5- yl)acetamide
The title compound was prepared from the product of step (i) (1.4g) and 4- cyanobenzenesulphonyl chloride (lg) by the method of Example 58 step (ii) as a white solid. Yield: 0.4 lg
MS: APCI(+ve) 450 (M+l) 'H NMR δ (CDCI3) 9.30(s, IH), 8.95(4 IH), 8.09(m, 2H), 7.99-7.94(m, 3H), 7.86-7.82(4 2H), 7.73(m, IH), 7.43(m, IH), 4.27(m, IH), 3.78(4 IH), 3.42(m, IH), 3.26(q, 2H), 2.98(d, IH), 2.82(d, IH), 2.55(dd, IH), 2.39(m, IH), 1.35(4 3H)
Example 95
(S)-2-[4-(4-Cyanobenzenesulphonyl)-3-methylpiperazm-l-yl]-N-(qumolin-5- yl)acetamide
Figure imgf000112_0001
i) (S)-2-(3-Methylpiperazm-l-yl)-N-(qumolin-5-yl)acetamide The subtitle compound was prepared from 2-chloro-N-(quinolin~5-yl)acetamide (lg) (J Indian Chem Soc, 1940, 17, 619-621) and (S)-2-methylpiperazine (0.5g) by the method of Example 58 step (i) as a white solid. Yield: 1.4g
MS: APCI(+ve) 285 (M+l) ii) (S)-2-[4-(4-Cyanobenzenesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide
The title compound was prepared from the product of step (i) (1.4g) and 4- cyanobenzenesulphonyl chloride (lg) by the method of Example 58 step (ii) as a white solid. Yield: 0.53g
MS: APCI(+ve) 450 (M+l)
'H NMR δ (CDCI3) 9.30(s, IH), 8.95(d, IH), 8.09(m, 2H), 7.99-7.94(m, 3H), 7.86-7.82(4 2H), 7.73(m, IH), 7.43(m, IH), 4.27(m, IH), 3.78(d, IH), 3.42(m, IH), 3.26(q, 2H), 2.98(d, IH), 2.82(d, IH), 2.55(dd, IH), 2.39(m, IH), 1.35(d, 3H) Example 96 cis-2-[4-(3-CyanobenzenesuIphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methanesulphonylphenyl)acetamide
Figure imgf000113_0001
i) 2-Chloro-N-(2-methyl-5-methanesulphonylphenyl)acetamide
The subtitle compound was prepared from 5-methanesulphonyl-2-methylaniline (0.82g) and chloroacetyl chloride (0.72ml) by the method of Example 33 step (iii) as a beige solid. Yield: 0.6 lg
MS: APCI -ve) 260 (M-1)
ii) cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2-methyl-5- methanesulphonylphenyl)acetamide The title compound was prepared from the product of step (i) (0.14g) and the product of Example 80 step (ii) by the method of Example 80 step (iii) as a white solid. Yield: 0.03g
MS: APCI(+ve) 505 (M+l)
'H NMR δ (CDC13) 8.84(bs, IH), 8.63(s, IH), 8.10(s, IH), 8.06(d, IH), 7.90(4 IH), 7:65(d, IH), 7.64(d, IH), 7.40(4 IH), 4.25(m, 2H), 3.14(s, 2H), 3.07(s, 3H), 2.74(4 2H), 2.40(s, 3H), 2.20(m, 2H), 1.60(4 6H)
Example 97 c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- amino-l-piperidinyl)methyl)phenyl] acetamide
Figure imgf000114_0001
i) 2-Methyl-5-((l,l-dimethyl)-l-dimethylethyl)silyloxymethyl-aniline
A mixture of 2-methyl-5-hydoxymethylaniline (lOg), tert-butyldimethylsilyl chloride (10.84g), imidazole (12.24g) in dry N,N-dimethylformamide (80ml) were stirred at ambient temperature for 18h. The mixture was partitioned between ethyl acetate and saturated brine. The organic phase washed with water, collected, dried (MgSO4) and solvent evaporated under reduced pressure to leave a brown gum which slowly crystalised on standing. Yield: 19.2g
MS:APCI(+ve) 252 (M+l)
ii) 2-Chloro-N-(2-methyl-5-((l,l-dimethyl)-l-dimethylethyl)silyloxymethyl)acetamide
The subtitle compound was prepared from the product of step (i) (18.3g) and chloroacetyl chloride (17.5ml) by the method of Example 33 step (iii) as a beige solid. Yield: 23g
MS: APCI(-ve) 326(M-1)
iii) cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- C(l,l-dimethyl)-l-dimethyl)silyloxymethyl)phenyl] acetamide
The subtitle compound was prepared from the product of step (ii) (1.25g) and the product of Example 80 step (ii) (lg) by the method of Example 80 step (iii) as a beige foam. Yield: 1.3g
MS: APCI(+ve) 571 (M+l) iv) c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- hydroxymethyl)phenyl] acetamide
A solution ofthe product of step (iii) (1.3g) in tetrahydrofuran (9ml) was treated with IM tetrabutylammonium fluoride in tetrahydrofuran (2.6ml) at ambient temperature. After stirring for 1.5h the solvent was evaporated under reduced pressure to leave a brown gum. Purification was by silica gel chromatography eluting with ethyl acetate/ iso-hexane (9:1) to give the subtitle compound as a white solid. Yield: 0.93g
MS: APCI(+ve) 457 (M+l)
v) α5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- iodomethyl)phenyl] acetamide
The product from step (iv) (O.lg) in tetrahydrofuran (2ml), N,N-diisopropylethylamine (0.15ml), potassium iodide (2mg) was treated with methanesulphonyl chloride (0.34ml). After stirring at ambient temperature for 40h. The solvent was evaporated under reduced pressure to leave a beige gum. This was used directly in the next step.
vi) cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- amino-l-piperidinyl)methyl)phenyl]acetamide The crude product from step (v) (0.2g) was treated with 1,1-dimethylethyl, 4- aminopiperidinyl-4-carboxylate (0.13g) in tetrahydrofuran (2ml) at 55 °C for 24h. The solvent was evaporated under reduced pressure. The residue was then treated with 4M hydrogen chloride in 1,4-dioxane (3ml) for 5h. The solvents were then evaporated under reduced pressure. Purification was by reverse phase HPLC to give the title compound as a white solid. Yield. 0.1 g
MS: APCI(+ve) 539 (M+l)
Η NMR δ (DMSO) 9.84(bs, IH), 9.19(s, IH), 8.33(s, IH), 8.16(m, 4H), 7.82(t, IH),
7.76(s, IH), 7.32(d, IH), 7.19(d, IH), 4.22(s, 2H), 4.1 l(m, 2H), 3.41(d, 2H), 3.25(bs, 2H), 3.10(s, 2H), 3.01(m, 2H), 2.70(4 2H), 2.40(m, 2H), 2.34(s, 3H), 2.08(4 2H), 1.96(dd, 2H), 1.75(q, 2H), 1.45(d, 6H)
Example 98 (R)-2-[4-(4-Methanesulphonylbenzenesulphonyl)-3-methylpiperazin-l-yl]-N- (quinolin-5-yl)acetamide
Figure imgf000116_0001
i) (R )-l,l-Dimethylethyl, (4-Methanesulphonylbenzenesulphonyl-3-methylpiperazm- 1-yl-l-carboxylate The subtitle compound was prepared from (R)- 1 , 1 -dimethylethyl, 3-methylpiperazin- 1 -yl- 1 -carboxylate (0.75g) (J. Med. Chem, 1993, 36(6), 690)and 4-methanesulphonyl- benzenesulphonyl chloride (0.96g) by the method of Example 58 step (ii) as white solid. Yield: 0.9g
'H NMR δ (DMSO) 8.15(d, 2H), 8.07(4 2H), 4.08(bs, IH), 3.85(bs, IH), 3.65(bs, IH), 3.33(s, 2H), 3.32(s, 3H), 3.09(t, IH), 1.36(s, 9H), 0.93(4 3H)
ii) (R )- l-(4-Methanesulphonylbenzenesulphonyl-3-methylpiperazine, hydrochloride salt The subtitle compound was prepared from the product of step (i) (0.209g) by the method of Example 27 step (iv) as a white solid. Yield: 0.15g
MS:APCI(+ve) 319(M+l) iii) (R)-2-[4-(4-Methanesulphonylbenzenesulphonyl)-3-methylpiperazin-l-yl]-N- (quinolin-5-yl)acetamide
The title compound was prepared from the product of step (ii) (0.14g) and 2-chloro-N- (quinolin-5-yl)acetamide (0.97g) (J Indian Chem Soc, 1940, 17, 619-621) by the method of Example 33 step (iv) as a white solid. Yield: 0.135g
MS: APCI(+ve) 503(M+1)
'H NMR δ (DMSO) 9.88(s, IH), 8.91(d, IH), 8.32(d, IH), 8.16(d, 2H), 8.09(d, 2H), 7.88(dd, IH), 7.73(m, 2H), 7.55(q, IH), 4.09(d, IH), 3.66(d, IH), 3.38(d, IH), 3.3 l(s, 3H), 3.22(s, 2H), 2.91(d, IH), 2.73(d, IH), 2.31(m, 2H), 2.15(t, IH), 1.21(4 3H)
Example 99
(R)-2-[4-(4-Acetanύdobenzenesulphonyl)-3-methylpiperazm-l-yl]-N-(quinolin-5- yl)acetamide
Figure imgf000117_0001
i) (R)-l,l-Dimethylethyl, (4-Acetamidobenzenesulphonyl-3-methylpiperazin-l-yI-l- carboxylate
The subtitle compound was prepared from (R)- 1,1 -dimethylethyl, 3-methylpiperazin- 1-yl- 1 -carboxylate (4g) (J. Med. Chem, 1993, 36(6), 690) and 4-acetamidobenzenesulphonyl chloride (4.68g) by the method of Example 58 step (ii) as white solid. Yield: 4.9g
MS: APCI(+ve) 398(M+1)
ii) (R)-l-(4-Acetamidobenzenesulphonyl)-3-methylpiperazine, hydrochloride salt The subtitle compound was prepared from the product of step (i) (4.9g) by the method of Example 27 step (iv) as a white solid. Yield: 4.38g
'H NMR δ (DMSO) 10.60(s, IH), 8.92(bs, IH), 8.91(4 2H), 8.04(t, IH), 7.85(4 2H), 7.78(d, 2H), 7.45(d, IH), 6.66(4 IH), 3.27(t, 2H), 3.06(m, 2H), 2.87(m, 2H), 2.73(m, 3H), 2.10(s, 3H), 1.30(d, 2H), 1.16(4 3H)
iii) (R)-2-[4-(4-AcetylammobenzenesuIphonyI)-3-methyIpiperazin-l-yl]-N-(qumolin- 5-yl)acetamide The title compound was prepared from the product of step (ii) (0.65g) and 2-chloro-N-
(quinolin-5-yl)acetamide (0.39g) (J Indian Chem Soc, 1940, 17, 619-621) by the method of Example 33 step (iv) as a white solid. Yield: 0.064g
MS: APCI(+ve) 439(M-42(+H,-Ac)) 'HNMR δ (DMSO) 9.89(s, IH), 8.91(s, IH), 8.31(4 IH), 7.87(m, IH), 7.75(s, 2H),
7.50(m, IH), 7.43(d, 2H), 6.63(4 2H), 6.01(s, 2H), 3.90(s, IH), 3.42(4 IH), 3.42(d, IH), 3.24(s, IH), 3.20(d, 2H), 2.86(4 IH), 2.68(4 IH), 2.31(4 IH), 2.18(t, IH), 1.18(4 3H)
Example 100 c s-2-[4-(3-CyanobenzenesuIphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- piperazinylmethyl)phenyl)acetamide
Figure imgf000118_0001
The title compound was prepared from the product of Example 97 step (v) (0.2g) and 1,1- dimethylethyl, piperazine- 1 -carboxylate (0.12g) by the method of Example 97 step (vi) to give the title compound as a white solid. Yield: 74mg
MS: APCI(+ve) 525 (M+l) 'H NMR δ (DMSO) 9.21 (s, IH), 9.0(bs, 2H), 8.33(s, IH), 8.17(4 2H), 7.82(t, IH), 7.69(s, IH), 7.28(d, IH), 7.16(d, IH), 4.14(m, 2H), 3.27(bs, 4H), 3.15(s, 2H), 3.05(bs, 2H), 2.69(d, 2H), 2.2 l(s, 3H), 2.0(4 2H), 1.44(4 6H)
Example 101 s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- piperidinylamino)methyl)phenyl)acetamide
Figure imgf000119_0001
The title compound was prepared from the product of Example 97 step (v) (0.2g) and 1,1- dimethylethyl, 4-aminopiperidinyl-l -carboxylate (0.12g) by the method of Example 97 step (vi) as a white solid. Yield: 34mg
MS: APCI(+ve) 539(M+1) 'H NMR δ (DMSO) 9.18(s, IH), 9.09(s, 2H), 8.81(m, IH), 8.60(m, IH), 8.33(s, IH), 8.15(d, 2H), 7.82(t, IH), 7.75(s, IH), 7.30(4 IH), 7.21(4 IH), 4.10(m, 4H), 3.40(4 2H), 3.32(s, 2H), 2.92(q, 2H), 2.68(4 2H), 2.23(s, 3H), 1.94(dd, 2H), 1.73(q, 2H), 1.43(4 6H)
Example 102 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- morpholinyl)methyl)phenyl)acetamide
Figure imgf000119_0002
The title compound was prepared from the product of Example 97 step (v) (0.2g) and morpholine (0.058g) by the method of Example_97 step (vi). The solvents evaporated under reduced pressure and the residue purified by reverse phase HPLC to give the title compound as a white solid. Yield: 97mg
MS: APCI(+ve) 526 (M+l) 'H NMR δ (DMSO) 10.1 l(bs, IH), 9.22(s, IH), 8.34(s, IH), 8.16(d, 2H), 7.83(d, IH),
7.78(d, IH), 7.33(d, IH), 7.21(d, IH), 4.31(s, 2H), 4.12(t, 4H), 3.63(m, 2H), 3.3(m, 4H),
2.70(4 2H), 2.23(s, 3H), 1.97(dd, 2H), 1.43(d, 6H)
Example 103 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(2- hydroxyethylamino)methyl)phenyl)acetamide
Figure imgf000120_0001
The title compound was prepared from the product of Example 97 step (v) (0.2g) and ethanolamine (0.04 lg) by the method of Example 97 step (vi). The solvents evaporated under reduced pressure and the residue purified by reverse phase HPLC to give the title compound as a white solid. Yield: 37mg
MS: APCI(+ve) 500(M+1)
'HNMR δ (DMSO) 8.27(s, IH), 8.18(4 IH), 8.02(4 IH), 7.74-7.82(m, 3H), 7.35(d, 2H), 7:25(d, IH), 4.27(t, 2H), 4.20(s, 2H), 3.83(t, 2H), 3.40(s, 2H), 3.25(s, IH), 3.14(t, 2H), 2.97(d, 2H), 2.33(s, 5H), 1.56(d, 6H)
Example 104 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(S,S)- (2,5-diazabicy clo [2.2.1 ] hept-2-yl)methy l)phenyl)acetamide
Figure imgf000121_0001
The title compound was prepared from the product of Example 97 step (v) (0.2g) and 1,1- dimethylethyl, (S,S)-2,5-diazabicyclo[2.2.1]heptane-5-carboxylate (0.13g) by the method of Example 97 step (vi) as a white solid. Yield: 107mg
MS: APCI(+ve) 537 (M+l) •
'H NMR δ (DMSO) 9.2(s, IH), 8.34(s, IH), 8.16(d, 2H), 7.83(d, IH), 7.79(s, IH), 7.31(d, IH), 7.24(d, IH), 4.46(s, IH), 4.32(m, 2H), 4.12(s, 2H), 3.35(d, 2H), 3.1 l(s, 2H), 2.68(d, 2H), 2.23(s, 3H), 1.98(t, 3H), 1.44(d, 6H)
Example 105 (R)-2-[4-(2-Pyridmesulphonyl)-3-methylpiperazm-l-yl]-N-(quinojl -5-yl)acetamide
Figure imgf000121_0002
i) (R )-l,l-Dimethylethyl, (2-Pyridinesulphonyl-3-methylpiperazin-l-yl-l-carboxylate A solution of 1,1-dimethylethyl, 3 -(R)-methylpiperazine-l -carboxylate (2g) (J. Med. Chem, 1993, 36(6), 690), 4-N,N'-dimethylaminopyridine (1.22g) in pyridine (10ml) was treated with 2-pyridinesulphonyl chloride (2.7g) at 0 °C. The ice bath was removed and the mixture further stirred for lh at ambient temperature. The mixmre was partitioned between dichloromethane and water. The organic phase further washed with brine, collected, dried (MgSO4) and solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with ethyl acetate/dichloromethane mixtures to give the subtitle compound as white solid. Yield: 3.3g MS: ESI(+ve) 342(M+1)
ii) (R )-l-(2-Pyridinesulphonyl-3-methyIpiperazme, hydrochloride salt
The subtitle compound was prepared from the product of step (i) (2.5g) by the method of Example 27 step (iv) as a white solid. Yield: 2.5g
MS: ESI(+ve) 242 (M+l)
iii) (R)-2-[4-(2-Pyridmesulphonyl)-3-methylpiperazm-l-yl]-N-(quinolin-5- yl)acetamide
The title compound was prepared from the product of step (ii) (0.6g) and 2-chloro-N- (quinolin-5-yl)acetamide (0.39g) (J Indian Chem Soc, 1940, 17, 619-621) by the method of Example 80 step (iii). Purification was by silica gel chromatography eluting with ethyl acetate to give a white solid. Yield: 0.41 g
MS: ESI(+ve) 424(M+1)
'H NMR δ (DMSO) 8.8(4 IH), 8.35(4 IH), 8.10(t, IH), 7.97(4 IH), 7.90(4 IH), 7.7(m, 3H), 7.55(m, IH), 4.10(m, IH), 3.7(m, IH) 3.5(t, IH), 3.3(m, 2H), 3.2(m, IH), 2.95(4 IH), 2.7(d, IH), 2.4-2.1(m, 2H), 1.2(4 3H)
Example 106 αs-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2-methyl-3-(4- amino-l-piperidinyl)methyl)phenyl]acetamide
Figure imgf000122_0001
i) 2-Methyl-3-((l,l-dimethyl)-l-dimethylethyl)silyloxymethylaniline The subtitle compound was prepared from 2-methyl-3-hydoxymethylaniline (5g) and tert- butyldimethylsilyl chloride (5.42g) by the method of Example 97 step (i) as an oil which crystalised on standing. Yield: 9.12g
MS: APCI(+ve) 252(M+1)
u) 2-Chloro-N-(2-methyl-3-((l,l-dimethyl)-l-dimethylethyl)silyloxymethyl)acetamide
The subtitle compound was prepared from the product of step (i) (4.13g) and chloroacetyl chloride (1.5ml) by the method of Example 33 step (iii) as a beige solid. Yield: 3.12g
MS:APCI(+ve) 328(M+1)
iii) cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- ((l,l-dimethyl)-l-dimethylethyl)silyloxymethyl)phenyl]acetamide The subtitle compound was prepared from the product of step (ii) (1.25g) and the product of Example 80 step (ii) (lg) by the method of Example 80 step (iii) as a cream solid. Yield: 1.5g
MS: APCI(+ve) 571 (M+l)
iv) c 5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- hydroxymethyl)pheny 1] acetamide
The subtitle compound was prepared from the product of step (iii) (1.4g) and IM tetrabutylammonium fluoride in tetrahydrofuran (2.7ml) by the method of Example 97 step (iv) as a white solid. Yield: lg
MS:APCI(+ve) 457(M+1)
v) cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2-methyl-3- iodomethyl)phenyl] acetamide The product from step (iv) (O.lg) in tetrahydrofuran (2ml), N,N-diisopropylethylamine (0.15ml), potassium iodide (2mg) was treated with methanesulphonyl chloride (0.34ml). After stirring at ambient temperature for 40h. The solvent was evaporated under reduced pressure to leave a beige gum. This was used directly in the next step.
vi) cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- amino-l-piperidinyl)methyl)phenyl] acetamide
The crude product from step (v) (0.2g) was treated with 1,1-dimethylethyl, 4- aminopiperidinyl-4-carboxylate (0.13g) in tetrahydrofuran (2ml) at 55 °C for 24h. The solvent was evaporated under reduced pressure. . The residue was then treated with 4M hydrogen chloride in 1 ,4-dioxane (3ml) for 5h. The solvents were then evaporated under reduced pressure. Purification was by reverse phase HPLC to give the title compound as a white solid. Yield. 0.068g
MS: APCI(+ve) 539 (M+l)
'H NMR δ (CDCVDMSO) 8.87(bs, IH), 8.67(bs, IH), 8.14(s, IH), 8.10(4 IH), 7.95(4 IH), 7.80(d, IH), 7.75(t, IH), 7.30(m, 2H), 4.30(bs, IH), 4.20(m, 2H), 3.10(s, 2H), 2.80(4 2H), 2.30(s, 3H), 2.20(m, 4H), 1.60(4 6H)
Example 107 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(4- piperidinylamino)methyl)phenyl)acetamide
Figure imgf000124_0001
The title compound was prepared from the product of Example 106 step (v) (0.2g) and 1,1- dimethylethyl, 4-aminopiperidinyl-l -carboxylate (0.12g) by the method of Example 106 step (vi) as a white solid. Yield: 38mg MS: APCI(+ve) 539(M+1)
'H NMR δ (DMSO) 9.33(bs, IH), 9.10(bs, IH), 8.8(bd, IH), 8.60(bd, IH), 8.37(s, IH), 8.20(m, IH), 7.90(t, IH), 7.40(d, IH), 7.30(m, 2H), 4.20(bs, 2H), 4.10(m, 2H), 3.10(s, 2H), 3.00(m, 2H), 2.7(m, 2H), 2.30(m, 2H), 2.20(s, 3H), 2.00-1.80(m, 4H), 1.40(s, 6H)
Example 108 c s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-(2-methyl-3-(l- piperazinylmethyl)phenyl)acetamide
Figure imgf000125_0001
The title compound was prepared from the product of Example 106 step (v) (0.2g) and 1,1- dimethylethyl, piperazine- 1 -carboxylate (0.12g) by the method of Example 106 step (vi) as a white solid. Yield: 74mg
MS : APCI(+ve) 525 (M+l )
'H NMR δ (DMSO) 8.34(s, IH), 8.20(m, 2H), 7.80(t, IH), 7.40(t, IH), 7.20(2xd, 2H), 4.20(m, 2H), 3.90(bs, 2H), 3.20(m, 6H), 3.00-2.60(m, 6H), 2.20(s, 3H), 2.00(m, 2H), 1.5Q(d, 6H)
Example 109 c 5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(S,S)- (2,5-diazabicyclo[2.2.1]hept-2-yl)methyl)phenyl)acetamide
Figure imgf000125_0002
The title compound was prepared from the product of Example 106 step (v) (0.2g) and 1,1- dimethylethyl, (S,S)-2,5-diazabicyclo[2.2.1]heptane-5-carboxylate (0.13g) by the method of Example 106 step (vi) as a white solid. Yield: 82mg
s MS: APCI(+ve) 537 (M+l)
Η NMR δ (DMSO) 8.38(s, IH), 8.20(m, 2H), 7.80(t, IH), 7.50(4 IH), 7.30(m, 2H), 4.40(s, IH), 4.30(m, 2H), 4.10(m, 2H), 3.30(m, 2H), 3.10(s, 2H), 2.80(m, 2H), 2.22(s, 3H), 2.00(m, 4H), 1.50(d, 6H) o Example 110 c 5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3-(l- morpholinyl)methyl)phenyl)acetamide
Figure imgf000126_0001
The title compound was prepare from the product of Example 106 step (v) (0.2g) and morpholine (0.058g) by the method of Example 106 step (vi) as a white solid. Yield: 69mg
MS: APCI(+ve) 526 (M+l)
'H NMR δ (DMSO) 8.34(s, IH), 8.20(m, 2H), 7.80(t, IH), 7.60(d, IH), 7.40(m, 2H), 4.40(s, 2H), 4.20(m, 2H), 4.00(bs, 2H), 3.70(bs, 2H), 3.30(bs+s, 6H), 2.80(d, 2H), 2.30(s, 3H), 2.00(m, 2H), 1.50(4 6H)
Example 111
C/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3-(2-
(l-pyrroIidinyl)ethoxy)phenyl)acetamide
Figure imgf000127_0001
i) 2-Methyl-3-((l,l-dimethyl)-l-dimethylethyl)silyloxyaniIine
The subtitle compound was prepared from 3-amino-2-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 15g
'H NMR δ (CDC13) 6.86(t, IH), 6.33(4 IH), 6.27(4 IH), 3.58(bs, 2H), 2.04(s, 3H), 1.01(s, 9H), 0.20(s, 6H)
ii) 2-Chloro-N-(2-methyl-3-((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide
The product from step (i) (5g), PyBrop (9.82g), chloroacetic acid (1.99g), N,N- diisopropylethylamine (11ml) in dichloromethane (100ml) were stirred at ambient temperature for 16h. The mixture was partitioned between water and dichloromethane, the organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with 10% diethyl ether in iso-hexane containing 1% triethylamine to give the subtitle compound as a pale yellow oil. Yield: 3.5g
'H NMR δ (CDCI3) 8.21(bs, IH), 7.48(4 IH), 7.09(t, IH), 6.68(d, IH), 4.23(s, 2H), 2.16(s,
3H), 1.02(s, 9H), 0.22(s, 6H)
iii) C s-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3-
((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (ii) (lg) and the product of
Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a beige solid. Yield: 1.6g 'H NMR δ (CDCI3) 8.67(s, IH), 8.12(s, IH), 8.03(4 IH), 7.85(4 IH), 7.67(t, IH), 7.59(4 IH), 7.07(t, IH), 6.64(d, IH), 4.05-4.10(m, 2H), 3.10(s, 2H), 2.73(d, 2H), 2.19(4 2H), 2.10(s, 3H), 1.54(s, 6H), 1.01(s, 9H), 0.22(s, 6H)
iv) C5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3- hydroxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (iii) (1.6g) and tetrabutylammonium fluoride (3.18ml) by the method of Example 97 step (iv) as a white solid Yield: 0.5g
MS APCI(+ve) 443 (M+l)
v) Cis-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-((2-methyl-3- (2-(l-pyrrolidmyl)ethoxy)phenyl)acetamide The product from step (iv) (0. lg), l-(2-chloroethyl)pyrrolidine hydrochloride (76mg), ceasium carbonate (0.36g) in l-methyl-2-pyrrolidinone (2ml) were stirred at 70 °C for 16h. The mixture was partitioned between ethyl acetate and water, the organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure. Purification was by reverse phase HPLC eluting with 5 to 90% methanol in 0.1% aqueous trifluoroacetic acid to give the the title compound as a white solid. Yield: 7mg
MS: APCI(+ve) 540(M+1)
'H NMR δ (CD3OD) 8.15(s, IH), 8.05(4 IH), 7.89(4 IH), 7.67(t, IH), 7.06(s, IH), 7.04(s, IH), 6.74(t, IH), 4.01-4.09(m, 4H), 2.99(s, 2H), 2.88(t, 2H), 2.61-2.66(m, 6H), 2.05(s, 3H), 1.95(dd, 2H), 1.71-1.77(m, 4H), 1.44(4 6H)
Example 112
(+) C/5-2-[4-(3-CyanobenzenesuIphonyl)-3,5-dimethyIpiperazm-l-yI]-N-((2-methyl-3-
(l-methylpiperidin-3-yI)methoxy)phenyl)acetamide
Figure imgf000129_0001
The title compound was prepared from the product of Example 111 step (iv) (O.lg) and (±) l-methyl-3-chloromethylpiperidine (83mg) by the method of Example 111 step (v) as a white solid. Yield: 19mg
MS: APCI(+ve) 554 (M+l)
'H NMR δ (CD3OD) 8.24(s, IH), 8.14(4 IH), 7.98(4 IH), 7.77(t, IH), 7.10-7.15(m, 2H), 6.78-6.81(m, IH), 4.12-4.18(m, 2H), 3.80-3.92(m, 2H), 3.09(s, 3H), 2.75-2.85(m, IH), 2.74(d, 2H), 2.3 l(s, 3H), 2.12(s, 3H), 1.64-2.17(m, 8H), 1.53(4 6H), 1.15-1.19(m, 2H)
Example 113
CXs-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-4-(2-
(l-pyrrolidinyl)ethoxy)phenyl)acetamide
Figure imgf000129_0002
i) 2-Methyl-4-((l,l-dimethyl)-l-dimethylethyl)silyloxyaniline
The subtitle compound was prepared from 4-amino-3-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 14g
'H NMR δ (CDC13) 6.53-6.58(m, 3H), 3.33(bs, 2H), 2.12(s, 3H), 0.98(s, 9H), 0.15(s, 6H)
ii) 2-Chloro-N-(2-methyl-3-((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide The subtitle compound was prepared from the product of step (i) (5g) by the method of Example 111 step (ii) as pale yellow oil. Yield: 5g
'H NMR δ (CDCI3) 8.06(bs, IH), 7.57-7.60(m, IH), 6.53-6.58(m, 3H), 3.33(bs, 2H), 2.12(s, 3H), 0.98(s, 9H), 0.15(s, 6H)
iii) C y-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethyIpiperazin-l-yl]-N-((2-methyl-4- ((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)phenyl)acetamide
The subitle compound was prepared from the product of step (ii) (lg) and the product of Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a white solid. Yield: 1.6g
'H NMR δ (CDCI3) 8.48(s, IH), 8.12(s, IH), 8.04(d, IH), 7.86(d, IH), 7.64-7.70(m, 2H), 6.67-6.70(m, 2H), 4.11-4.15(m, 2H), 3.08(s, 2H), 2.73(d, 2H), 2.22(s, 3H), 2.16(dd, 2H), 1.55(d, 6H), 0.97(s, 9H), 0.18(s, 6H)
iv) C75-2-[4-(3-CyanobenzenesuIphonyl)-3,5-dimethyIpiperazin-l-yl]-N-((2-methyl-4- hydroxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (iii) (1.6g) and tetrabutylammonium fluoride (3.21ml) by the method of Example 97 step (iv) as a white solid Yield: 0.4g
MS APCI(+ve) 443 (M+l)
v) Cs-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-4- (2-(l-pyrrolidinyl)ethoxy)phenyl)acetamide
The title compound was prepared from the product of step (iv) (O.lg) and l-(2- chloroethyl)pyrrolidine hydrochloride (76mg) by the method of Example 111 step (v) as a white solid. Yield: lOmg MS: APCI(+ve) 540 (M+l)
'H NMR δ (CD3OD) 8.24(s, IH), 8.15(d, IH), 7.98(d, IH), 7.77(t, IH), 7.30(d, IH), 6.83(d, IH), 6.77(dd, IH), 4.13-4.18(m, 2H), 4.10(t, 2H), 3.07(s, 2H), 2.91(t, 2H), 2.73(d, 2H), 2.65-2.69(m, 4H), 2.25(s, 3H), 2.04(dd, 2H), 1.79-1.86(m, 4H), 1.53-1.54(4 6H),
Example 114
(+) C 5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazm-l-yl]-N-((2-methyl-4-
(l-methylpiperidin-3-yl)methoxy)phenyl)acetamide
Figure imgf000131_0001
The title compound was prepared from the product of Example 113 step (iv) (O.lg) and (±) l-methyl-3-chloromethylpiperidine (83mg) by the method of Example 111 step (v) as a white solid. Yield: 19mg
MS: APCI(+ve) 554 (M+l)
'H NMR δ (CD3OD) 8.24(s, IH), 8.15(d, IH), 7.98(d, IH), 7.77(t, IH), 7.29(d, IH), 6.79(d, IH), 6.74(dd, IH), 4.13-4.16(m, 2H), 3.75-3.88(m, 2H), 3.08(s, 2H), 3.02-3.04(m, IH), 2.82-2.85(m, IH), 2.73(d, 2H), 2.29(s, 3H), 2.21(s, 3H), 1.62-2.10(m, 8H), 1.53(d, 6H), 1.09-1.13(m, IH),
Example 115
(+) C/ 2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-5-
(l-methylpiperidin-3-yl)methoxy)phenyl)acetamide
Figure imgf000132_0001
i) 2-Methyl-5-((l,l-dimethyl)-l-dimethylethyl)silyloxyaniline
The subtitle compound was prepared from 3-amino-4-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 15g
Η NMR δ (CDC13) 6.84-6.88(m, IH), 6.18-6.22(m, 2H), 3.52(bs, 2H), 2.08(s, 3H), 0.97(s, 9H), 0.17(s, 6H)
ii) 2-Chloro-N-(2-methyl-5-((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (i) (5g) by the method of Example 111 step (ii) as pale yellow oil. Yield: 5.3g
'H NMR δ (CDCI3) 8.19(bs, IH), 7.57(4 IH), 7.03(4 IH), 6.61(dd, IH), 4.22(s, 2H), 2.23(s, 3H), 0.98(s, 9H), 0.21(s, 6H)
iii) Cs-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-5- ((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)phenyl)acetamide
The subtitle compound was prepared from the product of step (ii) (lg) and the product of Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a white solid. Yield: l.'8g
'H NM δ (CDCI3) 8.64(s, IH), 8.12(s, IH), 8.04(d, IH), 7.87(4 IH), 7.68-7.70(m, 2H), 7.01(d, IH), 6.56(dd, IH), 4.09-4.16(m, 2H), 3.08(s, 2H), 2.72(4 2H), 2.22(s, 3H), 2.16(dd, 2H), 1.55(4 6H), 0.97(s, 9H), 0.19(s, 6H) iv) Cts-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperaziu-l-yl]-N-((2-methyl-5- hydroxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (iii) (1.81g) and tetrabutylammonium fluoride (3.24ml) by the method of Example 97 step (iv) as a white solid Yield: 0.8g
MS APCI(+ve) 443 (M+l)
v) (+) Cis-2- [4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl] -N-((2-methyl- 5-(l-methylpiperidin-3-yl)methoxy)phenyl)acetamide
The title compound was prepared from the product of step (iv) (O.lg) and (±) l-methyl-3- chloromethylpiperidine (76mg) by the method of Example 111 step (v) as a white solid. Yield: 5mg
MS: APCI(+ve) 540 (M+l)
'H NMR δ (CD3OD) 8.24(s, IH), 8.14(d, IH), 7.98(d, IH), 7.77(t, IH), 7.32(d, IH), 7.10(d, IH), 6.67(dd, IH), 4.12-4.18(m, 2H), 3.73-3.86(m, 2H), 3.09(s, 2H), 3.02-3.05(m, IH), 2.83-2.86(m, IH), 2.74(d, 2H), 2.29(s, 3H), 2.24(s, 3H), 1.58-2.1 l(m, 9H), 1.54(d, 6H), 1.09-1.13(m, IH),
Example 116
(+) C/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-6-
(J-methylpiperidm-3-yl)methoxy)phenyl)acetamide
Figure imgf000133_0001
i) 2-Methyl-6-((l,l-dimethyl)-l-dimethylethyl)silyIoxyaniline The subtitle compound was prepared from 2-amino-3-methylphenol (lOg) and tert- butyldimethylsilyl chloride(12.22g) by the method of Example 97 step (i) as a brown oil. Yield: 14g
'H NMR δ (CDC13) 6.53-6.70(m, 3H), 3.66(bs, 2H), 2.17(s, 3H), 1.02(s, 9H), 0.24(s, 6H)
ii) 2-Chloro-N-(2-methyl-6-((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (i) (5g) by the method of Example 111 step (ii) as pale yellow oil. Yield: 4.6g
'H NMR δ (CDCI3) 7.97(bs, IH), 7.07(t, IH), 6.86(d, IH), 6.72(d, IH), 4.22(s, 2H), 2.23(s, 3H), 1.00(s, 9H), 0.22(s, 6H)
iii) Cts-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-6- ((l,l-dimethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide
The subitle compound was prepared from the product of step (ii) (lg) and the product of Example 80 step (ii) (0.89g) by the method of Example 80 step (iii) as a white solid. This product was used directly in the next step
iv) Cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-6- hydroxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (iii) (2g) and tetrabutylammonium fluoride (3.18ml) by the method of Example 97 step (iv) as a white solid Yield: 0.8g
MS APCI(+ve) 441 (M-l)
v) (±) Os-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 6-(l-methylpiperidm-3-yl)methoxy)phenyl)acetamide The title compound was prepared from the product of step (iv) (O.lg) and (+) l-methyl-3- chloromethylpiperidine (76mg) by the method of Example 111 step (v) as a white solid. Yield: 26mg
MS: APCI(+ve) 540 (M+l)
'H NM δ (CD3OD) 8.29(s, IH), 8.17(4 IH), 7.98(4 IH), 7.78(t, IH), 7.17(t, IH), 6.87(s, IH), 6.84(s, IH), 4.19-4.20(m, 2H), 3.83-3.88(m, 2H), 3.12(s, 2H), 2.80-3.0(m, 3H), 2.28(s, 3H), 2.20(s, 3H), 1.6-2.1(m, 9H), 1.55(4 6H), 1.0-1.2(m,lH)
Example 117
C5-2-[4-(l-MethyUmidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-((2- methyl-3-(2-(l-pyrrolidinyl)ethoxy)phenyl)acetamide
Figure imgf000135_0001
i) C 5-l-(l-Methylimidazol-4-sulphonyl-4-yl)-2,6-dimethyl-4-phenylmethylpiperazine l-methylimidazol-4-sulphonyl chloride (19.45g) was added in small portions to a solution of cz'5'-4-benzyl-2,6-dimethylpiperazine (20g) in pyridine (53ml) at 120 °C. After heating for a further lOmin at reflux the solvent was evaporated under reduced pressure. The mixture was partitioned between dichloromethane and dilute sodium hydroxide solution. The organic phase collected, dried (MgSO4) and solvent evaporated under reduced pressure. Purification was by silica gel chromatography eluting with 0 to 5% methanol in dichloromethane to give the subtitle compound as pale yellow solid. Yield: 14.2g
'H NMR δ (CDC13) 7.22-7.46(m, 7H), 4.07-4.15(m, 2H), 3.73(s, 3H), 3.42(4 2H), 2.53(d, 2H), 2.08(dd, 2H), 1.46(4 6H)
ii) C5-l-(l-Methylimidazol-4-sulphonyl-4-yl)-2,6-dimethylpiperazine The subtitle compound was prepared from the product of step (i) (14.07g) by the method of Example 80 step (ii) as tan solid. Yield: 12.16g
MS: APCI (+ve) 259(M+1)
iu) C5-2-[4-(l-MethyUmidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-((2- methyl-3-((l,l-dj ιethyl)-l-dimethylethyl)silyloxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (ii) (0.82g) and the product of Example 111 step (ii) (lg) by the method of Example 80 step (iii) as a white solid. Yield: 1.6g
'H NMR δ (CDC13) 8.83(s, IH), 7.61(4 IH), 7.47(s, IH), 7.40(s, IH), 7.07(t, IH), 6.63(4 IH), 4.21-4.24(m, 2H), 3.75(s, 3H), 3.10(s, 2H), 2.65(d, 2H), 2.17(s, 3H), 1.56(d, 6H), 1.02(s, 9H), 0.22(s, 6H)
iv) Crø-2-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-((2- methyl-3-hydroxy)phenyl)acetamide
The subtitle compound was prepared from the product of step (iii) (1.51g) by the method of Example 111 step (iv) as a white solid. Yield: 0.4g
MS» APCI(+ve) 422 (M+l)
y) C/s-2-[4-(l-Methyhmidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-((2- methyl-3-(2-(l-pyrrolidinyl)ethoxy)phenyl)acetamide The title compound was prepared from the product of step (iv) (95mg) and l-(2- chloroethyl)pyrrolidine (83mg) by the method of Example 111 step (v) as a white solid. Yield: 19mg
MS: APCI(+ve) 519 (M+l) 'H NMR δ (CD3OD) 7.76(s, IH), 7.67(s, IH), 7.13-7.24(m, 2H), 6.84(d, IH), 4.12-4.19(m, 4H), 3.78(s, 3H), 3.1 l(s, 2H), 3.01(t, 2H), 2.67-2.76(m, 6H), 2.18-2.28(m, 5H), 1.54(d, 6H)
Pharmacological Analysis
Certain compounds such as benzoylbenzoyl adenosine triphosphate (bbATP) are known to be agonists ofthe P2X7 receptor, effecting the formation of pores in the plasma membrane (Drug Development Research (1996), 37(3), p.126). Consequently, when the receptor is activated using bbATP in the presence of ethidium bromide (a fluorescent DNA probe), an increase in the fluorescence of intracellular DNA-bound ethidium bromide is observed. The increase in fluorescence can be used as a measure of P2X7 receptor activation and therefore to quantify the effect of a compound on the P2X7 receptor.
In this manner, each ofthe title compounds ofthe Examples was tested for antagonist activity at the P2X7 receptor. Thus, the test was performed in 96-well flat bottomed microtitre plates, the wells being filled with 250 μl of test solution comprising 200 μl of a
6 -4 suspension of THP-1 cells (2.5 x 10 cells/ml) containing 10 M ethidium bromide, 25 μl of a high potassium buffer solution containing 10" M bbATP, and 25 μl ofthe high potassium buffer solution containing 3 x 10" M test compound. The plate was covered with a plastics sheet and incubated at 37 °C for one hour. The plate was then read in a
Perkin-Elmer fluorescent plate reader, excitation 520 nm, emission 595 nm, slit widths: Ex 15 nm, Em 20 nm. For the purposes of comparison, bbATP (a P2X7 receptor agonist) and rjyridoxal 5-phosphate (a P2X7 receptor antagonist) were used separately in the test as controls. From the readings obtained, a pIC50 figure was calculated for each test compound, this figure being the negative logarithm ofthe concentration of test compound necessary to reduce the bbATP agonist activity by 50%. Each ofthe compounds ofthe Examples demonstrated antagonist activity, having a PIC50 figure > 5.0.

Claims

C L A I M S
1. A compound of general formula
Figure imgf000138_0001
wherein,
X represents a nitrogen atom or a group C(R );
Y represents an oxygen or sulphur atom or a group NR ;
1 2 either R and R each independently represent a hydrogen atom or a C1-C alkyl
1 2 group but do not both simultaneously represent a hydrogen atom, or R and R together represent a group -CH2ZCH2-;
7
Z represents a bond, an oxygen or sulphur atom or a group CH2 or NR ; m is 0 or 1 ;
3
R represents a 5- to 10-membered unsaturated ring system which may comprise from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substimted by one or more substituents independently selected from halogen, nitro, cyano, NR8R9, CrC4 alkyl-C(O)NH-, NHR12C(O)-, CrC4 alkyl-SO2-, CrC4 alkyl-SO2NH-, CrC4 alkyl-NHSO2-, CrC4 alkoxy, and
CrC4 alkyl optionally substimted by one or more fluorine atoms;
4 R represents a phenyl or pyridinyl group, each of which is substituted in an ortho position with a substiment selected from halogen, CrC4 alkoxy, CrC4 alkylthio, and C C^. alkyl optionally substimted by one or more fluorine atoms, the phenyl or pyridinyl group being optionally further substituted by one or more substituents independently selected from halogen, cyano, hydroxyl, CrC4 alkylthio, CrC4 alkyl-NH-, NHR13-CrC4 alkyl-, CrC4 alkyl-SO2-, CrC4 alkyl-SO2NH-, CrC4 alkyl-NHSO2-, CrC4 alkyl-C(O)NH-, CrC4 alkyl-NHC(O)-, -D-G, CrC4 alkoxy optionally substimted by -NR R or by R , and C1-C4 alkyl optionally substituted by one or more fluorine atoms or by one or more hydroxyl groups, 4 or R represents a 9- or 10-membered unsaturated bicyclic ring system which may comprise from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the bicyclic ring system being optionally substimted by one or more substituents independently selected from halogen, oxo, C1-C alkyl, C1-C4 alkoxy, CrC4 alkylthio and -NR10RU;
D represents an oxygen atom or a group (CH2)n or CH2NH; n is 1, 2 or 3; G represents a piperazinyl, morpholinyl or 2,5-diazabicyclo[2.2.1]heptyl group, or
G represents a piperidinyl group optionally substituted by amino;
R represents a hydrogen atom, or a hydroxyl or Cj- alkoxy group;
R represents a hydrogen atom, or a cyano, nitro, hydroxyl, C]_ -C4 alkyl or
CrC4 alkoxy group;
7 8 9 R , R and R each independently represent a hydrogen atom or a Cj-C4 alkyl group;
R and R each independently represent a hydrogen atom or a C^C^. alkyl group, or R and R together with the nitrogen atom to which they are attached form a 5- or 6- membered saturated heterocyclic ring comprising one or two ring nitrogen atoms;
12
R represents a hydrogen atom, or a C O^ alkyl group optionally substituted by ammo;
13
R represents a hydrogen atom, or a CrC4 alkyl group optionally substituted by hydroxyl;
R and R each independently represent a hydrogen atom or a C1-C4 alkyl group
14 15 optionally substituted by hydroxyl, or R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated heterocyclic ring comprising one or two ring nitrogen atoms; and
R represents a l-(C1-C -alkyl)-piperidinyl group;
4 with the proviso that when m is 0, X is N and Y is O, then R does not represent
2-benzothiazolyl; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1, wherein X represents a nitrogen atom.
3. A compound according to claim 1 or claim 2, wherein Y represents an oxygen atom.
3
4. A compound according to any one of claims 1 to 3, wherein, in R , the 5- to 10- membered unsaturated ring system is selected from phenyl, pyridinyl, pyrimidinyl, naphthyl, furanyl, pyrryl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tefrazolyl, pyrazinyl, quinolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, triazinyl, benzothiazolyl, benzooxazolyl, imidazopyrazinyl, triazolopyrazinyl, naphthyridinyl, furopyridinyl, thiopyranopyrimidinyl, pyridazinyl, quinazolinyl, pteridinyl, triazolopyrimidinyl, triazolopyrazinyl, thiapurinyl, oxapurinyl, deazapurinyl, thiazolopyrimidinyl, indolinyl, benzooxadiazolyl, benzothiadiazolyl, tetrahydroisoquinilinyl, 2-(isoxazol-3-yl)thienyl, and tWenopyrimidinyl.
5. A compound according to any one ofthe preceding claims, wherein, in R , the ring system is optionally substituted by one or more substituents independently selected from methyl, amino, cyano, methoxy, chloro, nitro, NH2C(O)-, CH3C(O)NH-, CH3SO2-, CH3SO2NH- and NH2CH2CH2NHC(O)-.
6. A compound according to any one ofthe preceding claims, wherein, in R , an ortho substituent in the phenyl or pyridinyl group is halogen or CrC4 alkyl optionally substituted by one or more fluorine atoms.
7. A compound according to any one of claims 1 to 5, wherein, in R , the 9- or 10- membered unsaturated bicyclic ring system is selected from naphthyl, benzimidazolyl, quinolinyl, indolinyl, isoquinolinyl, benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, benzthiazolyl, benzoxazolyl and quinazolinyl.
8. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 which is selected from:
(+)-N-(2,6-Dimethylphenyl)-2-(3-methyl-4-(thieno[2,3-βT]pyrimidin-4-yl)piperazin-l- yl)acetamide, 5 cz5-[2-(3,5-Dimethyl-4-(thieno[2,3-<5T]pyrimidin-4-yl)piperazin-l-yl)]-N-(2,6- dimethylphenyl)acetamide,
(+)-2-[3-Methyl-4-(4-methylphenyl)piperazin-l-yl]-N-(2,6-dimethylphenyl) acetamide, cz5-N-[3-Hydroxymethyl-2-methylphenyl]-2-(3,5-dimethyl-4-(thieno[2,3-
Figure imgf000141_0001
(R)-2-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3-ethylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide, cz*5-2-[3,5-Dimethyl-4-(tMeno[2,3-(i]pyrimidin-4-yl)piperazin-l-yl]-N-(2- methylphenyl)acetamide, is cz'5'-N-(2-Chlorophenyl)-2-[3,5-dimethyl-4-(tMeno[2,3-^pyrimidin-4-yl)piperazin-l- yl] acetamide, ct5-N-(2-Chlorophenyl)-2-[3,5-dimethyl-4-(9-methyl-9H-purin-6yl)piperazin-l- yl] acetamide, cz5-2-(3,5-Dimethyl-4-(tMeno[2,3-(i]pyrimidin-4-yl)piperazin-l-yl)-N-(isoquinolin-0 5-yl)acetamide, cis-2-(3 ,5-Dimethyl-4-thieno [2,3 -< ]pyrimidin-4-yl)piperazin- 1 -yl)-N-(quinolin-5- yl)acetamide, cz'j-2-(3,5-Dimethyl-4-(thieno[2,3-(f]pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- methylsulphonamidophenyl)acetamide, 5 cw-2-(3,5-Dimethyl-4-(thieno[2,3-(/]pyrimidin-4-yl)piperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide, cz'_f-2-(3,5-Dimethyl-4-(thieno[2,3-fiTlpyrimidm-4-yl)piperazm-l-yl)-N-(3- methylpyridin-2-yl)acetamide, cz*5-2-(3,5-Dimethyl-4-(tln^no[2,3-rf]pyrimidin-4-yl)piperazin-l-yl)-N-(isoquinolin-0 l-yl)acetamide, ew-4-(4-Amino-5-cyanopyrimidin-2-yl)-3,5-dimethylpiperazin-l-yl)-N-(2- chlorophenyl)acetamide, cz5-2-(4-Benzenesulphonyl-3,5-dimethylpiperazin-l-yl)-N-(2-chloro- phenyl)acetamide, (+)-N-(2, 6-Dimethylphenyl)-2- [(3 -methyl-4-thiazolo(5 ,4- >yrimidin-7-yl)piperazin- l-yl]acetamide, cw-N-(2-Chlorophenyl)-2-[(3 ,5-dimethyl-4-quinazolin-4-yl)piperazin- 1 - yl] acetamide,
N-(2-Chlorophenyl)-2-[(8-(thieno[2,3-< ]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]oct- 3 -yl] acetamide,
N-(2-Methylphenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
2-[8-(9-Methyl-9H-purin-6-yl)-3,8-diazabicyclo[3.2.1 ]oct-3-yl]-N-(quinolin-5- yl)acetamide, N-(Quinolin-5-yl)-2-[8-thiazolo[5,4-^]pyrimidin-7-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
N-(2-Methylphenyl)-2-[(8-thiazolo[5,4-(i]pyrimidin-7-yl)-3,8-diazabicyclo[3.2.1 ]oct- 3 -yl] acetamide,
N-(2-Methyl-5-(methylsulphonyl)amidoρhenyl)-2-[8-(9-methyl-9H-purin-6-yl)-3,8- diazabicyclo[3.2.1 ]oct-3-yl]acetamide,
^N-[2-Methyl-5-(methylsulphonyl)amidophenyl]-2-[(8-thiazolo[5,4-< ]pyrimidin-7-yl)- 3 , 8 -diazabicyclo [3.2.1 ] oct-3 -yl] acetamide,
N-[2-Methyl-5-(me1hylsulphonyl)amidophenyl]-2-[4-(thieno[2,3-( ]pyrimidin-4-yl)- 3,8-diazabicyclo[3.2.1]oct-3-yl]acetamide, cz5-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5-
(l-piperazinylmethyl)phenyl)acetamide, hydrochloride salt,
N-(2-Methylphenyl)-2-[(8-(thieno[2,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1 ]oct-3- yl] acetamide,
N-[5-(Methanesulphonylamido-2-methylphenyl)-2-[8-(thieno[2,3-d]pyrimidin-4-yl)-8- azabicyclo[3.2. l]oct-3-yl]acetamide, N-(2-Methyl-5-(l-piperazinylmethyl)phenyl)-2-[(8-(thieno[2,3-d]pyrimidin-4-yl)-3,8- diazabicyclo[3.2. l]oct-3-yl]acetamide, cz5-N-(5-(2-Aminoethoxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4-(thieno[2,3- d]pyrimidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt, cw-N-(5-(2-(N-Methylamino)ethoxy)-2-methyl-phenyl)-2-(3,5-dimethyl-4-(thieno[2,3- d]pyrimidin-4-yl)piperazin-l-yl)acetamide, hydrochloride salt, cz5,-N-(5-(2-(N-Methylamino)ethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl)-3,5- dimethyl)piperazin- 1 -yl)acetamide, cz'i'-N-[5-(2-Aminoethoxy)-2-methyl-phenyl)-2-(4-benzenesulphonyl-3,5- dimethyl)piperazin- 1-yl] acetamide, hydrochloride salt,
N-(2-Oxo-2,3-dihydro-lH-indol-4-yl)-2-(8-thieno[2,3-d]pyrimidin-4-yl-3,8- diazabicyclo[3.2.1]oct-3-yl)acetamide
N-(3-Fluoro-2-methyl-phenyl)-2-((8-quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]oct-3- yl)acetamide, N-(2-Methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
N-(3-Fluoro-2-methylphenyl)-2-[8-(benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide, cz5-N-(3-Fluoro-2-methyl-phenyl)-2-(4-benzenesulphonyl)-3,5-dimefhyl)piperazin-l- yl)acetamide,
"N-(2-Methylphenyl)-2-[8-(3-cyanobenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3- yl] acetamide,
2-[8-(3-Methoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, 2-[8-(Benzo[l,2,5]oxadiazole-4-sulρhonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide,
2-[8-(Benzo[l,2,5]thiadiazole-4-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide,
2-[8-(5-Chlorothieno-2-yl)sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, 2-[8-(2-Chlorobenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide,
2-[8-(5-Chloro-2-methoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, 2-[8-(4-Acetylaminomethoxybenzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-
(2-methylphenyl)acetamide,
N-(2-Methylphenyl)-2-[(8-(3-methyltMeno[2,3-d]pyrimidin-4-yl)-3,8- diazabicyclo [3.2.1 ] oct-3 -yl] acetamide, cis-2-(3 ,5-Dimethyl-4-(thieno [2,3-d]pyrimidin-4-yl)piperazin- 1 -yl)-N-( 1 -methyl- 1 H- benzoimidazol-2-yl)acetamide, cw-2-(3,5-Dimethyl-4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-l-yl)-N-(2-methyl-5- (4-piperidinyloxy)phenyl)acetamide, hydrochloride salt, cz-f-2-(3,5-Dimethyl-4-benzenesulphonyl)piperazin-l-yl)-N-(2-methyl-5-(4- piperidinyloxy)phenyl)acetamide, cz'5'-2-(3,5-Dimethyl-4-(quinazolin-4-yl)piperazin-l-yl)-N-(2-methyl-5-(4- piperidinyloxy)phenyl)acetamide, ct5-2-(3,5-Dimethyl-4-(4-quinazolinyl)piperazin-l-yl)-N-(2-methyl-5-(piperazin-4- yl-methyl)phenyl)acetamide, cis-2-(3 ,5-Dimethyl-4-(4-quinazolinyl)piperazin- 1 -yl)-N-(2-methyl-5-(2-(N- methylamino)ethoxy)phenyl)acetamide,
'"Cz*-f-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz'i'-N-(2-Methylphenyl)-2-[4-(3-nitrobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]- acetamide, cz5-2-[4-(3-Aminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cw-2-(3,5-Dimethyl-4-(3-cyanobenzenesulphonyl)piperazin-l-yl)-N-(quinolin-5- yl)acetamide, cis-2-(3 ,5-Dimethyl-4-(4-cyanobenzenesulphonyl)piperazin- 1 -yl)-N-(quinolin-5- yl)acetamide, cz5-2-(4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide, ew-2-(4-(4-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl)-N-(3-fluoro-2- methylphenyl)acetamide, cz' '-2-[4-(3-Acetylaminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz5,-2-[4-(3-Aminocarbonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cw-2-[4-(3-Methanesulphonylaminobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]- N-(2-methylphenyl)acetamide, cis -2-[4-(2-Methanesulphonylbenzenesulphonyl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(3- methoxy-2-methylphenyl)acetamide, cz>s-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(3- fluoro-2-methylphenyl)acetamide, cz'5-2-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-
(quinolin-5-yl)acetamide, cz_'-2-[4-(l-Methylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-(3- methoxy-2-methylphenyl)acetamide, cz'-?-2-[4-( 1 -Methylimidazol-4-sulphonyl-4-yl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(3 - fluoro-2-methylphenyl)acetamide,
'" cz' 1s,-2-[4-(l-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide,
, cw-2-[4-(2-Aminoethylaminocarbonylbenzenesulphonyl)-3,5-dimethylpiperazin- 1 - yl]-N-(2-methylphenyl)acetamide, cis-2-[4-( 1 , 1 ,2,2-Tetrahydroisoquinilin-7-sulphonyl-7-yl)-3 ,5-dimethylpiperazin- 1 - yl]-N-(2,6-dimethylphenyl)acetamide, cz'5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2,6- dimethylphenyl)acetamide, cz5-2-[4-(4-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz'-r-2-[4-(2-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2,6- dimethylphenyl)acetamide, hydrochloride salt, cz5,-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- chlorophenyl)acetamide, 2-[8-(Isquinolin-l-yl)-3,8-diazabicyclo[3.2. l]oct-3-yl]-N-(2- methylphenyl)acetamide, cz*5-2-[4-(4-Acetamidobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- trifluoromethylphenyl)acetamide, ct5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methanesulphonamidophenyl)acetamide,
2-[8-(4-Benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, 2-[8-(2-Benzenesulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N-(2- methylphenyl)acetamide, cz'5'-2-[4-(l,2-Dimethylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N- (quinolin-5-yl)acetamide, cz_7-2-[4-(5-Chloro-l,3-dimethylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl]-N-(3-methoxy-2-methylphenyl)acetamide,
2-[8-(2-(Isoxazol-3-yl)thiophen-5-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N- (2- methylphenyl)acetamide,
2-[8-(l,l,2,2-Tetrahydroisoquinilin-7-sulphonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-N- (2-methylphenyl)acetamide, ez 2-[4-(5-Chloro-l,3-dimethylpyrazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l- yl] -N-(2-methylphenyl)acetamide, cz5-2-[4-(3,5-Dimethylisoxazole-4-sulphonyl-4-yl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cz'5'-2-[4-(2-Methanesulphonylbenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2- methylphenyl)acetamide, cis-2-[4-(3 -Cyanobenzenesulphonyl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(3-methoxy-2- methylphenyl)acetamide, eti,-2-[4-(4-Methanesulphonylbenzenesulphonyl)-3 ,5-dimethylpiperazin- 1 -yl]-N-(2- methylphenyl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiρerazin-l-yl]-N-(5-cyano-2- methylphenyl)acetamide, ct-?-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiρerazin-l-yl]-N-(5-acetamido-2- methylphenyl)acetamide,
(R)-2-[4-(4-Cyanobenzenesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide,
(S)-2-[4-(4-Cyanobenzenesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5- methanesulphonylphenyl)acetamide, cz-f-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(4- amino-l-piperidinyl)methyl)phenyl]acetamide,
(R)-2-[4-(4-Methanesulphonylbenzenesulphonyl)-3-methylpiperazin-l-yl]-N- (quinolin-5-yl)acetamide,
(R)-2-[4-(4-Acetamidobenzenesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5- yl)acetamide, cz'-5,-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- piperazinylmethyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiρerazin-l-yl]-N-(2-methyl-5-(4- piperidinylamino)methyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulρhonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(l- morpholinyl)methyl)phenyl)acetamide, c/5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-5-(2- hydroxyethylamino)methyl)phenyl)acetamide, cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylρiperazin-l-yl]-N-(2-methyl-5- (S,S)-(2,5-diazabicyclo[2.2.1 ]hept-2-yl)methyl)phenyl)acetamide, (R)-2-[4-(2-Pyridinesulphonyl)-3-methylpiperazin-l-yl]-N-(quinolin-5-yl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(4- amino- 1 -piperidinyl)methyl)phenyl] acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(4- piperidinylamino)methyl)phenyl)acetamide, ct5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3-(l- piperazinylmethyl)phenyl)acetamide, ct5,-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-(2-methyl-3- (S,S)-(2,5-diazabicyclo[2.2.1 ]hept-2-yl)methyl)phenyl)acetamide, c/5-2-[4-(3-CyanobenzenesuIphonyl)-3,5-dimethylpiperazin- 1 -yl]-N-((2-methyl-3-(l - morpholinyl)methyl)phenyl)acetamide, ct5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-3-(2- ( 1 -pyrrolidinyl)ethoxy)phenyl)acetamide,
(±) cz5,-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 3 -(1 -methylpiperidin-3 -yl)methoxy)phenyl)acetamide, cz5-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl-4-(2- ( 1 -pyrrolidiny I)ethoxy)phenyl)acetamide,
(±) cz'5'-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 4-( 1 -methylpiperidin-3 -yl)methoxy)phenyl)acetamide, (±) cz -2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin- 1 -yl]-N-((2-methyl-
5-(l-methylpiperidin-3-yl)methoxy)phenyl)acetamide,
(+) cw-2-[4-(3-Cyanobenzenesulphonyl)-3,5-dimethylpiperazin-l-yl]-N-((2-methyl- 6-(l -methylpiperidin-3-yl)methoxy)phenyl)acetamide, and cis-2-[4-(l -Methylimidazol-4-sulphonyl-4-yl)-3,5-dimethylpiperazin- 1 -yl]-N-((2- methyl-3-(2-(l-pyrrolidinyl)ethoxy)phenyl)acetamide.
9. A process for the preparation of a compound of formula (I) as defined in claim 1, which comprises
(a) reacting a compound of general formula
Figure imgf000149_0001
wherein X, Y, R , R and R are as defined in formula (I), with a compound of general formula (III), R 3 -(SO2)m-L 1 , wherein L1 represents a leaving group and m and R 3 are as defined in formula (I); or (b) when X represents a nitrogen atom and Y represents an oxygen atom, reacting a compound of general formula
Figure imgf000149_0002
wherein m, R 1 , R2 and R 3 are as defined in formula (I), with a compound of general formula
Figure imgf000149_0003
wherein L 2 represents a leaving group and R 4 is as defined in formula (I); or
(c) reacting a compound of general formula
Figure imgf000149_0004
wherein L 3 represents a leaving group and m, X, Y, R 1 , R2 and R 3 are as defined in formula (I), with a compound of general formula (Nil), H2Ν - R 4, wherein R 4 is as defined in formula (I);
and optionally after (a), (b) or (c) converting the compound of formula (I) obtained to a pharmaceutically acceptable salt or solvate thereof.
10. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 for use in therapy.
13. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 for use in the treatment of rheumatoid arthritis.
14. A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 for use in the treatment of chronic obstructive pulmonary disease.
15. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in therapy.
16. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating rheumatoid arthritis.
17. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease.
18. A method of effecting immunosuppression which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 to a patient in need thereof.
19. A method of treating rheumatoid arthritis which comprises admimstering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 to a patient in need thereof.
20. A method of treating chronic obstructive pulmonary disease which.comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 8 to a patient in need thereof.
PCT/SE2000/002580 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives WO2001046200A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
NZ519498A NZ519498A (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
BR0016543-3A BR0016543A (en) 1999-12-22 2000-12-18 New piperidine and piperazine derivatives
DE60004564T DE60004564T2 (en) 1999-12-22 2000-12-18 NEW PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
AU25648/01A AU776592B2 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
CA002394095A CA2394095A1 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
MXPA02006261A MXPA02006261A (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives.
AT00989102T ATE247123T1 (en) 1999-12-22 2000-12-18 NEW PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
EP00989102A EP1242427B1 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives as p2x7 receptor antagonists
US10/168,094 US6969713B2 (en) 1999-12-22 2000-12-18 Piperidine and piperazine acetamide derivatives
JP2001547110A JP2003518126A (en) 1999-12-22 2000-12-18 New piperidine and piperazine derivatives
IL15020100A IL150201A0 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
IL150201A IL150201A (en) 1999-12-22 2002-06-12 Piperidine and piperazine derivatives, process for their production, pharmaceutical compositions comprising them and use thereof in therapy
NO20023037A NO20023037L (en) 1999-12-22 2002-06-21 New piperidine and piperazine derivatives
US11/125,335 US20050272745A1 (en) 1999-12-22 2005-05-10 Novel piperidine and piperazine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904738A SE9904738D0 (en) 1999-12-22 1999-12-22 Novel compounds
SE9904738-3 1999-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/125,335 Continuation US20050272745A1 (en) 1999-12-22 2005-05-10 Novel piperidine and piperazine derivatives

Publications (2)

Publication Number Publication Date
WO2001046200A1 true WO2001046200A1 (en) 2001-06-28
WO2001046200A8 WO2001046200A8 (en) 2002-02-28

Family

ID=20418266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/002580 WO2001046200A1 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives

Country Status (17)

Country Link
US (2) US6969713B2 (en)
EP (1) EP1242427B1 (en)
JP (1) JP2003518126A (en)
KR (1) KR100733548B1 (en)
CN (1) CN1330657C (en)
AT (1) ATE247123T1 (en)
AU (1) AU776592B2 (en)
BR (1) BR0016543A (en)
CA (1) CA2394095A1 (en)
DE (1) DE60004564T2 (en)
IL (2) IL150201A0 (en)
MX (1) MXPA02006261A (en)
NO (1) NO20023037L (en)
NZ (1) NZ519498A (en)
SE (1) SE9904738D0 (en)
WO (1) WO2001046200A1 (en)
ZA (1) ZA200204307B (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082855A1 (en) * 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
US6720452B2 (en) 1999-12-09 2004-04-13 Astrazeneca Ab Adamantane derivatives
WO2004058270A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases
WO2005014555A1 (en) * 2003-07-21 2005-02-17 Aventis Pharmaceuticals Inc. 4,5-dihydro-imidazole as p2x7 ion channel blockers
US6881754B2 (en) 1999-12-17 2005-04-19 Astrazeneca Ab Adamantane derivatives
US6927219B2 (en) 2001-11-12 2005-08-09 Pfizer Inc. N-alkyl-adamantyl triazinyl benzamide derivatives
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US7214677B2 (en) 2001-11-12 2007-05-08 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
WO2008011476A3 (en) * 2006-07-18 2008-12-31 Gen Hospital Corp Compositions and methods for modulating sirtuin activity
WO2009053459A1 (en) 2007-10-26 2009-04-30 Glaxo Group Limited 4-benz0yl-1-substituted-piperazin-2-0ne derivatives as p2x7 modulators
EP2105164A1 (en) 2008-03-25 2009-09-30 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2011054820A1 (en) 2009-11-03 2011-05-12 Universidad Del País Vasco Methods and compositions for the treatment of white matter ischemia
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2013024291A3 (en) * 2011-08-18 2013-04-18 Ucb Pharma S.A. Therapeutically active fused pyrimidine derivatives
WO2013068458A1 (en) * 2011-11-10 2013-05-16 Ucb Pharma S.A. Therapeutically active thiazolo-pyrimidine derivatives
WO2014057080A3 (en) * 2012-10-12 2014-07-10 H. Lundbeck A/S N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
US9290511B2 (en) 2011-11-15 2016-03-22 Xention Limited Thieno-pyrimidines, useful as potassium channel inhibitors
CN107427499A (en) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 Immunomodulator
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
JP2005504043A (en) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． Peptidomimetics of biologically active metal peptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
BRPI0410349A (en) * 2003-05-12 2006-05-30 Pfizer Prod Inc p2x7 receptor benzamide inhibitors
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2005107804A1 (en) * 2004-05-06 2005-11-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for respiratory ailment
RU2006146675A (en) * 2004-06-29 2008-07-10 Пфайзер Продактс Инк. (Us) METHOD FOR PRODUCING 5- [4- (2-HYDROXYPROPYL) -3,5-DIOXO-4,5-DIHYDRO-3H- [1,2,4] TRIAZIN-2-IL] BENZAMIDE DERIVATIVES BY REMOVING PROTECTION FROM INTERMEDIATE PRODUCTS, SODA HYDROXYL
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
WO2006004880A2 (en) * 2004-06-30 2006-01-12 Schering Corporation Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
WO2006064780A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
CA2771592A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
EA032823B1 (en) * 2014-08-16 2019-07-31 Сувен Лайф Сайенсиз Лимитед Process for large scale production of n-[4-(1-cyclobutyl piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3029241A (en) * 1962-04-10 Phenylpbperazinylacyl anilines
JPS50108264A (en) * 1974-02-07 1975-08-26
FR2346011A1 (en) * 1976-02-02 1977-10-28 Orsymonde (4)-Phenyl-(1)-dimethylacetanilido-piperazine and salts - esp. for treating cardiovascular circulatory disorders
EP0074768A2 (en) * 1981-09-03 1983-03-23 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Alkanoylanilides
JPH03141258A (en) * 1989-10-25 1991-06-17 Kowa Co Novel piperazine derivative
EP0582164A1 (en) * 1992-07-31 1994-02-09 Bristol-Myers Squibb Company Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles
JPH06247942A (en) * 1993-02-22 1994-09-06 Kyowa Hakko Kogyo Co Ltd Piperazine derivative
WO1999031096A1 (en) * 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
WO1999059582A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2980797A (en) * 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
SE9704544D0 (en) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (en) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (en) 1999-04-09 2002-05-15 Astrazeneca Ab Adamantane derivatives
SE9901875D0 (en) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (en) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3029241A (en) * 1962-04-10 Phenylpbperazinylacyl anilines
JPS50108264A (en) * 1974-02-07 1975-08-26
FR2346011A1 (en) * 1976-02-02 1977-10-28 Orsymonde (4)-Phenyl-(1)-dimethylacetanilido-piperazine and salts - esp. for treating cardiovascular circulatory disorders
EP0074768A2 (en) * 1981-09-03 1983-03-23 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Alkanoylanilides
JPH03141258A (en) * 1989-10-25 1991-06-17 Kowa Co Novel piperazine derivative
EP0582164A1 (en) * 1992-07-31 1994-02-09 Bristol-Myers Squibb Company Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles
JPH06247942A (en) * 1993-02-22 1994-09-06 Kyowa Hakko Kogyo Co Ltd Piperazine derivative
WO1999031096A1 (en) * 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
WO1999059582A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 57, 1962, Columbus, Ohio, US; abstract no. 3443I, SHIN HAYAO ET AL.: "New sedative and hypotensive phenylpiperazine amides" XP002951486 *
CHEMICAL ABSTRACTS, vol. 84, no. 9, 1 March 1976, Columbus, Ohio, US; abstract no. 59466U, MARUYAMA, ISAMUET ET AL. page 527; XP002951485 *
DATABASE CAPLUS [online] KOWA K.K.: "Preparation of piperazine derivatives as antiarrhythmics", XP002951481, accession no. STN international Database accession no. 1991:656226 *
DATABASE CAPLUS [online] KYOWA HAKKO KOGYO KK: "Preparation of quinazolinylpiperazineacetamide derivatives", XP002951480, accession no. STN international Database accession no. 1995:324637 *
J. ORG. CHEM., vol. 26, 1961, pages 3414 - 3419 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720452B2 (en) 1999-12-09 2004-04-13 Astrazeneca Ab Adamantane derivatives
US7297818B2 (en) 1999-12-17 2007-11-20 Astrazeneca Ab Adamantane derivatives
US7132457B2 (en) 1999-12-17 2006-11-07 Astrazeneca Ab Adamantane derivatives
US6881754B2 (en) 1999-12-17 2005-04-19 Astrazeneca Ab Adamantane derivatives
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US7214677B2 (en) 2001-11-12 2007-05-08 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
US7235549B2 (en) 2001-11-12 2007-06-26 Pfizer Inc. Benzamide, heteroarylamide and reverse amides
US6927219B2 (en) 2001-11-12 2005-08-09 Pfizer Inc. N-alkyl-adamantyl triazinyl benzamide derivatives
WO2003082855A1 (en) * 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
WO2004058270A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases
US7176202B2 (en) 2002-12-31 2007-02-13 Pfizer Inc. Benzamide inhibitors of the P2X7 receptor
US6974812B2 (en) 2002-12-31 2005-12-13 Pfizer Inc. Benzamide inhibitors of the P2X7 Ereceptor
US7326792B2 (en) 2003-07-21 2008-02-05 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
US7741493B2 (en) 2003-07-21 2010-06-22 Aventis Pharmaceuticals Inc. Heterocyclic compounds as P2X7 ion channel blockers
WO2005014555A1 (en) * 2003-07-21 2005-02-17 Aventis Pharmaceuticals Inc. 4,5-dihydro-imidazole as p2x7 ion channel blockers
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
WO2008011476A3 (en) * 2006-07-18 2008-12-31 Gen Hospital Corp Compositions and methods for modulating sirtuin activity
WO2009053459A1 (en) 2007-10-26 2009-04-30 Glaxo Group Limited 4-benz0yl-1-substituted-piperazin-2-0ne derivatives as p2x7 modulators
EP2105164A1 (en) 2008-03-25 2009-09-30 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2011054820A1 (en) 2009-11-03 2011-05-12 Universidad Del País Vasco Methods and compositions for the treatment of white matter ischemia
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2011141194A1 (en) 2010-05-14 2011-11-17 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9227984B2 (en) 2011-08-18 2016-01-05 Ucb Pharma S.A. Therapeutically active fused pyrimidine derivatives
WO2013024291A3 (en) * 2011-08-18 2013-04-18 Ucb Pharma S.A. Therapeutically active fused pyrimidine derivatives
WO2013068458A1 (en) * 2011-11-10 2013-05-16 Ucb Pharma S.A. Therapeutically active thiazolo-pyrimidine derivatives
US9096614B2 (en) 2011-11-10 2015-08-04 Ucb Pharma S.A. Therapeutically active thiazolo-pyrimidine derivatives
US9290511B2 (en) 2011-11-15 2016-03-22 Xention Limited Thieno-pyrimidines, useful as potassium channel inhibitors
US9108938B2 (en) 2012-10-12 2015-08-18 H. Lundbeck A/S Cyclic amines
WO2014057080A3 (en) * 2012-10-12 2014-07-10 H. Lundbeck A/S N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
US9415055B2 (en) 2012-10-12 2016-08-16 H. Lundbeck A/S Cyclic amines
US9593105B2 (en) 2012-10-12 2017-03-14 H. Lundbeck A/S Cyclic amines
US9861639B2 (en) 2012-10-12 2018-01-09 H. Lundbeck A/S Cyclic amines
US10124010B2 (en) 2012-10-12 2018-11-13 Mindimmune Therapeutics, Inc. Cyclic amines
EP3536689A1 (en) * 2012-10-12 2019-09-11 MindImmune Therapeutics, Inc. 2-(cyclic amineethyl)benzamide derivatives as p2x7 inhibitors
CN107427499A (en) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 Immunomodulator
US10533014B2 (en) 2014-11-05 2020-01-14 Flexus Biosciences, Inc. Immunoregulatory agents
CN107427499B (en) * 2014-11-05 2021-04-16 弗莱塞斯生物科学公司 Immunomodulator
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
US11932601B2 (en) 2014-11-05 2024-03-19 Flexus Biosciences, Inc. Immunoregulatory agents

Also Published As

Publication number Publication date
KR100733548B1 (en) 2007-06-28
WO2001046200A8 (en) 2002-02-28
ZA200204307B (en) 2003-08-29
CN1330657C (en) 2007-08-08
NO20023037L (en) 2002-08-22
CA2394095A1 (en) 2001-06-28
US20050272745A1 (en) 2005-12-08
AU2564801A (en) 2001-07-03
CN1434827A (en) 2003-08-06
AU776592B2 (en) 2004-09-16
EP1242427A1 (en) 2002-09-25
US6969713B2 (en) 2005-11-29
DE60004564D1 (en) 2003-09-18
JP2003518126A (en) 2003-06-03
SE9904738D0 (en) 1999-12-22
KR20020069221A (en) 2002-08-29
MXPA02006261A (en) 2002-12-05
NO20023037D0 (en) 2002-06-21
DE60004564T2 (en) 2004-06-24
ATE247123T1 (en) 2003-08-15
BR0016543A (en) 2002-09-17
IL150201A0 (en) 2002-12-01
US20030013721A1 (en) 2003-01-16
NZ519498A (en) 2004-02-27
IL150201A (en) 2008-06-05
EP1242427B1 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
EP1242427B1 (en) Novel piperidine and piperazine derivatives as p2x7 receptor antagonists
RU2582610C2 (en) Quinoline derivatives and melk inhibitors containing same
US7304077B2 (en) Chemical compounds
ES2392963T3 (en) Benzamide derivatives useful as histone deacetylase inhibitors
US8637543B2 (en) Quinoline derivatives as kinase inhibitors
US11008308B2 (en) Quinazolinones as PARP14 inhibitors
US20030162764A1 (en) Pyrimidine A2b selective antagonist compounds, their synthesis and use
KR20010108394A (en) Novel Compounds
JP2013519732A (en) Arylcarboxamide derivatives as sodium channel inhibitors for the treatment of pain
JP2009501745A (en) Piperazinone derivatives useful as histamine H3 receptor antagonists and / or inverse agonists
US7238691B2 (en) Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
KR20040084920A (en) Chemical Compounds
ES2201509T3 (en) DERIVATIVES OF QUINOLINA-4-CARBOXAMIDE AS AN ANTAGONIST OF THE NK-2 AND NK-3 RECEPTORS.
RU2345990C2 (en) Piperidine derivatives as modulators of activity of ccr5 receptor, method and intermediate compounds for obtaining them, and pharmaceutical compositions containing them
EP1883636A1 (en) Substituted piperidine antagonist of hi receptor to be used for the treatment of rhinitis
EP1904484A1 (en) Compounds
US20170291907A1 (en) Thienopyrimidine Compounds
US11827640B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators
NO171908B (en) ANALOGY PROCEDURE FOR PREPARATION OF 4- (AROYLAMINO) PIPERIDINBUTANAMIDE DERIVATIVES
UA80302C2 (en) Quinazoline derivatives as src tyrosine kinase inhibitors, process for their preparation, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 25648/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002/04307

Country of ref document: ZA

Ref document number: 200204307

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000989102

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2394095

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 519498

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 150201

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10168094

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 547110

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006261

Country of ref document: MX

Ref document number: 1020027008039

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008190453

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027008039

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000989102

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000989102

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 519498

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519498

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 25648/01

Country of ref document: AU